Can we improve how we diagnose osteomyelitis in the diabetic foot? by Harman, Kim
  
Can we improve how we diagnose osteomyelitis 
in the diabetic foot? 
 
 
 
Kim Harman  
A thesis submitted in part fulfilment for the award 
of Professional Doctorate in Health 
School of Health 
University of Bath 
March 2010  
 
 
 
 
COPYRIGHT 
Attention is drawn to the fact that copyright of this thesis rests with its 
author. This copy of the thesis has been supplied on condition that anyone 
who consults it is understood to recognise that its copyright rests with its 
author and that no quotation from the thesis and no information derived 
from it may be published without the prior written consent of the author. 
 
This thesis may be made available for consultation within the University 
Library and may be photocopied or lent to other libraries for the purposes of 
consultation. 
  
 
 
 
 
I, Kim Harman, confirm that this dissertation and the work presented in it 
are my own achievement.  
 
 
1. Where I have consulted the published work of others this is clearly 
attributed. 
2. Where I have quoted from the work of others the source is always 
given. With the exception of such quotations this dissertation is 
entirely my own work. 
3. I have acknowledged all main sources of help. 
4. If my research follows on from previous work or is part of a larger 
collaborative research project I have made clear exactly what was 
done by others and what I have contributed myself.  
5. I have read and understand the penalties associated with plagiarism. 
 
 
In submitting my dissertation, I give permission for the title of my work to 
be published on the School for Health’s website and for an e copy of my 
work to be available via the University of Bath Library. 
 
 
Signed 
Date 
Student number 059054692 
 
 1 
Contents  
 
 
Acknowledgements. ............................................................................................... 8 
 
 
Abstract .................................................................................................................. 9 
 
 
Abbreviations ....................................................................................................... 10 
 
 
Glossary of terms ................................................................................................. 11 
 
 
Chapter 1 Background ........................................................................................ 14 
 
1.1Definition of diabetes .....................................................................................14 
1.2 The health impact of diabetes ........................................................................15 
1.3 Diabetic foot disease .....................................................................................16 
1.4 Pathways to ulceration...................................................................................20 
1.5 Factors affecting ulcer development and healing capacity..............................21 
Figure 1.1 Pathways to foot ulceration in the diabetic patient ..........................22 
1.6 Amputations in diabetes - a brief summary....................................................26 
 
 
Chapter 2 Introduction........................................................................................ 29 
 
2.1 Literature review search strategy ...................................................................29 
2.1.1 Review of haematological markers; ........................................................29 
2.1.2 Review of imaging; ................................................................................30 
2.1.3 Review of ulcer classification system; ....................................................30 
2.2 Defining osteomyelitis ..................................................................................30 
2.3 Osteomyelitis as a specific complication in diabetes ......................................33 
2.4 Diagnosing osteomyelitis ..............................................................................37 
2.4.1 Gold standard diagnosis..........................................................................37 
2.4.2 Other tests used clinically .......................................................................39 
2.4.3 Imaging techniques in the diagnosis of osteomyelitis ..............................40 
2.4.4 Reference test for diagnosis ....................................................................43 
2.5 The immune response....................................................................................44 
2.6 The acute phase reaction................................................................................45 
2.7 Inflammatory blood markers; non specific.....................................................46 
2.7.1 Neutrophil count.....................................................................................48 
2.7.2 Haemoglobin ..........................................................................................50 
2.7.4 Erythrocyte Sedimentation Rate..............................................................56 
2.7.5 Plasma Viscosity ....................................................................................57 
 2 
2.7.6 Procalcitonin ..........................................................................................59 
2.8 Proposed studies using inflammatory blood markers .....................................63 
2.9 Proposed studies using SPECT/CT................................................................65 
2.10 The study and wound classification .............................................................65 
2.10.1 Ulcer classification systems ..................................................................65 
 
 
Chapter 3 Methodology The use of inflammatory blood markers in the 
diagnosis of osteomyelitis..................................................................................... 70 
 
3.1 Research question..........................................................................................70 
3.2 Aim...............................................................................................................70 
3.3 Research objectives .......................................................................................70 
3.4 Protocol.........................................................................................................71 
3.5 Summary.......................................................................................................72 
3.6 Keywords......................................................................................................72 
3.7 Confounding factors......................................................................................72 
3.7.1 Recognition of confounding factors ........................................................73 
3.7.2 Managing confounding factors ...............................................................73 
3.8 Multiple versus single markers ......................................................................74 
3.9 Setting of research studies .............................................................................74 
3.10 Sample ........................................................................................................75 
3.11 Method; Ethical statement ...........................................................................75 
3.12 Method; Ethical considerations....................................................................76 
3.13 Inclusion / exclusion criteria........................................................................77 
3.14 Consent .......................................................................................................77 
3.15 Method; Wound assessment ........................................................................78 
3.16 Method; venepuncture .................................................................................80 
3.17 Data collection tool .....................................................................................82 
3.18 Method; Imaging studies .............................................................................82 
3.19 Analysis; of the blood markers ....................................................................82 
3.20 Measurement of the specific inflammatory blood markers ...........................83 
3.20.1 Haemoglobin and Neutrophil Count......................................................83 
3.20.2 Plasma Viscosity ..................................................................................83 
3.20.3 C Reactive Protein ................................................................................83 
3.20.4 Procalcitonin ........................................................................................84 
 
 
Chapter 4 Results The use of inflammatory blood markers in the diagnosis of 
osteomyelitis ......................................................................................................... 85 
 
4.1 Statistical analysis of results of blood samples...............................................85 
4.2 Sample characteristics - age...........................................................................86 
Table 4.1 sample characteristics - gender ............................................................86 
Table 4.2 sample characteristics - type of diabetes...............................................86 
Table 4.3 sample characteristics – diabetes treatment ..........................................86 
4.3 HbA1c levels.................................................................................................86 
 3 
Table 4.4 sample characteristics – duration since diagnosis .................................86 
Table 4.5 numbers of wound types ......................................................................87 
Table 4.6 descriptive statistics in all wound types for each inflammatory marker 87 
4.3 Summary statistics for each marker in each state separately...........................87 
Table 4.7 summary statistics of each inflammatory marker in each wound 
condition .........................................................................................................88 
Figure 4.4.1 Comparison of Neutrophil Count in all wound conditions............89 
Figure 4.4.2 Comparison of Haemoglobin level in all wound conditions 
(excludes renal impairment) ............................................................................90 
Figure 4.4.3 Comparison of CRP level in all wound condition.........................90 
Figure 4.4.5 Comparison of Procalcitonin level in all wound conditions..........91 
4.5 Receiver Operator Characteristic Curves .......................................................91 
Figure 4. 5.1 Receiver Operator Characteristic Curve – clean wounds .............92 
Figure 4.5.2 Receiver Operator Characteristic Curve – cutaneous infection in 
wounds............................................................................................................93 
Figure 4.5.3 Receiver Operator Characteristic Curve – suspected osteomyelitis 
infected wounds ..............................................................................................94 
Figure 4.5.4 Receiver Operator Characteristic Curve – confirmed osteomyelitis 
infected wounds ..............................................................................................95 
4.6 Logistic Regression analysis without recognising confounders ......................96 
Table 4.8 Logistic Regression analysis without recognising potential 
confounders predicting all wound types...........................................................96 
4.7 Logistic Regression analysis with recognised potential confounders..............96 
Table 4.9 Potential confounders in regression analysis predicting clean   
wounds............................................................................................................97 
Table 4.10 Potential confounders in regression analysis predicting wounds with 
cutaneous infection..........................................................................................97 
Table 4.11 Potential confounders in regression analysis predicting wounds with 
suspected osteomyelitis ...................................................................................98 
Table 4.12 Potential confounders in regression analysis predicting wounds with 
confirmed osteomyelitis ..................................................................................98 
Table 4.13 Comparison of C Reactive Protein in all individuals with type 2 
diabetes to those with type 2 diabetes AND on Metformin and BMI >25 kg / m2 
for all wound types..............................................................................................99 
Table 4.14 Correlations between inflammatory markers in clean wounds ............99 
Table 4.15 Correlations between inflammatory markers in wounds with cutaneous 
infection............................................................................................................100 
Table 4.16 Correlations between inflammatory markers in suspected  
osteomyelitis .....................................................................................................100 
Table 4.17 Correlations between inflammatory markers in confirmed 
osteomyelitis .....................................................................................................101 
 
 
Chapter 5 Discussion The use of inflammatory blood markers in the diagnosis 
of osteomyelitis ................................................................................................... 102 
 
5.1 Sample characteristics .................................................................................102 
 4 
5.2.1 Neutrophil Count ..................................................................................104 
5.2.2 Haemoglobin ........................................................................................104 
5.2.3 C Reactive Protein................................................................................104 
5.2.4 Plasma Viscosity ..................................................................................104 
5.2.5 Procalcitonin ........................................................................................105 
5.3 Inflammatory blood markers in clean wounds .............................................105 
5.4 Inflammatory blood markers in cutaneous infection ....................................105 
5.5 Inflammatory blood markers in suspected osteomyelitis ..............................107 
5.6 Inflammatory blood markers in proven osteomyelitis ..................................107 
5.7 Receiver Operator Characteristic curve in clean wounds..............................107 
5.8 Receiver Operator Characteristic curve in cutaneous infection.....................107 
5.9 Receiver Operator Characteristic curve in suspected osteomyelitis ..............108 
5.10 Receiver Operator Characteristic curve in proven osteomyelitis.................108 
5.11 Regression models with no confounders in clean wounds ..........................108 
5.12 Regression models with no confounders in cutaneous infection .................109 
5.13 Regression models with no confounders in suspected osteomyelitis...........109 
5.14 Regression models with no confounders in proven osteomyelitis ...............109 
5.15 Regression models with confounders in clean wounds...............................109 
5.15.1 No antibiotic use.................................................................................109 
5.15.2 Use of Insulin .....................................................................................110 
5.15.3 Use of Metformin ...............................................................................110 
5.15.4 Predominantly neuropathic wounds ....................................................110 
5.16 Regression models with confounders in cutaneous infection......................111 
5.16.1 No antibiotic use.................................................................................111 
5.16.2 Use of Insulin .....................................................................................111 
5.16.3 Use of Metformin ...............................................................................112 
5.16.4 Predominantly neuropathic wounds ....................................................112 
5.17 Regression models with confounders in suspected osteomyelitis ...............113 
5.17.1 No antibiotic use.................................................................................113 
5.17.2 Use of Insulin .....................................................................................113 
5.17.3 Use of Metformin ...............................................................................114 
5.17.4 Predominantly neuropathic wounds ....................................................114 
5.18 Regression models with confounders in proven osteomyelitis....................114 
5.18.1 No antibiotic use.................................................................................114 
5.18.2 Use of Insulin .....................................................................................115 
5.18.3 Use of Metformin ...............................................................................115 
5.18.4 Predominantly neuropathic wounds ....................................................115 
5.19 Comparative results to other studies for Neutrophil Count .........................115 
5.20 Comparative results to other studies for Haemoglobin ...............................116 
5.21 Comparative results to other studies for C Reactive Protein.......................117 
5.22 Comparative results to other studies for Plasma Viscosity .........................119 
5.23 Comparative results to other studies for Procalcitonin ...............................120 
5.24 Comparative results for other confounders.................................................121 
5.24.1 Metformin use ....................................................................................121 
5.24.2 Antibiotic use .....................................................................................122 
5.25 Correlation effect of inflammatory markers with no confounders ..............123 
5.25.1 Clean wounds .....................................................................................123 
 5 
5.25.2 Cutaneous infection ............................................................................124 
5.25.3 Suspected osteomyelitis ......................................................................124 
5.25.4 Confirmed osteomyelitis .....................................................................125 
5.26 Correlation effect of inflammatory markers with confounders ...................125 
5.26.1 Clean wounds .....................................................................................125 
5.26.2 Cutaneous infection ............................................................................125 
5.26.3 Suspected osteomyelitis ......................................................................126 
5.26.4 Confirmed osteomyelitis .....................................................................126 
5.27.1 Correlation and the marker of Neutrophil Count .................................126 
5.27.2 Correlation and the marker of Haemoglobin .......................................127 
5.27.3 Correlation and the marker of C Reactive Protein ...............................127 
5.27.4 Correlation and the marker of Plasma Viscosity..................................127 
5.27.5 Correlation and the marker of Procalcitonin........................................127 
 
 
Chapter 6 Methodology The use of SPECT/CT in the diagnosis of osteomyelitis
............................................................................................................................ 128 
 
6.1 Research question........................................................................................128 
6.2 Research aim...............................................................................................128 
6.3 Research objective ......................................................................................128 
6.4 Protocol.......................................................................................................128 
6.5 Summary.....................................................................................................129 
6.6 Keywords....................................................................................................129 
6.7 Rationale of method ....................................................................................129 
6.7.1 Imaging techniques used.......................................................................130 
6.8 Imaging and the disease of diabetes.............................................................130 
6.9 Confounding factors....................................................................................131 
6.9.1 Recognition and Managing of confounding factors...................................131 
6.10 Sample ......................................................................................................132 
6.11 Method; Ethical statement .........................................................................133 
6.12 Method; Ethical considerations..................................................................133 
6.13 Inclusion  / exclusion criteria .....................................................................134 
6.14 Consent .....................................................................................................135 
6.15 Method of study ........................................................................................136 
16.15.1 Using MRI as the reference test ........................................................136 
6.16 Methodology.............................................................................................137 
6.16.1 Magnetic Resonance Image acquisition protocol.................................138 
6.16.2 Single Photon Computed Tomography / Computed Tomography Image 
acquisition protocol.......................................................................................139 
6.17 Diagnosing Osteomyelitis in a MRI scan ...................................................140 
6.18 Diagnosing Osteomyelitis in a SPECT/CT scan.........................................140 
6.19 Analysis of imaging results........................................................................141 
 
 
Chapter 7 Results The use of SPECT/CT in the diagnosis of osteomyelitis .... 142 
 
 6 
7.1 Sample characteristics .................................................................................142 
7.2 Scan results .................................................................................................143 
Table 7.2.1 Patient 1......................................................................................143 
Table 7.2.2.Patient 2......................................................................................144 
Table 7.2.3 Patient 3......................................................................................144 
Table 7.2.4 Patient 4......................................................................................145 
Table 7.2.5 Patient 5......................................................................................146 
Table 7.2.6 Patient 6......................................................................................147 
Table 7.2.7 Patient 7......................................................................................148 
Table 7.2.8 Patient 8......................................................................................148 
Table 7.2.9 Patient 9......................................................................................149 
Table 7.2.10 Patient 10..................................................................................150 
 
 
Chapter 8 Discussion The use of SPECT/CT in the diagnosis of osteomyelitis151 
 
 
Chapter 9 General Discussion, Recommendations and Conclusions ............... 154 
 
 
Chapter 10 Appendices...................................................................................... 158 
 
10.1 Ethics approval..........................................................................................158 
10.2 Ethics approval for amendment .................................................................161 
10.3 Research and Development approval .........................................................165 
10.4 Research and Development approval following ethics amendment ............168 
10.5 Patient Information Sheet ..........................................................................170 
10.6 Consent form.............................................................................................175 
10.7 Data collection tool ...................................................................................177 
10.8 Proposed consensus criteria for diagnosing osteomyelitis in the diabetic    
foot ...................................................................................................................180 
10.9 Histograms and summary statistics of each inflammatory marker in each 
wound condition ...............................................................................................182 
Neutrophil Count in clean wounds.................................................................183 
Haemoglobin in clean wounds (not including renal impairment) ...................183 
CRP in clean wounds ....................................................................................184 
Plasma Viscosity in clean wounds .................................................................184 
Procalcitonin in clean wounds .......................................................................185 
Neutrophil Count in cutaneous infection........................................................185 
Haemoglobin in cutaneous infection (not including renal impairment) ..........186 
CRP in cutaneous infection ...........................................................................186 
Plasma Viscosity in cutaneous infection ........................................................187 
Procalcitonin in cutaneous infection ..............................................................187 
Neutrophil Count in suspected osteomyelitis .................................................188 
Haemoglobin in suspected osteomyelitis (not including renal impairment) ....188 
CRP in suspected osteomyelitis .....................................................................189 
Plasma Viscosity in suspected osteomyelitis..................................................189 
 7 
Procalcitonin in suspected osteomyelitis........................................................190 
Neutrophil Count in proven osteomyelitis .....................................................190 
Plasma Viscosity in proven osteomyelitis ......................................................192 
Procalcitonin in proven osteomyelitis ............................................................192 
10.10 Regression analysis results ......................................................................193 
10.10.1 Regression models without confounders ...........................................193 
10.10.1.1 Regression models without confounders in clean wounds ..............193 
10.10.1.2Regression models without confounders in cutaneous infected  
wounds..........................................................................................................193 
10.10.1.3  Regression models without confounders in suspected      
osteomyelitis .................................................................................................194 
10.10.1.4  Regression models without confounders in confirmed     
osteomyelitis .................................................................................................194 
10.10.2 Regression models with confounders ................................................195 
10.10.2.1 Regression models with confounders in clean wounds ...................195 
10.10.2.2 Regression models with confounders in cutaneous infected      
wounds..........................................................................................................196 
10.10.2.3 Regression models with confounders in suspected osteomyelitis ....199 
10.10.2.4 Regression models with confounders in confirmed osteomyelitis ...200 
 
 
References .......................................................................................................... 203 
 
 
 
 8 
 
 
 
Acknowledgements. 
 
 
I wish to thank all my family and friends for their constant help during the long 
process of writing this thesis, for their unfailing support and encouragement to 
continue and belief that it would be finished.  Also to the staff within the Diabetes 
and Endocrine Centre, the Pathology and Imaging departments of the Royal 
United Hospital, Bath and Queens University, Belfast who provided clinical help, 
to Baileys Instruments for providing the 10 gramme monofilament for neuropathy 
testing and to Becton Dickinson pre-analytical diagnostics for providing the 
venepuncture materials.  
 
I also wish to thank my supervisors Dr Gordon Taylor Senior Lecturer Medical 
Statistics of the University of Bath and Dr Tony Robinson Consultant 
Endocrinologist at the Royal United Hospital, Bath.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9 
 
Abstract  
 
Soft tissue infection in a diabetic foot with an ulcer is often clinically obvious but the 
diagnosis of osteomyelitis underlying a diabetic foot ulcer is challenging. It has been 
calculated that there are over 1 million amputations worldwide for diabetes related 
complications every year, many preceded by an ulcer complicated by osteomyelitis.  
 
This research encompasses two studies attempting to add to the ways in which 
osteomyelitis is diagnosed.  
 
The first was examining the role of inflammatory blood markers in recognising and 
separating ulcers with cutaneous infection from both suspected and proven 
osteomyelitis. The response of the body to produce these markers when an injury 
occurs is well known but arguments exist as to the capacity of the individual with 
diabetes to do so. Despite the recognition and allowance for common confounding 
factors no trend was found. This study may have been more difficult than originally 
thought due to the many interactions of the diseased state of diabetes, the drugs used 
to control it and the many other confounders that would have influenced the 
inflammatory process and as such the level of the markers.  
 
The second study was comparing a new form of scanning technique (SPECT/CT) to 
the technique most commonly used as a ‘gold standard’ – MRI. The results of each 
type of scan were compared to the clinical diagnosis and each other. The SPECT/CT 
scan appears to show some good results and may be a more suitable scan for 
individuals who are unable to have a MRI for example due to the need to introduce a 
renally excreted drug to help make the images clearer but it does mean introducing a 
small amount of radiation into the individual. 
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Abbreviations 
 
 
 
 
ANC – Absolute Neutrophil Count 
BMI – Body Mass Index 
CKD – chronic kidney disease 
CRP – C Reactive Protein 
CVD – cardiovascular disease 
CT – computed tomography 
Cutinf – cutaneous infection 
Conom – confirmed osteomyelitis 
eGFR – estimated Glomerular Filtration Rate 
ESR – erythrocyte sedimentation rate 
Hb – Haemoglobin 
HbA1c – glycosylated Haemoglobin 
MRI – Magnetic Resonance Image/ing 
NC – Neutrophil Count 
NHS – National Health Service 
PCT – Primary Care Trust 
PCN - Procalcitonin 
PV –Plasma Viscosity 
PVD – peripheral vascular disease 
ROC – Receiver Operator Characteristic (of a curve) 
SPECT/CT – Single Photon Computed Tomography / Computed Tomography 
Susom – suspected osteomyelitis 
WBC – white blood cell 
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Glossary of terms 
 
Anaemia; a reduction in the Haemoglobin level below what is considered to be 
normal. The precise level to be considered pathological in this study is that proposed 
by the National Kidney Foundation (2001) of 11 g/ dl irrespective of gender.  
 
Body Mass Index; is determined by a person's height and weight. Because the BMI 
calculation requires only height and weight, it is inexpensive and easy to use. The 
Metric System uses the formula weight in kilograms divided by height in meters 
squared (weight (kg) / height (m)2). 
  
C Reactive Protein; an acute phase inflammatory mediator which is an 
immunoglobulin which in an antigen complex triggers the complement cascade. It 
has the property of being able to bind to a polysaccharide in the cell wall of 
pneumococci bacteria, the fraction of the wall being fraction ‘C’. The bacterial 
polysaccharides and phospholipids released by the damaged tissue also become 
activators of the Complement pathway. At the cellular level C Reactive Protein 
initiates opsinisation and phagocytosis of invading cells. It also binds to and 
detoxifies endogenous toxic substances produced as a result of tissue damage. 
‘Normal’ levels considered to be <5mg per litre.  
 
Cardiovascular disease; determined by the prescription and use of medications 
including anti-hypertensives, diuretics, beta-adrenoceptor blocking drugs, nitrates, 
calcium-channel blocking drugs (and other antianginal drugs), anticoagulant and 
antifibrinolytic drugs (when clearly used for cardiac disease), and lipid regulating 
drugs. 
 
Charcot (neuro-arthropathy); a non-infectious destruction of bone and joint found in 
individuals with neuropathy. 
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Chronic Kidney Disease; a decline in renal function noted to have been occurring 
over a period of time over the normal expected age related decline of <1ml/min/year. 
 
estimated Glomerular Filtration Rate (eGFR); Estimated using the Modification of 
Diet in Renal Disease (MDRD) method. The formula for this method uses serum 
creatinine, age and gender to determine renal function. It is recognised this may 
under estimate the extent of kidney damage present (Chudleigh, Dunseath, Peter et al 
2008) and no account was taken of the confounding factor of obesity. The bias of the 
MDRD increases with increasing body weight (ibid) which may be significant in 
type 2 diabetes. The same method was however used throughout the study. 
 
HbA1c; In the haemoglobin of the erythrocytes glucose sticks to the haemoglobin to 
make a 'glycosylated haemoglobin' molecule, called haemoglobin A1C or HbA1C. 
The more glucose in the blood, the more haemoglobin A1C or HbA1C will be 
present in the blood. As erythrocytes live for 8 -12 weeks before they are replaced by 
measuring the HbA1C it can produce a mean blood glucose over the last 8-12 weeks. 
A normal non-diabetic HbA1C is 3.5-5.5%. In diabetes 6.5% indicates ‘good’ 
metabolic control.  
Neuropathy; unable to detect a 10g monofilament in at least three sites from a total 
of ten tested (following the work of Leese et al 2007 and Leese 2007). 
 
Neutrophil Count; the number of neutrophils in a blood sample. One that is 
considered to be ‘normal’, that is without any pathology present to either cause either 
depression or elevation of the level, in venous blood is in this research defined as  
2 – 7.5 x 109 per litre. 
 
Peripheral Vascular Disease (PVD); the absence of one foot pulse in the affected 
foot either by palpation by hand or using a hand held Döppler. 
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Plasma Viscosity; a measure of the proteins in the blood. An increase occurs in the 
inflammatory reaction. The increase reduces the viscosity. ‘Normal’ in this series is 
between 1.5 and 1.72 mpas. 
 
Procalcitonin; under normal metabolic conditions is produced and secreted by the C 
cells of the thyroid. In severe bacterial infections and sepsis the origin is 
extrathyroidal. In marked inflammatory conditions the principal source is 
‘nonneuroendocrine parenchymal cells’ e.g. lung, liver, kidney, fat, muscle and 
stomach. The normal level is very low < 0.5 ng/ml. The level measured in the assay 
method used was 0.005 – 25 ng / ml. 
 
Reduced renal function; a reduction from the laboratory ‘normal’ level of 
90ml/min/1.73m2 for an estimated Glomerular Filtration Rate (eGFR) on at least 3 
occasions within the last 6 months prior to the clinic visit at which consent was 
taken. 
 
Renal anaemia; the anaemia associated with reduced renal function, in this study it 
was assumed to be present when the estimated Glomerular Filtration Rate (eGFR) 
was below 60ml/min in the six months preceding consent. 
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Chapter 1 Background  
 
This chapter will provide an explanation of the conditions that are both causative and 
contributory to the diabetic foot syndrome. It will attempt to explain why the 
problem of diabetic foot disease is so complex and why the prevention and treatment 
of ulcers, and in particular the complication of osteomyelitis, is so problematic. 
 
1.1Definition of diabetes 
 
‘Diabetes is an illness that is life long and chronic.  It is generally not acute, it is 
without a treatment that facilitates cure, but can be controlled. As a disease it is not 
painful and is not seen initially as life threatening, particularly in those with type 2 
diabetes’ (Fox and MacKinnon 2002). Diabetes mellitus was defined by the World 
Health Organisation in 1999 in the document ‘Definition, Diagnosis and 
Classification of Diabetes Mellitus and its Complications’ (World Health 
Organisation 1999) as ‘a chronic disease, in which inherited and/or acquired Insulin 
deficiency occurs. i.e. the pancreas does not produce enough Insulin or when the 
body cannot effectively use the Insulin it produces. This leads to an increased 
concentration of glucose in the blood (hyperglycaemia). Such a deficiency results in 
increased concentrations of glucose in the blood, which in turn damage many of the 
body's systems, in particular the blood vessels and nerves’. In addition to this clarity 
was provided about types of diabetes. This reduced the confusion caused by the 
various classifications. Prior to this definition, different descriptions of the various 
forms of the disease existed, using age or treatment type rather than pathology as a 
means of classification. This can be seen when seeing Insulin Dependent, juvenile 
onset or type 1 diabetes as one form and Non-Insulin Dependent, maturity onset or 
type 2 diabetes as another. This confusion was particularly the case when elderly 
people with type 2 diabetes became Insulin requiring – a stage of the disease process. 
Type 2 never becomes type 1. The accepted classification is now using the 
 15 
nomenclature type 1 and type 2. In Britain Diabetes UK, the largest United Kingdom 
charity involved in diabetes care for both health care professionals and people with 
diabetes, endorsed the changes in this document. This revision of the classification of 
the disease came about by following the clinical stages of the disease regardless of 
aetiology (as this may be unknown). 
 
1.2 The health impact of diabetes 
 
It is suggested that the world is facing an epidemic of type 2 diabetes (Wild et al 
2004). The worldwide prevalence of diabetes now exceeds 200 million, and is 
predicted to rise to more than 360 million in the next 20 years (ibid). Diabetes UK 
(2006) has used a model called the ‘Diabetes Population Prevalence model’ to 
estimate that in 2010 5% of the population of England will have diabetes. The 
Yorkshire and Humber Public Health Observatory estimate this to be some 2091783 
people in the United Kingdom (types 1 and 2 combined) (YHPHO 2009). Shaw et al 
(2010) combining prevalence studies suggest in the United Kingdom this figure 
would be 2140000 for the age group 20-79 years. Using the Diamond diabetes 
database as a proxy for a register as none exists locally this gives 22670 from a 
population of some 500000 in the catchment area of the hospital trust – 4.5%. 
 
The complications associated with long-term hyperglycaemia are many. Diabetes is a 
multi-system, multi-organ disease. In the lower limb the major complications relate to 
impaired circulatory capacity due to athero and arterio sclerosis and damage to the 
nervous system. These are discussed in more detail later. 
  
Diabetes, in developed countries, is a leading cause of death and contributes 
enormously to disability and reduced life expectancy (Amos, McGarty and Zimmet 
1997). This morbidity clearly has an enormous impact on healthcare resources 
(Mason et al 1999a). Foot ulceration is believed to occur in some 15% of the diabetes 
population during their lifetime (NHS Centre for Reviews and Dissemination 1999).  
Singh, Armstrong and Lipsky (2005) with updated figures advocate the figure could 
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be as high as 25%. In fact diabetic foot ulceration has a considerable morbidity of 
itself (Mason et al 1999b). They, again, suggested ulceration is found in some 5% of 
all people with type 2 diabetes. Currie et al in 1996 produced figures illustrating 
diabetes is responsible for 5.5% of all hospital admissions, 6.4% of out patient 
attendance and 9.4% bed-days in the British National Health Service. Foot 
osteomyelitis specifically is also recognised as an expensive and morbid disease 
(Henke et al 2005). Gordois et al (2003) estimated foot ulceration and amputations 
associated with diabetes consumed 5% of the National Health expenditure in 2001 
(some £3 billion). The National Health Service National Diabetes Support Team has 
suggested the financial burden of diabetic foot disease in 2008 (for the United 
Kingdom alone) was in the order of some £252 million per annum. 
 
A significant number of patients with diabetes will have multiple hospital admissions 
following surgery because of further episodes of foot ulceration and further 
amputations (Schofield et al 2006). The survival for those who develop foot disease 
resulting in amputation is very poor with a two year mortality of up to 50% 
(Ragnarson and Apelqvist 2004, Tentolouris et al 2004 and Schofield et al 2006). 
 
1.3 Diabetic foot disease 
 
While the spectrum of diabetes-related foot disease comprises chronic ulceration 
(with or without associated infection of soft tissue and / or bone), critical ischaemia 
and acute Charcot foot, most attention is focused on the management of the chronic, 
non-healing ulcer (Jeffcoate et al 2008). The health burden of diabetic foot disease is 
huge and has been recognised as an economic burden for both patients and their 
families (Boulton et al 2005) and as the most costly societal part of diabetes care 
(Reiber et al 1998, NHS Centre for Reviews and Dissemination 1999). More hospital 
beds are occupied by patients with diabetes associated foot problems than all of the 
other complications combined (Elkeles and Wolfe 1991). This is despite diabetes 
itself being the leading cause of both renal failure and also blindness in the working 
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age population. Patients with diabetes have a ten fold greater risk of soft tissue 
infection and bone infection in the lower extremity compared with healthy individuals 
(Singh, Armstrong and Lipsky 2005, Lavery et al 2006, Dinh, Abad and Safdar 
2008). The need for hospitalisation in foot disease often heralds the need for 
amputations (Dinh, Abad and Safdar 2008). Foot ulceration is recognised to be 
associated with frequent visits to health care professionals (Lipsky et al 2004). It is 
estimated some 20% of patients with diabetes with a foot infection are hospitalized at 
some point (Crolle et al 1996, Chatha et al 2005). In their large study of 1666 
consecutive patients Lavery, Armstrong and Wunderlich (2006) saw the development 
of a foot infection increases the risk of hospitalisation 55.7 times (95% CI 30.3 -102.2 
p<0.001) and the risk of amputation 154.5 times (95% CI 58.5 – 468.5 p < 0.001).  It 
has been suggested a diabetic foot problem increases the risk of non-traumatic 
amputation to 15 times that of the non-diabetic population (Krentz and Bailey 2001). 
Crolle et al (1996) estimate diabetes accounts for 80% of ‘infectious amputations’, 
Lavery et al (2006) place this nearer 90%.  It has been calculated that there are over 1 
million amputations worldwide for diabetes related complications every year (Bakker 
et al 2005) which equates to someone, somewhere, losing a leg because of diabetes 
every 30 seconds of every day (ibid). The data available locally for the numbers 
admitted for lower extremity amputations using Hospital Episode Statistics was in 
2003 (latest figures available) an age standardised ratio (in the general population) in 
Avon, Gloucestershire and Wiltshire Strategic Health Authority was 4 per 100000, 
Bath and North East Somerset Primary Care Trust being lower at 2 per 100000 (Ho 
2006). The data on both incidence and prevalence of osteomyelitis is not kept in part 
due to the difficulty in accurate diagnosis of the condition. Despite advances in the 
recognition of osteomyelitis the, now old, study by Gürlek  et al (1998) shows an 
odds ratio of osteomyelitis being a predictor of amputation with an odds ratio of 3.73 
(95% CI 1.08 – 12.6 p=0.04). Lipsky (2008) describes the development of 
osteomyelitis of the foot being a ‘potentially catastrophic event for a person with 
diabetes’. 
 
Although now long standing, the work of world-renowned diabetes physician Jan 
Apelqvist and his team in 1994 suggested costs associated with ulceration and non-
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traumatic amputation range from 43000 –65000 US dollars (1990 currency rates) per 
person per amputation. These figures are more useful than many of the preceding 
ones as it includes the costs that are necessary after amputations including 
rehabilitation and care provided in primary care. The range recognises the cost 
differences of minor and major surgery with the total cost to healing.  The Eurodiale 
study (Prompers, Huijberts, Schaper et al 2008) has updated this costing in a well 
constructed study using prospective data collection. In thirteen European countries 
data was collected and analysed over a weighted resource utilisation scheme and 
recognised the ‘highest costs per patient were for hospitalisation, antibiotics and 
amputations and other surgery’. Based upon data from 821 patients the costs 
compared to the work of Apelqvist et al (1994) the cost was € 10000 today compared 
to € 7412 (at 2005 exchange rates).  Economic comparisons are difficult because of 
many differences including study design (prospective vs. retrospective and primary 
vs. specialist care), selection of patients, type of foot lesions, type of healthcare 
systems and settings, treatment practice and time for analyses. Boulton et al (2005) 
also suggest the need to clarify proportional costs for different uses of resources in 
relation to total costs. 
 
Any clinician treating a patient with a diabetic foot infection should be considering 
several issues, key amongst these being how broad spectrum the antibiotic regimen 
should be and by what route (oral or intra-venous) should it be administered, when 
urgent surgical or other speciality consultations are required, and whether 
hospitalization is required (Jeffcoate and Harding 2003 and Lipsky et al 2004). It has 
been suggested the most important factor affecting these decisions is the clinical 
severity of the infection (Lipsky et al 2004 and Bakker et al 2005). The reasoning 
being made on sound evidence that poor treatment is likely to produce adverse 
outcomes that may ultimately mean loss of limb. Unfortunately at present clinicians 
have little evidence-based guidance for identifying which patients have a ‘severe’ 
foot infection or which clinical findings are associated with a poor outcome 
(Macfarlane and Jeffcoate 1997).  
 
 19 
Infection can be divided into three categories: superficial, local soft tissue and 
spreading (cellulitis), and osteomyelitis (Jeffcoate and Harding 2003). The liability to 
infection occurring with sensory neuropathic ulceration means that extensive tissue 
damage, and indeed destruction can occur rapidly, possibly without the injury being 
apparent.  Depth of wound was purported to be an accurate indicator by the Infectious 
Diseases Society of America’s Diabetic Foot Infection Classification System (Lipsky 
et al 2004a) and this now has been validated to predict outcomes of diabetic foot 
infection in a well conducted longitudinal trial of 1666 patients (Lavery et al 2007). 
The results of this study show statistical significance towards risk for any amputation, 
including higher-level amputation and any lower extremity amputation with 
increasing infection severity, all at p<0.001. In this same study the presence of 
infection to joint and / or bone level was noted to be in the ‘moderate’ to ‘severe’ 
categories with only ‘mild’ infection not contributing to the likelihood of the above 
noted outcomes.    
 
Acute osteomyelitis is frequently seen from contiguous spread from such tissue 
damage (Embil 2000), becoming chronic due to the lack of sensation allowing it to 
pass unnoticed (ibid).  Foot infection is perhaps the most important manifestation of 
diabetic foot disease owing to the potential for osteomyelitis, septic arthritis, and 
generalised sepsis with endotoxic shock, the latter having a 40%- 90% mortality rate 
(Sartoris 1994). There are also the consequences of a relatively high rate of limb 
amputation and poor long-term prognosis for survival being one of the most serious 
and costly problems associated with diabetes mellitus (Leichter et al 1988).  Chronic 
osteomyelitis typically has an insidious presentation, involving necrotic or ischaemic 
bone and surrounding soft tissue (Lipsky 1997). Almost all diabetic patients with foot 
osteomyelitis have chronic contiguous infections (ibid). A study by Roglic and Unwin 
(2010) estimates using the latest WHO life tables, country specific diabetes 
prevalence and relative risk of death for a person with diabetes, that in 2010, in 
Europe, the %age of deaths, attributable to diabetes will be 11% in age group 20-79 
years.  
 
 20 
The burden of diabetic foot disease is probably set to increase in the future since the 
contributory factors to foot disease, such as peripheral neuropathy and vascular 
disease, were present in more than 10% of people at the time of diagnosis of type 2 
diabetes in work which is now old (UKPDS 33 1998). The prevalence of diabetes has 
risen significantly since this time (see health impact). 
 
1.4 Pathways to ulceration 
 
The specific complications that occur to make the syndrome of ‘the diabetic foot’ are 
peripheral neuropathy, liability to infection and a reduced peripheral arterial blood 
flow – ischaemia, as described by Edmonds et al in their seminal paper of 1986. 
Slovenkai (1998) adds deformity in his ‘major threats’ to the diabetic foot. 
 
Foot wounds are amongst the most common and severe complications of diabetes 
(Singh, Armstrong and Lipsky 2005). This has also meant that they are responsible 
for the most frequent cause of diabetes associated hospitalization (ibid).  
 
The neuropathy that develops can be, in part, a loss of protective sensation - this is the 
major factor, allowing minor damage to pass unnoticed. Other neuropathies include 
motor imbalance with abnormal pressures associated with it leading to ulceration 
(Plank, Graham and Hyer 2000) and also local sympathetic denervation, this having 
the result of changing the levels of hydration in the skin (Hill et al 1999).  
 
The liability to infection occurring with sensory neuropathic ulceration means that 
extensive tissue damage and indeed destruction can occur rapidly, possibly without 
the injury being apparent. 
The poor circulation due to accelerated arteriosclerosis and increased atheroma 
formation leads to 
� Poor tissue perfusion (Krentz and Bailey 2001) 
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� A reduced inflammatory response in reaction to damage 
� A reduced ability to fight infection  
� A reduced ability to allow healing to occur (Hill et al 1999). 
 
The neuropathy of the autonomic nerves intensifies the poor inflammatory response 
potentially causing it to be greatly reduced. Both neuropathy and vasculopathy are 
strong independent risk factors for the incidence of foot ulcers (McNeely et al 1995). 
 
The interaction of these to produce the syndrome of the diabetic foot is illustrated 
well by the diagram in Figure 1.1 on page 22. 
 
1.5 Factors affecting ulcer development and healing capacity 
 
The assessment of the etiologic causes and determinants of potential to heal the 
diabetic foot include judgment as to the degree of nerve damage, circulatory 
impairment and extent of infection. There are numerous methods of estimating these 
aspects.  
 
It is now well accepted that peripheral neuropathy is an important pathophysiological 
risk factor for developing foot ulcers (McNeely et al 1995). Nerve damage, or 
neuropathy, has several features that affect the foot. Most commonly recognised is the 
numbness that allows damage to go undetected. Other elements include damage to 
nerves supplying foot muscles. The result of this is in small muscle paralysis and a 
structurally altered foot shape – becoming more prone to trauma and autonomic nerve 
damage. The poor autonomic functioning produces a foot with a poor inflammatory 
response to injury and a poor recovery from cold exposure both of which can allow 
unsuspected tissue damage to occur. The loss of pain sensation is usually clinically 
assessed by the use of a monofilament, a tuning fork or by the application of a  
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Figure 1.1 Pathways to foot ulceration in the diabetic patient  
(from Williams and Pickup 1999) 
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controlled electrical voltage using an instrument called a biothesiometer (or 
neurothesiometer). The latter two measuring response to vibration. 
 
These testing mechanisms can all be criticised for being evaluations of subjective 
attributes of sensations evoked by natural stimulation of cutaneous stimulation 
(American Diabetes Association and the American Academy of Neurology 1988). 
Diagnostic tests should fulfil the following criteria: validation (presence of an 
independent reference standard, adequate spectrum and number of patients, 
standardization, and soundly based selection), predictive value, manageability 
(reproducibility, performance in clinical practice) and hierarchy (implying that 
patients with the same score have difficulties or problems with the same items) 
(Meijer et al 2000).  It should be recognised that the clinical assessment should be 
tailored to the type of study, rapid, relatively simple measures may at times be 
appropriate as in this instance (American Diabetes Association and the American 
Academy of Neurology 1988). 
 
At present there is no international agreement on either the anatomic sites or number 
of sites to be tested using monofilaments (Forouzandeh et al 2005).  Nor is there 
agreement about what constitutes a significant loss of sensation to this testing method 
(ibid). Without consistent, reliable, measurements when testing sensation any form of 
assessment will not produce meaningful results (Mawdsley et al 2004). The 
sensitivity and specificity of tuning forks (used at the hallux) and monofilaments 
(used at eight sites) appear from the work of Miranda-Palma et al (2005) to be 
similar. Their research does appear to have followed the typical practice of use of the 
instruments and as such is practically useful in a clinical setting.  
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In work comparing a tuning fork to a Neurothesiometer, the tuning fork was found to 
be unreliable (O’Neill, McCann, Lagan 2006). The authors of this paper admit to the 
sample being very small (n=21) and accept with it being potentially biased based 
upon only one testing site with an overall agreement of the tools of 66.2%. 
Biothesiometry is one of few quantitative measures of neuropathy suitable for use in a 
busy clinical environment (Cassella, Ashford and Kavanagh-Sharp 2000).  
Of the screening methods the most reliable, valid and simple to use the monofilament 
emerges as the method of choice (McNeely et al 1995, Meijer et al 2000 and Meijer 
et al 2002). Olmos, Cataland, O’Dorisimo (1995) and Burton (2001) include 
cheapness in their list of positive attributes to the monofilament. The principle behind 
the use of the 10g monofilament is simple. It is calibrated to buckle when a force of 
10g is exerted, if the patient cannot feel the pressure the foot is considered to be 
neuropathic (Olmos et al 1995). The standardization of length and thickness of the 
filament is such that they buckle at reproducible forces. This means the amount of 
pressure administered when applied to the skin is more a function of the instrument 
rather than of the examiner (ibid) – this is clearly very important. However it is 
difficult to interpret the results of some of the papers to determine the methods and 
determination of the results. This is because in part to the inability to ensure the 
research subjects have understood the procedure to be undertaken (Holewwski et al 
1998) and that clinicians have undertaken a standardised methodology (ibid and 
Thomson et al 2001). Different methodologies may give dissimilar results and make 
it difficult to compare the data between clinicians and centres (ibid). After reading the 
work by Holewski et al (1998) and Burton (2001) the assessment procedure that was 
determined to be the most effective was the use of a monofilament on all of the 
metatarsal heads and also the plantar surface of the hallux with pathological loss of 
sensation being an inability to feel three, or more, of the six sites, tested. This is not 
dissimilar to the suggestion by McGill et al (1999) of the loss being determined by 
the loss of recognition at the first and fifth metatarsal heads.  
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Diabetes is the most powerful risk factor for peripheral arterial disease (Stuart et al 
2004). The unreliable nature of signs and symptoms of lower limb arterial 
insufficiency in diabetes means non invasive tests are essential to achieve effective 
screening (Fagila et al 1998).  
 
Assessment of arterial circulation, in the absence of the technically difficult and not 
easily available to all, (colour duplex scan and digital pulse pressures,) uses simple 
palpation or use of a döppler to determine presence or absence of pulses. This has 
been shown to be adequate for screening (Leese et al 2007).  
 
The simple palpation of pedal pulses has been assessed, against other screening 
methods, and found to be ‘highly sensitive .. in individuals with .. diabetes’ 
(Williams, Harding and Price 2005). However of note is the fact that the same authors 
report a reduced sensitivity and poor specificity of using pulse palpation when 
associated with neuropathy. Other factors have been noted to make the test subjective 
including ambient room temperature (Williams, Price and Harding 2003.)  
 
The evaluation of circulation can be seen to include skin changes characteristic of a 
‘foot at risk’ (Springett and White 2002). These changes are indicative of the 
potential for slow, or no, healing (ibid). The measurement of an Ankle: Brachial 
Pressure Index has not been found to be reliable (De Graaf et al 2001, Weatherley et 
al 2006). This was both using a döppler probe and DINAMAP™ blood pressure 
monitor.  An Ankle: Brachial Pressure Index is a ratio determined by the comparison 
of systolic arterial blood pressure in the arm to the foot; it should ideally be 1 i.e. the 
same in both vessels. Diabetes associated calcification of the vessel will elevate it as 
the calcified lower limb vessel will not be able to be compressed in reading the blood 
pressure making the value above 1, poor peripheral blood flow can reduce it below 1. 
Overall Leese et al (2006 and 2007) have demonstrated that using palpation of pedal 
pulses and using a monofilament to assess neuropathy can detect individuals likely to 
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be at ‘low, moderate or high risk of ulceration’ and predict capacity to heal or not. 
The tool they developed, and validated uses ‘simple’ pedal pulse palpation. The 
simplicity of this validated assessment method means it was adopted in this study. 
The recognition of the measures of sensory neuropathy being imperfect means any 
classification system such as that proposed by Leese et al (2006) and the S(AD) SAD 
developed by Macfarlane and Jeffcoate (1999) are qualitative and have a descriptive 
taxonomy. Some of the different ulcer classification systems have been evaluated and 
found to be useful for clinical classification, audit or research – never all. 
   
From the above it can be seen that the diabetic foot is a complex collection of disease 
processes that interact to cause further complications and that the recognition of 
pathology can itself be problematic. 
 
The risk for bone infection is recognised from a study by a well respected group of 
physicians interested in the diabetic foot as almost seven fold higher among patients 
in whom the wound penetrates to underlying bone (Lavery et al 2006). Despite the 
best efforts of even experienced clinicians many persons with osteomyelitis require a 
lower extremity amputation (Lavery et al 2008). Recognition of the severity of 
infection remains difficult. This study was developed in the anticipation that the use 
of simple blood tests may assist the early recognition of osteomyelitis.  
 
1.6 Amputations in diabetes - a brief summary 
 
It has been suggested by Vamos et al (2010) the most costly and devastating end 
point of diabetic foot problems is lower extremity amputation. The clinical prognosis 
for these individuals is very poor. Kald, Carlsson and Nilsson (1989), Reiber, Boyko 
and Smith (1995), and Toursarkissan et al (2002) all recognising between 9% and 
20% requiring a further amputation within twelve months and between 28% and 51% 
within five years.  
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In a prospective study of amputations Nather et al (2008) found 95% had diabetes and 
stepwise logistical regression analysis indicated the significance of both peripheral 
vascular disease and infection. Another study by Fosse et al (2009) shows a crude 
rate, not including traumatic etiologies, of 349/100 000 of amputations in people with 
diabetes. This makes it twelve times higher in people with diabetes compared to not 
having diabetes. These later figures were produced using a nationally based hospital 
discharge database recording major diagnoses and procedures based on International 
Classification of Diseases (ICD) version 10 coding. The acknowledgement that 
diabetes per se is not provided with a specific cost allowance may result in 
underreporting. Vamos et al (2010) using a very thorough search of ICD 10 codes 
with hospital episode statistics have shown an alarming rise in both major and minor 
amputations in type 2 diabetes. They suggest in the period of 1996-2005 minor 
amputations have risen from 2.4 to 4.1 per 100000 population, with major 
amputations rising from 2.0 to 2.7 per 100000 population. The personal and societal 
cost of any amputation is clearly immense in diabetes (Vamos et al 2010). 
 
Osteomyelitis as an infective process is a common precursor of amputation 
particularly in diabetes. The other factors affecting healing in diabetes often result in 
amputation being used as cure where medical treatments fail. This is acknowledged 
by Ebsov, Schroeder and Holstein (1994), Jeffcoate and van Houtum (2004) and 
Congdon (2006) who all suggest that the upward trend is likely to reflect the increase 
in incidence and prevalence, improved survival of diagnosed individuals, greater 
awareness of diabetic foot disease and improved specialist services being available to 
individuals who may have previously died with an unhealed ulcer. 
 
This chapter has given some background into why diabetic foot disease and in 
particular bone infection is so problematic and needs further investigation. 
 
The following chapters will give further information about the literature searching 
strategy of the material used within this thesis, and the background to the work 
carried out, the nature, diagnosis and impact of osteomyelitis, the immune respsonse 
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to infection, the methodologies involved in the studies performed and discussion of 
the results found. 
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Chapter 2 Introduction 
 
This chapter will establish the purpose of the studies of this thesis in relation to the 
work that has been performed in the area to date. It will explain the concepts of the 
reaction that occurs following an infection and how the studies undertaken here 
relate to this. 
 
2.1 Literature review search strategy 
 
The literature was searched for material written from the 1970 to the present day for 
articles about diabetes foot disease and both imaging techniques and blood markers. 
Little work about the subject areas has been written and so a considerable time 
period was required to be examined. Additionally the various ulcer classification 
systems were considered to determine which maybe of use within the study. The 
databases used included CINAHL, MEDLINE, British Nursing Index, Embase and 
AMED. The only limit being placed being ‘Humans’. 
 
 
2.1.1 Review of haematological markers;  
 
The search for the use of blood tests in the recognition, diagnosis or monitoring of 
osteomyelitis included using the terms ‘foot ulcer’, ulcer* (as a truncation for ulcers 
and ulceration) and ‘diagnos*, as above, ‘bone infection’ and ‘osteomyelitis’ with 
the expressions of ‘acute phase reaction’ and ‘inflammatory marker’. In addition 
each marker was included into this baseline search with the different terms 
commonly used for each marker, for example Leukocytes (and Leucocytes, or white 
blood cells) as a broad term and also Neutrophils specifically and both plasma and 
blood viscosity (and rheology). The different spellings of Haemoglobin and anaemia 
between the English and American medical publications was recognised and 
included in the search strategy. 
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Only one study was found to be prospective with consecutive recruitment and 
include both in and out patients (Newman et al 1991). The vast majority of papers 
found were found to only have studied hospital in patients and as such were of 
limited applicability to this study. This is a surprise as the use of an out patient 
setting to deliver diabetes care is not unique to the British Isles.  
 
2.1.2 Review of imaging; 
 
The search terms included ‘imag*’ as a truncation of image and imaging ‘diabet*’, 
‘diagnos*’, Diabetes and diabetic being truncated to ‘diabet*’ to include both, 
diagnos* being a truncation of diagnosis and diagnostic. 
 
 
2.1.3 Review of ulcer classification system;  
 
The search terms used were diabet*, ulcer*, both as before, and classif* to find the 
classifications and then combing each of the found systems with varying 
terminology to determine reliability, validity and robustness.  
 
2.2 Defining osteomyelitis 
 
Bone infection in the diabetic foot is always a complication of a pre-existing infected 
foot wound (Hartemann-Heurtier and Senneville 2008). Despite this the diagnosis of 
osteomyelitis underlying a diabetic foot ulcer is challenging because of the lack of a 
single, non invasive, highly sensitive and specific test (Dinh, Abad and Sadfar 2008).  
 
A continuum has been recognised by Lipsky (1997) that involves soft-tissue 
infection, leading to osteitis and on to osteomyelitis. As a pathophysiological 
sequence it is very difficult to discern where an individual wound lies, as the signs 
and symptoms are subtle and no different between bone and soft-tissue (ibid). The 
 31 
recognition of bone infection is compounded by the fact that there is no consensus in 
defining osteomyelitis (Berendt and Lipsky 2004). As a result of this diagnosis has 
often been made on a combination of good clinical judgement and tailored 
investigations (ibid). To make it more confused Delcourt et al (2004) maintain that 
diagnosis is often difficult clinically but Paluska (2004) agrees with Berendt and 
Lipsky (2004) suggesting the diagnosis is primarily a clinical one. Treece et al 
(2004) agree stating ‘because there is a relative scarcity of scientific evidence on 
which to base decisions management programmes are to a large extent defined by 
the experience and skill of the individual clinician, as well as their preconceptions, 
available resources and the conventions and constraints of local health care’. 
Although clinical judgement may be misleading in the low grade infections due to 
lack of clinical manifestations (Newman et al 1991) it is proposed as a measure to be 
used in the initial classification of the ulcers in this study followed by imaging where 
appropriate (see later).  
 
Using the clinical ‘probe to bone’ test, or visualising bone, will be used as an 
inclusion criterion is justified as this simple clinical test has a high specificity 
(Newman 1991, Grayson et al 1995, Crolle et al 1996, Chatha et al 2005). Jeffcoate 
and Lipsky (2004) are bold enough to categorically state ‘bone that is visible at the 
base of an ulcer is likely to be infected’.  The author regularly uses this in clinical 
examination, with other factors if osteomyelitis is suspected. Grayson et al (1995) 
also recognised 66% sensitivity and a positive predictive value of 89% for this 
simple clinical test.  Kaleta, Fleischli and Reilly (2001) used this investigation as a 
diagnostic test in their study of osteomyelitis. Arguments have been made against the 
claimed sensitivity and predictive values of this test on the grounds of pre-test 
probability (Shone et al 2006). The result of these latter researchers suggested a 
prevalence of 20.2% of ulcers are complicated by osteomyelitis and was based on 
clinical signs of infection. Both reports give a high prevalence rate but it is important 
to recognise that they were both conducted in specialist clinics where the rate may be 
expected to be higher. Even more lately Lavery et al (2007) have suggested, 
 32 
comparing the probe to bone test to their gold standard of positive bone biopsy 
culture, which produced a positive predictive value of between 57% and 62%.  A 
possible criticism of the original research is that it was based on in-patients that were 
in hospital because of infection; a possible criticism of the later work by Shone et al 
(2006) is that it only involved 81 patients.  Only in the paper by Lavery et al (2007) 
is a definition of a positive test given as ‘palpating a hard or gritty substance’. They 
also raise the problems associated with inter-rater and intra-rater reliability that has 
yet to be evaluated in any study. However the available evidence to date does not 
justify using any one, or combination of, clinical findings as a diagnostic criterion 
(Jeffcoate and Lipsky 2004). 
 
In addition to the lack of definition of what the disease process actually is there is no 
clear agreement as to when the process can be classified as acute or chronic. The 
stage of osteomyelitis is defined as being related to the clinical course, or 
histological findings, or duration by Paluska (2004). There is some agreement 
between Mandell (1996), Jones, Anderson and Stiles (1997), Lew and Waldvogel 
(1999), Cunha (2002) and Paluska (2004) when they refer to chronicity relating to 
time – specifically over 10 days according to Lew and Waldvogel. ‘A continuous 
low grade’ is a definition used by Mandell (1996).  Haas and McAndrew (1996) state 
chronic osteomyelitis is defined by its ‘refractoriness to cure by antimicrobials 
alone’. 
 
A scheme for the diagnosis of diabetic foot osteomyelitis for research purposes was 
reported by Berendt et al in 2008 (see Appendix 8). This was in an attempt to ensure 
that comparisons of outcomes at different medical centres could be compared.  The 
report was from a consensus from the International Working Group on the Diabetic 
Foot and consisted of extensive literature searching and expert opinion. The paper 
reporting the suggested scheme acknowledges that a consensus diagnostic scheme 
for research requires greater specificity than clinical practice that requires sensitivity. 
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Additionally it is recognised that where no single criterion is sufficiently reliable to 
make an absolute diagnosis the results of a range of clinical, laboratory and imaging 
findings is likely to be beneficial. This is where this reported research may add to the 
body of knowledge about the use of laboratory data. 
 
The sequence of events when infection in a diabetic foot spreads can be rapid, 
occurring in days or even hours, especially in an ischaemic limb (Lipsky et al 2004). 
This is illustrating again the need for accurate diagnosis. The role foot ulceration has 
in association with pedal osteomyelitis is graphically illustrated by Bamberger, Daus 
and Gerding (1987) when they claim 94% of bone infection is directly associated 
with ulceration. Infection plays a major role in healing impairment, hospitalization 
and limb loss (Jeffcoate and Harding 2003). Dealing with osteomyelitis has been 
suggested to be the most difficult and controversial aspect in the management of 
diabetic foot infections recognised by all Lipsky (1997), Embil (2000), Snyder et al 
(2000), Snyder (2000) Lipsky et al (2004) citing Eckman et al (1995), and Jeffcoate 
and Lipsky (2004) to emphasise this point. This also reinforces the importance of 
early and accurate diagnosis. 
 
2.3 Osteomyelitis as a specific complication in diabetes 
 
 
The lifetime risk of developing a foot ulcer, the most common precursor to 
osteomyelitis, is about 25% for individuals with diabetes (Singh, Armstrong and 
Lipsky 2005). A well conducted study using a large number of patients in a 
prospective longitudinal study and including out patients by Lavery et al (2006) 
indicates over half develop some form of infection and some 20% develop bone 
culture - proven osteomyelitis. Although soft tissue infection in a diabetic foot with 
an ulcer is often clinically obvious, the diagnosis of osteomyelitis underlying a 
diabetic foot ulcer is often challenging (Dinh, Abad and Sadfar 2008). Osteomyelitis 
(bone infection) most commonly occurs in elderly patients when they have diabetes 
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or peripheral vascular disease (Mader, Shirtliff and Calhoun 1997, Cunha 2002). 
Vascular disease itself is a complication of diabetes. The true prevalence of 
osteomyelitis in diabetic foot ulcers is not known (Giurato and Uccioli 2006). 
Wrobel and Connolly (1998) and Newman et al (1991) suggest from complex 
studies it may be as high as 60%. This Newman et al (ibid) study used bone biopsy 
and culture that is not commonly performed in the United Kingdom. Jones, 
Anderson and Stiles (1987) note the ’high rate’ of occurrence in people with diabetes 
in their series studying osteomyelitis in a general hospital. Typically bone 
contamination results from the spread of infection from soft tissue in an ongoing 
process that can take several weeks. Major pathogens adhere to bone by expressing 
adhesion factors for components of bone matrix (Hartmann-Heurtier and Senneville 
2008). Accurate diagnosis of osteomyelitis is essential to optimise outcomes (Dinh, 
Abad and Sadfar 2008). It is an infection involving the periosteum, cortex and/or 
medullary canal (Cunha 2002). It has been estimated that osteomyelitis complicates 
approximately 30% of diabetic foot infections (Keidar et al 2005 and Jeffcoate et al 
2008). It is clinically difficult to distinguish between infective and neuropathic 
lesions of bone (the latter being called either Charcot joints or neuroarthropathy) 
(Berendt and Lipsky 2004) and yet it is crucial as the treatment is radically different, 
although both often end up resulting in a lower extremity amputation (ibid). This is 
because osteopenia, bone destruction and bone repair is common to both conditions 
(ibid). Bone infection however is almost always a consequence of neuropathic skin 
ulceration, leading to soft tissue infection and subsequent bone involvement (Mader, 
Shirtliff and Calhoun 1997, Berendt and Lipsky 2004). The risk of infection is seven 
times higher in those whose wound penetrates to the underlying bone (Lavery et al 
2006). Despite this work by Jeffcoate et al (2008) as the representatives of the 
International Working Group on the Diabetic Foot there are no clear protocols for 
the defining and treating osteomyelitis of the foot in diabetes. A progress report has 
been produced by Berendt et al (2008) using a combination of clinical, imaging and 
laboratory results to produce a suggestive diagnostic algorithm but this has yet to be 
validated. This algorithm does not include all the tests reported in this thesis 
investigating the use of inflammatory blood markers. 
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There is no clear evidence what proportion of ulcers are complicated by 
osteomyelitis. Estimates have been made and have been discussed earlier. A very 
crude estimate made by the author using doctors specifically interested in diabetes 
and podiatrists interested in diabetes at a national conference about diabetes gave 
wide ranging estimates of the number felt to have bone infection. This varied from 
5% to 60% in doctors and from 2% to 40% in podiatrists. Lavery et al (2007) in a 
longitudinal cohort study found 247 of 1666 patients developed foot wounds (15%) 
and of these osteomyelitis was found in 30 (12%). They say that of these 30 12% had 
a foot wound and 20% a foot infection. It is not clear if the infection was a 
complication of the wound, it would be reasonable to suggest so but the researcher 
has experience of a Magnetic Resonance Imaging (MRI) scan suggesting bone 
infection in an individual with no open wound following bone surgery some months 
previously. Using the minimum number of individuals attending the researcher’s 
specialist diabetes foot clinic for whom a MRI scan in 2007 was requested as a proxy 
15 from a total of 158 (9%) attending a specialist diabetes foot clinic may have had 
osteomyelitis. In 2008 again 158 patients were seen 12 had an MRI scan (7.5%) and 
26 admissions occurred. This is not a true representation as some will have been 
diagnosed from the clinical presentation of bone in the base of an ulcer and / or plain 
X ray. Nor does this figure include those for whom a MRI was ordered when they 
were an in patient. Other reasons for attending the clinic also exist and for some of 
these there will be reasons for requesting MRI scans. It is known this will be 
primarily Charcot neuroarthropathy and also at least two patients had fractures and 
one a soft tissue syndrome. These three diagnoses were made only after the MRI 
scan. Using admission as a proxy 34 individuals were admitted to an acute General 
Hospital the prime reason would have been to administer intra venous antibiotics for 
‘severe’ infection. These 34 individuals accounted for some 45 episodes of care with 
a range of number of admissions per individual being between 1 and 4. In 2009, up 
to the end of November the number of individuals seen was 177 with the number of 
visits ranging from 1 to 15. The total number of admissions was 45. The number sent 
for MRI scans was 22. None of the years has recognised those individuals who are 
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admitted direct from primary care, it only accounts for those who were admitted via 
the specialist Diabetes Foot Clinic.  
 
Using Hospital Episode Statistics of amputations can also be used to act as a proxy 
for numbers with osteomyelitis and this too is not without its problems. Hospital 
Episode Statistics themselves are not without criticism. They have in the authors 
experience missed admissions related to diabetic foot disease when using the codes 
to trawl for patients to include in an audit. This under estimation, in this case of 
amputations, has also been recognized following a prospective study in a relatively 
stable population by Rayman et al (2004). Comparing their prospective data with 
data Hospital Episode Statistics collected using the International Classification of 
Diseases 9th revision between 4.2 and 8.7% of amputations were missed. This means 
we may be missing (and under treating) a large proportion of patients. 
 
Some of the patients with osteomyelitis require hospitalization for diagnostic studies, 
surgery to remove infected or necrotic bone and / or lengthy (and usually parental) 
antibiotic therapy (Lavery et al 2009). Despite recent advances many patients with 
osteomyelitis fail with aggressive medical therapy and resort to surgical therapy 
(Haas and McAndrew 1996). An early diagnosis of osteomyelitis is essential to 
optimise therapeutic intervention (Tan and File 1999, Delcourt et al 2004, Zgonis 
and Roukis 2005). A precise diagnosis of osteomyelitis and the causative organism is 
clearly preferable when a prolonged course of therapy, usually antibiotics, or local 
debridement or amputation is advised (Grayson et al 1995, Crolle et al 1996).  
 
The optimal approach to diagnosing (and managing) osteomyelitis in the foot in 
diabetes is unclear (Jeffcoate and Lipsky 2004). Delays in diagnosis occur because 
infection can mimic other medical conditions (see Charcot earlier) and often the 
classical clinical signs are absent particularly when associated with diabetes (Cunha 
2002, Paluska 2004, Jeffcoate and Lipsky 2004). Lipsky et al (2004) suggest more 
than 50% of patients do not exhibit the classic local signs of pain and swelling or 
systemic signs of chills, fever, and metabolic disturbance (Paluska 2004). Tan and 
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File (1999) advocate searching for deep infection, notably osteomyelitis, when any 
suspicion of infection occurs in the diabetic foot. Typically in diabetes this would be 
suggested by deep plantar ulceration (Cunha 2002). Even in specialized foot care 
centres peripheral arterial occlusive disease and osteomyelitis still represent the 
greatest challenge in the strife for limb salvage (Kraus et al 2002). Jeffcoate and 
Game (2006) candidly say ‘the presence of osteomyelitis has major implications for 
limb salvage’, Cavanagh et al (2005), also bluntly, point out that sometimes 
‘infection puts an individual s life at risk’. In this reported research the foot ulcer is 
taken to mean the common and classical ‘mal perforans’ ulceration.  
 
If the infection extends into fascial planes and foot compartments it may ultimately 
result in serious systemic illness, excessive soft tissue loss or compromise the 
mechanics of the foot, any of which may make amputation the only option (Hill, 
Holtzman and Buse 1999). 
 
2.4 Diagnosing osteomyelitis 
 
 
The diagnosis of osteomyelitis underlying a diabetic foot ulcer is challenging as few 
clinical features are useful in making the diagnosis. Accurate and timely diagnosis of 
osteomyelitis is extremely important to prevent proximal migration of the infection 
and amputation (Kaleta, Fleischli and Reilly 2001). 
 
2.4.1 Gold standard diagnosis 
 
The definitive diagnosis of osteomyelitis is made using a biopsy to culture 
organism(s) from the site of infection (Wu et al 2007). The rate of positive diagnosis 
even with image guidance for biopsy sighting is reportedly low (41 of 75) (ibid). The 
fear of introducing infection and the need for a surgical practitioner to perform the 
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biopsy make the consideration of non invasive imaging strategies far more attractive 
(Kapoor et al 2007).  
 
Bone specimens, obtained either percutaneously or at the time of surgery, may 
become contaminated, resulting in a false-positive test result, or the infected area 
may be missed during sampling (i.e. sampling error), resulting in a false-negative 
result (Dinh, Abad and Safdar 2008). Culture results may be false negative if the 
patient has recently had antibiotic therapy. Histopathological examination results 
may be false negative if the bone has evidence of necrosis or inflammation for other 
reasons (ibid). 
 
The definition of what constitutes a reliable microbiological test in osteomyelitis 
remains controversial (Hartemann-Heurtier and Senneville 2008). It has been 
suggested that the results of superficial sample cultures do not correlate with those of 
bone (Wheat et al 1986 and Sutton et al 2000). Wheat et al (1986) performed a 
prospective study on one hundred and thirty one infections in patients with diabetes 
and foot wounds. The enquiry examined individuals admitted to an acute teaching 
hospital and the final analysis was on fifty four infectious episodes. This reduction in 
numbers was due to specimens that were unable to be taken without contact with the 
ulcer or other openly draining lesions and as such were classified as unreliable. A 
comparison of organisms found in reliable and unreliable specimens showed that 
reliable specimens were more closely related to clinical findings. The work by 
Sutton et al (2000) was a retrospective review of diabetes associated suspected bone 
infection. The definition of a positive result for osteomyelitis was in-precise in that it 
was by either positive bone culture or histology or imaging and prolonged follow up. 
This poor association has also been confirmed in a study by Senneville et al (2006) 
where surface swab culture and bone fragments taken transcutaneously via normal 
skin had a low correlation of results. This study was on individuals in whom no 
antibiotic therapy had been used for the four weeks preceding biopsy which although 
ideal it is rarely achievable. This is because of the ethical dilemma of not treating a 
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clinically evident infection. The superficial ulcer cultures were included if taken at 
least three days prior to biopsy. This low relationship maybe in part due to the 
surface swab finding skin commensal bacteria, the deeper tissue sampling showing 
the obligative and facultative anaerobes found in deep tissue infection. No studies 
appear to have compared the two methods available for bone sampling – 
transcutaneous needle aspiration and percutaneous bone biopsy. 
 
2.4.2 Other tests used clinically 
 
As a result of the paucity of accuracy in diagnosis has often been made on a 
combination of good clinical judgement and tailored investigations (Lipsky 1997). 
To make it more confused Delcourt et al (2004) maintain that diagnosis is often 
difficult clinically but Paluska (2004) agrees with Berendt and Lipsky (2004) 
suggesting the diagnosis is primarily a clinical one. Treece et al (2004) agree with 
the basis being clinical stating ‘because there is a relative scarcity of scientific 
evidence on which to base decisions management programmes are to a large extent 
defined by the experience and skill of the individual clinician, as well as their 
preconceptions, available resources and the conventions and constraints of local 
health care’. Although it should be remembered clinical judgment may be misleading 
in the low grade infections due to lack of clinical manifestations as noted and 
discussed by Newman et al (1991) and Delcourt et al (2004).  
 
The controversies of not having a precise definition and with that a firm diagnostic 
criteria have been discussed in section 2.2 
  
The most definitive work so far has been by The International Working Group on the 
Diabetic Foot. They have published a paper headed by Berendt et al (2008) on 
‘Diabetic foot osteomyelitis: a progress report on diagnosis and a systematic review 
of treatment’ in which a diagnostic algorithm is proposed. This is in Appendix 10.8. 
This algorithm has yet to be validated. It includes criteria of bone biopsy, MRI, plain 
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X ray, Erythrocyte Sedimentation Rate (as the only inflammatory blood marker) and 
clinical signs and symptoms. 
 
2.4.3 Imaging techniques in the diagnosis of osteomyelitis 
 
It has been suggested that the use of imaging studies may help diagnose or better 
define and detect pathological findings in bone (Lipsky et al 2004). However the 
many diagnostic tests offered often yield equivocal results (ibid). Great care must be 
exercised in determining the usefulness of the imaging tests as, of necessity; they 
have been evaluated in patients selected on the grounds of clinical suspicion. This 
means the results are heavily influenced by the pre-test probability of the presence of 
disease (Wrobel and Connelly 1998). Although the need for well designed studies 
with a post-test diagnostic probability has been recognised these do not appear to 
have been performed (Lipsky et al 2004). Additionally many of the studies that are 
set up to assess the diagnostic characteristics of these imaging tests have limitations 
regarding the choice of reference test to conclusively establish the diagnosis of 
osteomyelitis (Dinh, Abad and Safdar 2008). 
 
Plain radiographs have the advantage of being convenient, inexpensive and 
reproducible (Paluska 2004). However early in the disease process plain radiographs 
will be normal, (Longjohn, Zionts and Scott 1995) or, not clearly differentiating 
between both infection and Charcot joint (Grayson et al 1995). The osteolytic 
changes of bone loss are not evident on plain film until between 30% and 50% of 
bone mineral has been removed (Waldvogel, Medoff and Swartz 1970, Paluska 
2004). Jeffcoate and Lipsky (2004) reckon on this being at approximately 4 weeks 
post disease. The differences in reported sensitivity, 43%-75%, and specificity, 75%-
83%, suggest that this should not be used as a definitive diagnostic test (Boutin et al 
1998 and Tumeh and Tohmeh 1991 both cited in Paluska 2004). False positive plain 
film X rays have been noticed to be associated with neuropathic joints, degenerative 
or inflammatory arthritis (Crim and Seeger 1994).   
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Magnetic Resonance Imaging (MRI) is used commonly as the gold standard in the 
United Kingdom (where bone biopsy although the accepted criterion is rarely used, 
Jeffcoate and Lipsky 2004) to recognise infection because it presents both a detailed 
accurate image. This includes areas of soft tissue oedema and bone abscesses 
(Mader, Cripps and Calhoun 1999).  MRI reveals active medullary osteomyelitis as 
an area of abnormal marrow with altered signal. Marrow oedema gives the same 
altered signal and as such reduces the specificity because of other disease processes 
such as acute Charcot neuroarthropathy. 
 
Sartoris (1994) has performed a meta analysis on ten previous studies to assist 
recognition of abnormal soft tissue signals with MRI. It is also more sensitive and 
precedes these changes than plain film or simple Computerised Tomography (Crim 
and Seeger 1994). MRI can be used to give good structural visualization and spatial 
resolution (Paluska 2004), superior contrast resolution and a multiplanar 
examination (Flemming, Murphey and McCarthy 2005). Reported sensitivities are 
high ranging from 88%-100% with a specificity of 53%- 94% (ibid). It is recognised 
that specialist technical and interpretive skills are required to achieve these levels 
(Berendt and Lipsky 2004).  
 
This puts forward the suggestion of another test, for example inflammatory blood 
markers, being used in addition.  Another meta-analysis of MRI studies has shown 
that the procedure performs well in the diagnosis of osteomyelitis of the foot and 
ankle in adults (Kapoor et al 2007). This study was well conducted in that it 
acknowledges the problems associated with the combination of the studies; notably 
using English language only articles, few studies followed the assessment of 
individuals with scan results read blind to other diagnostic techniques or with biopsy 
as a confirmatory tool, however the presence or absence of Charcot foot was not 
typically documented and it is recognised that this is one of the potential differential 
diagnoses particularly in the diabetic population.  The advancements made in the 
technique are also acknowledged as possible ways of diagnosis being made with 
greater certainty in the more recent studies, for example the use of Gadolinium as a 
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tracer in suspected infection and the use of secondary diagnostic signs such as 
cortical breaks in diagnosis of Charcot neuroarthropathy.  
 
Nuclear medicine techniques alone usually are considered to be either bone scans or 
leukocyte scans. Nuclear medicine techniques of leucocyte scanning involve the 
introduction of a nuclear label by intra venous injection. The label, or tracer, has 
been developed so that it attaches to anti-granulocyte monoclonal antibodies in the 
blood. The diagnosis is made by the recognition of areas of inflammation, recognised 
by increased blood flow, and hence uptake of the marker, has been found not to be 
particularly sensitive. Bone marrow cannot be visualized directly causing difficulty 
in determining the extent of disease (Sartoris 1994). Boorgula et al (2004) looking at 
34 patients reckoned on a 55.55% sensitivity with a 11.7% false negative result 
which is not acceptable in a disease process that can have such rapid deterioration 
and devastating consequences. The false positives can be due to neuropathic joint 
changes and cellulitis – both very common in the diabetic foot (Crim and Seegar 
1994). It has been proposed the false negative result level can be overcome and 
‘confirmation of a negative result with confidence’ be given if a fourth scan is taken 
at 24 hours after the initial introduction of the marker (Jones, Chalmers and Dunlop 
2001, Rubello et al 2004.)  Rubello et al (2004) also suggest however that ‘if 
evidence of a high uptake intensity in the early LeukoScan imaging was a strong 
indicator of infection and delayed imaging in these cases did not improve 
specificity’. This study to provide this evidence against the fourth scan was 
performed on some 220 patients 78 of who had diabetes and an associated infected 
foot ulcer. The sensitivity did not change from 91.9% but increases were noted in the 
specificity from 75.0% to 87.5%, the negative predictive value from 70.5% to 73.6% 
and the positive predictive value from 93.4% to 96.6%. 
 
All bone scans are recognised to give false negatives in patients with markedly 
diminished blood flow to the extremities (Eckman et al 1995, Embil 2000) which is 
known to be the case frequently in diabetes. Early changes are picked up but are not 
specific to infection (Kapoor et al 2007). False positives also occur because of the 
similar uptake in both Charcot neuroarthropathy and infection (ibid). White blood 
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cell scans are not easily interpreted to differentiate soft tissue infection from bone 
infection (ibid). 
 
Computerised Tomography (CT) is a well established technique that allows 
examination of bones and joints in any anatomic plane required (Flemming, 
Murphey and McCarthy 2005). It is more sensitive to cortical bone changes than 
plain X Rays (Crim and Seeger 1994). Used alone its sensitivity is reduced from 
87% in the calcaneus to 25-33% in the mid foot where many diabetic foot lesions 
occur (ibid).  When the transition from infected to healthy bone extends over 
multiple layers of scan it has been argued from a clinical view point that a degree of 
subjectivity is required to predict the proximal margin of disease (Sartoris 1994). 
 
Bone scintigraphy and labelled white cell scans are sensitive in the detection of bony 
pathology but the nature of complex three dimensional anatomy of the foot means 
localization of the abnormality has in the past been difficult (Fielding et al 2006). 
The new hybrid Single Photon Emission Computed Tomography / Computer 
Tomography (SPECT/CT) offers the opportunity to combine the functional 
information of nuclear medicine with the accurate anatomical information provided 
by CT (ibid).  The multi planar images can then be reconstructed mathematically to 
produce a three dimensional set of images (Gemmell and Staff 1998). The diagnostic 
information is provided by the action of the injected pharmaceutical drug; a 
radioactive marker. The radioactivity is simply to allow recognition of the 
localization of the drug and as such is provided by a very low dose (Sharp 1998).  
 
2.4.4 Reference test for diagnosis 
 
To confirm the presence of osteomyelitis in the proposed research an imaging 
technique will be used. The imaging techniques for diagnostic approaches suggested 
by Berendt and Lipsky (2004) are plain radiograph alone in many cases despite its 
poor sensitivity and Magnetic Resonance Imaging (MRI) (in preference to isotope 
scanning due to the better sensitivity and specificity). Paluska (2004) suggests the 
 44 
use of plain radiographs, nuclear medicine testing, Computerised Tomography (CT) 
or MRI. Despite apparent confusion and contradiction over the choice of technique 
due to the highest sensitivity and specificity being obtained by using a MRI scan this 
will be used to as the reference test to recognise infection in this study reported here.  
Diagnostic sensitivity has been reported to be between 90% and 100% by (Eckman 
et al 1995, Crolle et al 1996, Craig et al 1997 and Enderle et al 1999). The problem 
is distinguishing between other causes of bone marrow oedema. Nevertheless 
Enderle et al (1999) report positive and negative predictive values of 93% and 100% 
respectively. 
 
2.5 The immune response 
 
 
The immune response developed in reaction to the infection of osteomyelitis, like all 
infections, is as for that to foreign substances – it is acquired immunity. Acquired 
immunity involves two parts; the humoral immunity involving antibody production 
plus complement and cell-mediated immunity. Complement is a serum enzyme 
cascade usually activated by antibody-antigen complexes; the enzymes released are 
capable of lysing cells and bacterial cells to which antibody is attached.  
 
The humoral response includes the production of immunoglobulins. 
Immunoglobulins are glycoproteins present in serum and tissue fluid produced on 
exposure to antigen.  
 
Neutrophils are the characteristic cells of acute inflammation playing an important 
role in non-specific immunity engulfing and digesting micro organisms.  
 
Complement is a series of plasma proteins that become bound to antibody-antigen 
complexes in a specific sequence (cascade) which contributes to humoral immunity 
in two main ways. Firstly the binding of complement and/or antibody to the surface 
of a micro organism attracts phagocytes. This binding is sometimes called 
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opsinisation, opsinisation facilitates phagocytosis. Phagocytes are cells that engulf 
and digest foreign material e.g. bacteria. Secondly complement fixation, the fixation 
of complement to the surface of a micro organism results in opsinisation and if the 
complement cascade is completed lysis of the cell. (This binding can occur by two 
major routes – the classical and alternative pathways.)  
 
Cell mediated immunity involves the activation of T cells where antibody plays a 
subordinate role. The activation of lymphokine mediators from T cells includes the 
production of chemotactic leucocyte factors; this process of cell attraction includes 
the recruitment of Neutrophils into the area. Neutrophils are one division of white 
blood cells (Leucocytes) of which they constitute approximately 60%. They are 
sometimes termed polymorphonuclear granulocytes. They bear surface receptors for 
Immunoglobulins A, G and complement components. The importance of this 
reaction in the situation of osteomyelitis is the interaction of the factors with cells is 
the elimination of bacteria resistant to phagocytosis. 
 
2.6 The acute phase reaction 
 
 
This is a term that is used to describe a complex range of physiological changes that 
happen following inflammatory tissue damage including trauma, infection and burns. 
There are haemodynamic changes including a leucyocytosis and changes in the 
concentration of many plasma proteins plus systemic effects seen when an individual 
becomes pyrexic. This includes a rise in complement proteins and immunoglobulins. 
Note that the reaction and production of these changes are not specific to infection.  
 
Quantitative measurements of acute phase proteins can be useful in noting the 
presence and extent of inflammation. As the markers are markers of inflammation 
and are non - specific to infection any individual with a disease known to be 
associated with inflammation was excluded in this research. 
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The measurement of this reaction can be performed by the examination of the blood 
for changes in cellular concentrations e.g. Leucocyte count, and specifically in this 
study Neutrophil Count, the changes in plasma proteins affecting the Plasma 
Viscosity e.g., fibrinogen, the release of chemicals that play a part in the 
inflammatory process such as C Reactive Protein. 
 
The speed of reaction of the different components of this process is of variable onset. 
The time taken for the different reactions to peak and decline makes the 
measurement process involved. The complexity of the recognition of the different 
stages of the inflammatory, and hence healing and repairing processes, can be 
determined using different markers of the process.  As the markers are not specific to 
the different types of injury they are often termed ‘non specific’.  
 
2.7 Inflammatory blood markers; non specific 
 
Biomarkers of sepsis are clinically useful only if they fulfil certain requirements. 
These are clearly related to the therapeutic consequences of either treating or 
withholding treatment. The requirements are in part related to the biochemical 
properties of stability, half-life of induction and elimination, range of concentration 
and relationship to disease severity, response to therapy and prognosis (Meisner 
2005).  
 
Questions have been raised about the response of people with diabetes to develop 
these inflammatory markers (Armstrong et al 1996, Leichter et al 1998, Oncul et al 
2006). It has been recognised that the cardinal signs of infection can be both 
mimicked and obscured by the diabetes associated complications of ischaemia or 
neuropathy (Cavanagh et al 2005).  The changes in the microvessels affect both 
delivery of the cells required and the inflammatory response (Sannomyia, Pereira 
and Garcia-Leme 1990). It is well recognised that diabetes as a disease process 
affects both the circulatory and nervous systems (Edmonds et al 1986). The effect 
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this may have on the ability to produce inflammatory markers has not been fully 
examined. 
 
The work that has previously been published on the potential confounding factors 
within diabetic foot disease has not been detailed in its definitions of the 
confounding disease processes. The lack of clarity as to the way in which the 
diagnosis of confounding disease was made means that this current work was not 
able to be fully compared against previous work. This lack of clarity is found for 
disease processes such as cardiovascular and peripheral vascular disease and 
neuropathy. All are reported to be causative in potential effects on inflammatory 
blood markers yet there is no information on how the disease was defined or 
diagnosed in many of the studies. 
 
Each marker that had potential to be used within this study is now discussed. The 
previous studies found using non-specific inflammatory blood markers in diagnostic 
testing have been used mainly to monitor either systemically unwell patients with 
sepsis and multi organ failure or paediatric patients in the recovery process from 
septic arthritis and bone infection. Those looking at the disease process in adults 
have focused on the vertebral bones (Kemp et al 1973, Caragee, Kim and van der 
Vlugt 1997, Cunha 2002) where Mader, Shirtliff and Calhoun (1997) suggest it is the 
most common site. All suggest this form of osteomyelitis is chronic or sub-acute, 
similar to that occurring in the foot in diabetes. Kemp et al (1973), Frederickson, 
Yuan and Olans (1978) and Caragee, Kim and van der Vlugt (1997) all suggest the 
use of multiple markers.  
 
Four papers only Upchurch, Keagy and Johnson (1997), Kaleta, Fleischli and Reilly 
(2001), Cunha (2002) and Jeandrot et al (2008) have specifically looked at typical, 
or classic, diabetic foot ulceration and associated osteomyelitis despite its frequency 
and potential to be associated with increased morbidity, not least of which is lower 
limb amputation, and morbidity, as well.  
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2.7.1 Neutrophil count 
As opposed to a broad count of all Leucocytes the sub group of Neutrophils was 
examined for potential. The reasoning behind looking at Neutrophils in particular is 
that their prime function is to ingest and kill bacteria. As the cause of osteomyelitis 
is most commonly bacterial infection this is clearly rational.  There does not appear 
to be any influence on the ability to develop an increase in white cells when infection 
requires the mobilisation of these types of cell that may influence the use of this test 
with the exception of known disease of the white cells themselves.  
 
The use of raised Leucocyte count is regarded as sensitive but not specific indicators 
for the presence of infection in paediatric patients (Jackson and Nelson 1982, Hiew, 
Tan and Cheng 1992 and Unlika-Kallio et al 1994).  
Li et al (2004) have used raised Leucocytes to examine septic arthritis in adults 
retrospectively. They found a poor sensitivity missing approximately 50% when 
looking at Leucocyte count alone. The confirmation of an infected joint in the Li et 
al (ibid) paper was by positive culture from joint fluid aspirated or frank pus in 
arthroscopy. 
It should be noted that defects in leucocyte chemotactic factors have been observed 
when a poor inflammatory response occurs (Bagdale, Root and Bulger 1974, Tan et 
al 1975 and Molenaar et al 1976). The complications associated with chronic 
hyperglycaemia that are the prime problems of diabetic foot disease, namely 
neuropathy and ischaemia, are compounded by the metabolic derangement known to 
be aggravating chemotaxis in the polymorphonuclear leukocytes (Bagdale, Root and 
Bulger 1974). In their review Molenaar et al (1976) also recognise decreased cell 
adhesiveness and cell movement, decreased bacteriocidal activity and possible 
deficiencies in serum complement in individuals with diabetes. Certainly from 
clinical experience it is apparent that the classic response associated with infection is 
noted to be reduced to that expected for a comparable degree of tissue damage. 
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Armstrong et al (1996a) suggest 54% of patients with a diabetic foot infection 
diagnosed clinically have a normal white cell count, with Leichter et al (1998) 
reporting only 25.5% having a raised count in infection. This reduced white cell 
count maybe due to their compromised systemic response to infection (Caragee et al 
1997, Lewis et al 1998, Jeffcoate and Game 2006). Armstrong et al (1996a) and 
Armstrong et al (1996b) describe these finding in patients that have been admitted to 
hospital as a result of the infection which may suggest it is ‘severe’. In the later 
paper it is also recognised that there was no stratification by type of infection which 
they suggest may be soft tissue alone versus osteomyelitis. A definition of ‘severe’ is 
missing. Lipsky et al (2007) describe a prospective study in which an elevated white 
cell count was found to be associated with failure to treat adequately an infection 
after ten days in-patient treatment with antibiotics. This study appears to be robust in 
that it was a prospective design with a large number of patients at 402 but regrettably 
it excluded those with osteomyelitis so is of limited applicability to this proposed 
study. Critical limb ischaemia was also not included and this is certainly of concern 
to those involved in the care of the diabetic foot as it is strongly associated with limb 
loss. 
 
Only two studies to date have been found which has looked at Neutrophil levels 
(Pittet et al 1999 and Al-Gwaiz and Babay 2007). This first study was a retrospective 
cohort study of diabetic foot infections. Retrospective studies can be considered to 
have a selection bias result by the inclusion of the sicker patients with an abnormal 
baseline parameter. The Neutrophil Count in this series was not among the 
independent factors that predicted treatment failure. The study group was patients 
admitted because of their foot problem and as such do fit the suggestion of more 
poorly patients in retrospective work. The cell count however was not looked at in 
isolation but as an indicator of ‘sign of infection’ together with the temperature of 
individuals. The total number of individuals for whom this complete information 
(temperature and Neutrophil Count) was available from a total study population of 
ninety-one was only twenty-nine.  
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Al-Gwaiz and Babay (2007) appear to have studied patients who were hospital in-
patients with a confirmed bacterial infection (by culture). It is unclear if this is blood 
cultures or of tissue e.g. bone culture. The assumption that the patients were in 
patients follows from the statement about them having bacterial cultures performed, 
this would be most unusual in an out patient setting. This study was carried out to 
determine the diagnostic usefulness of three different methods of examining the 
effect of bacterial infections on Neutrophils which are in the statement below. They 
state that ‘the relationship between acute infectious diseases and white blood cell 
count (WBC), Absolute Neutrophil Count (ANC) and an increased number of band 
neutrophils has been recognized for many years’ but do not substantiate this with any 
references. They provide an analysis suggesting sensitivity of the different methods 
including a column for ‘severe’ infections but this term is not defined in the text. The 
lack of detail in this paper does not assist in the usefulness of using it as a 
comparative piece of work.  
 
The method of analysis used for monitoring Neutrophil activity in this thesis study 
was absolute count. This is in line with the paper by Al-Gwaiz and Babay (2007) 
who following the analysis of different evaluations of white blood cells found 
absolute count the most sensitive in predicting bacterial infection. This was in the 
population of age 1 year to 70 years and compared absolute count, band cells, Döhle 
bodies and neutrophil vacuoles.  
 
The fact of osteomyelitis being an infectious disease suggested the use of Neutrophil 
count would be prudent so it was included in the final choice of markers. 
2.7.2 Haemoglobin 
 
Diabetes as a chronic disease is likely to produce an acquired anaemia non- immune 
anaemia (Al-Khoury et al 2006), in addition to the effect of renal disease affecting 
the production of erythropoietin and as such produce anaemia. Anaemia associated 
with chronic disease is a normochromic normocytic variety. The presence of chronic 
kidney disease has been shown to potentially increasing the prevalence of anaemia 
by a factor of four (ibid). Diabetes alone, i.e. without recognised kidney disease, may 
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account for some 16% of patients with anaemia (O’Mara 2008). The O’Mara paper 
used that definition of the National Kidney Foundation. In chronic renal disease a 
reduction in erythropoietin production leads to a reduction in erythrocyte production, 
and a normochromic normocytic anaemia. The anaemia caused by infection is that of 
chronic disease.  
 
Anaemia has been recognized previously in patients with diabetes and found to be 
more complex and multi-faceted using a hierarchical study review of ten papers 
(Balshaw-Greer, Davies and Casey 2005). This is particularly so for those with the 
complications of albuminuria and reduced renal function (Thomas and Rampersad 
2004).  
 
Leichter et al (1988) in a series of 55 patients with diabetes and serious foot 
infections, clinical anaemia measured by Haemoglobin level was not found to be 
present. There is no definition of what they consider to be ‘serious’ or ‘anaemia’. 
The impact of renal function is not mentioned in detail with the only sentence used 
stating ‘tests of renal function reflected mild to moderate abnormalities for the 
group’. 
 
Furthermore a long term reduction in Haemoglobin level, but not to a level 
diagnostic of anaemia, has been found in people with diabetes (Craig et al 2005). 
Thomas et al (2003) in a study of 820 patients found an undiagnosed prevalence of 
23% using the WHO definition. This was comparing these people with diabetes to 
the general population and comparable renal disease and iron stores. As no level of 
Haemoglobin is definitive for people with diabetes to be either normal or abnormal 
the measurement of its level will continue to be used in the proposed research. The 
mean age of this Thomas study group was likely to be similar to that in the proposed 
study at 62.2 years and with 95% of Caucasian decent. 
 
The recognition of the possible effect suggested by Ting et al (2006) of Metformin 
causing a reduction in serum Vitamin B12 and as such anaemia its use was noted. 
 52 
(The Adetunji et al (2009) paper discounting this effect came out after data 
collection was complete.) 
 
The definition of anaemia in studies can be seen to be variable. However a level of 
less than or equal to 11g/dl (irrespective of gender) has been suggested in guidelines 
to show benefit to patients if improved (National Kidney Foundation 2001). The 
gender specific definition of anaemia by the World Health Organisation (WHO) 
(1968) is less than 13g/dl in men and less than 12g/dl in women. 
 
The measurement of Haemoglobin as an indicator of an infectious chronic disease – 
osteomyelitis led to its inclusion in the study. Renal anaemia was attempted to be 
excluded by excluding individuals on known renal replacement therapy or with two 
eGFR results less than 60 ml/min within the preceding 6 months to consent. 
 
2.7.3 C Reactive Protein 
 
C Reactive Protein is an immunoglobulin which in an antigen complex triggers the 
complement cascade. It is called C Reactive Protein as it has the property of being 
able to bind to a polysaccharide in the cell wall of pneumococci bacteria, the fraction 
of the wall being fraction ‘C’. The bacterial polysaccharides and phospholipids 
released by the damaged tissue also become activators of the complement pathway. 
At the cellular level C Reactive Protein initiates opsinisation and phagocytosis of 
invading cells. It also binds to and detoxifies endogenous toxic substances produced 
as a result of tissue damage. Levels are not influenced by anaemia or heart failure. It 
is highly sensitive due to large incremental changes. 
 
C Reactive Protein is known to be higher in the population of people with diabetes as 
a background level (Sattar 2006a). This work has not however differentiated what, if 
any, effect foot ulceration (and this with / without infection) has on the level. The 
work is recognition of diabetes as a cardiovascular disease.  
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C Reactive Protein is triggered to rise ‘several hundred fold’ (Kallio et al 1997) by 
tissue damage that maybe either infectious or ischaemic (Khachatourians et al 2002). 
 
Unlika-Kallio et al (1994) claim C Reactive Protein is a better marker than 
Erythrocyte Sedimentation Rate (in paediatric patients) in bone infection. C Reactive 
Protein level is a rapid indicator of inflammation and tissue necrosis (Unlika-Kallio, 
Kallio and Petola 1994). The rapid development of C Reactive Protein is a reason for 
its preferred use making it a ‘better’ marker so say Petola and Räsänen (1982). They 
used C Reactive Protein to assist in the diagnosis of osteomyelitis in children. Roine 
et al (1997) state C Reactive Protein is a better predictor of sequela prone paediatric 
patients.  
 
Upchurch, Keagy and Johnson (1997) have demonstrated a rise in C Reactive 
Protein in people with diabetes and associated foot ulcers when cutaneous infection 
is present. What is not clear in this small study is whether any investigation, or 
indeed suspicion, of the presence of osteomyelitis was considered. Where there is the 
potential for medication to have an affect on the result no detail about either dosage 
or length of use has been reported. Medication that may cause an alteration in the 
result was simply noted as being prescribed. Metformin is the most likely cause 
where it has been suggested it may have a specific interaction involved in the 
synthesis or secretion of C Reactive Protein (Carter et al 2005). It is likely that 
patients within the proposed research are being treated with this drug. In a double-
blind placebo controlled trial Carter et al (ibid) found statistically significantly lower 
levels of C Reactive Protein after 12 and 24 weeks treatment with Metformin after 
starting with similar levels of marker and similar levels of metabolic control of the 
diabetes as a disease. This was in ‘overweight’ individuals. Body Mass Index is not 
routinely considered in the diabetes foot clinic and was not available for all the 
individuals as many had their diabetes care in primary care alone – the diabetes 
database is for specialist care only. This study used the same definition as Carter et 
al (ibid) in defining overweight as a BMI greater than 25 kg /m2. 
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In this Carter et al (ibid) study the fact that acute infection can raise the level was 
recognised and individuals with a level of > 10 mg/l were excluded from the 
analysis. This alteration in C Reactive Protein has been noted before in a trial by Chu 
et al (2002) that was set up to look at the reduction of cardiovascular risk factors that 
C Reactive Protein is considered to be one of. No detail of the medication dose was 
given in this paper by Carter et al (2005) or that by Chu et al (2002). This means it is 
difficult to consider this as a potential confounder to results in papers that follow.  
 
Diabetes as a disease is itself recognised to be a risk factor for cardiovascular 
disease. Cardiovascular disease and diabetes together have been further studied with 
C Reactive Protein.  The increase in C Reactive Protein is also noted with Insulin 
resistance (Nesto 2004) – a metabolic syndrome associated with type 2 diabetes in 
particular. Chronic subclinical inflammation is a component of the Insulin resistance, 
or metabolic, syndrome in which cardiovascular risk factors including type 2 
diabetes occurs (ibid). He does however make the point that the raised level is 
actually the upper end of normal and may not be detected by the usual assay 
methodology.   
 
Considering peripheral vascular disease as a variant of cardiovascular disease and 
recognising that it too is common in diabetes a study by Yu et al (2004) has shown 
by multivariant regression analysis that higher serum levels of C Reactive Protein 
and longer duration of diabetes (with no definition to support this expression) were 
both independently associated with peripheral vascular disease in type 2 diabetes. 
The study was cross sectional and involved 30 patients with vascular disease as 
defined by the use of an Ankle: Brachial Pressure Index (ABPI) and comparing them 
to 60 with what was considered to be normal. The level of inflammatory marker was 
statistically significantly raised but the methodology can be questioned. The use of 
an Ankle: Brachial Pressure Index is not always satisfactory in people with diabetes 
due to vessel calcification producing false high readings suggestive of normality 
when in fact disease is present. 
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Recent predictive models that appropriately account for the possible confounding 
factors within coronary heart disease and C Reactive Protein levels ‘the magnitude of 
the association is considerably attenuated towards the null’ (Lawlor et al 2005). The 
authors suggest that the marker should be used to predict coronary heart disease but 
may not be casually related to it. So it maybe, that this confounding factor can be 
discounted when looking at individuals with known cardiovascular disease. However 
more recently it has been suggested that ‘evidence that C Reactive Protein does not 
cause cardiovascular disease does not mean that inflammation plays no role in 
atherosclerosis’ – part of lower extremity peripheral vascular disease (Davey-Smith, 
Thompson and Lawlor 2006). These findings support, albeit not strongly, the 
abnormal levels of C Reactive Protein found generally in people with diabetes with 
associated complications discussed above. 
 
Jeandrot et al (2008) again studied in patients as opposed to out patients with the 
study attempting to differentiate foot ulcers with bacterial colonisation from 
infection. The study, on antibiotic naive patients, is difficult to justify ethically when 
infection is suspected.  Osteomyelitis is not always obvious clinically so the results 
of this study maybe of limited comparability to the currently reported study. It is not 
clear how those with diabetes were used as controls were either included or excluded 
with the other known factors that can raise inflammatory markers. The assay method 
for C Reactive Protein was different to that available routinely as it was able to 
measure levels below 5mg/l. 
 
Generally C Reactive Protein is thought to be more specific for infection than 
Erythrocyte Sedimentation Rate (Haas and McAndrew 1996, Wall 1998).  
 
Lew and Waldvogel (1999) have recognised the need to distinguish people with 
diabetes as a sub group clinically. They state the need to consider this set because of 
the important contributing factors of the metabolic consequences of the disease 
process, poor blood supply, bone ischaemia and neuropathy all adding to bone 
destruction. 
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C Reactive Protein is routinely used in the Royal United Hospital, Bath for 
monitoring response to antibiotic therapy so it was included to determine if it was of 
use in recognising osteomyelitis. The potential confounders including cardio and 
peripheral vascular disease were noted as was the use of Metformin. 
 
2.7.4 Erythrocyte Sedimentation Rate 
 
There are multiple influences on Erythrocyte Sedimentation Rate include age, fluid 
balance, nutritional status, and hormonal changes (Khachatourians et al 2003) plus 
others that alter the fibrinogen levels including diabetes and significantly, as they are 
associated with diabetes, heart disease and end-stage renal failure, (Kaleta, Fleischli 
and Reilly 2001). It is uncertain if anti-inflammatory medication decreases 
Erythrocyte Sedimentation Rate (Bridgen 1999).  Bridgen (1999) cites Sox and 
Laing (1986) when he includes obesity in his list of influences but says it is ‘not of 
clinical significance’. This is because Erythrocyte Sedimentation Rate reflects the 
concentration of fibrinogen and immunoglobulins in the plasma (Kallio et al 1997). 
Obesity is in part causative of type 2 diabetes, the most common form of diabetes 
and as such this may be of note. The study however was not set up to consider Body 
Mass Index as part of the protocol. It was however collected post study to look at 
any potential correlation with C Reactive Protein but many individuals did not have 
the data available as their diabetes care was in primary care and the information not 
available to the researcher. 
 
The use of raised Erythrocyte Sedimentation Rate is regarded as sensitive but not 
specific indicators for the presence of infection in paediatric patients (Jackson and 
Nelson 1982, Hiew, Tan and Cheng 1992 and Unlika-Kallio et al 1994). 
 
Li et al (2004) have used raised Erythrocyte Sedimentation Rate to look at septic 
arthritis in adults retrospectively. They found a poor sensitivity 10% having a 
‘relatively low or normal’ level.  
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Kaleta, Fleischli and Reilly (2001), Berendt and Lipsky (2004) and Berendt et al 
(2008) advocate the use of an indicative raised level of Erythrocyte Sedimentation 
Rate at 70mm/h. Berendt and Lipsky (2004) declare that above this level is specific 
for infection. But only ‘possibly’ diagnostic for osteomyelitis being when there is 
‘no other plausible explanation’ (Berendt et al 2008). Possibly being taken to mean 
‘but on balance less rather than more likely’. 
 
In his study of elderly patients with diabetes Cunha (2002) suggests with no rationale 
that an Erythrocyte Sedimentation Rate of greater than 100mm / hour is an 
inexpensive but non – specific test of osteomyelitis. 
Erythrocyte Sedimentation Rate was not included in the final study as it is not a 
standardised quality controlled test. 
 
2.7.5 Plasma Viscosity 
 
The use of Plasma Viscosity as opposed to Erythrocyte Sedimentation Rate is more 
practical in that using a standardised laboratory test ensures quality control. It also 
has the advantages of not being affected by anaemia (one of the potential 
confounding factors) and is abnormal earlier than Erythrocyte Sedimentation Rate 
(Fleck and Meyers 1995). Additionally there is little effect on the level due to age. 
The only age limitation in the presented work was to be over 18 years old. Plasma 
Viscosity is affected by the proteins of large molecular size including fibrinogen and 
some immunoglobulins. The results are only slightly changed with age (as 
fibrinogen increases), with no differences between the genders and as previously 
stated independence from the effects of anaemia, plus they are available quickly.  
 
Plasma Viscosity has been seen to rise rapidly after the onset of infection (Paluska 
2004). This paper was about osteomyelitis but not specifically as a complication of 
diabetes associated foot lesions. However it does have a section dedicated to the 
problems of osteomyelitis in diabetes. 
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Plasma Viscosity has been shown in patients with type 2 diabetes to be ‘abnormal’, 
that is raised above what is considered ‘normal’ (MacRury et al 1990, Coppola et al 
1997). The first study, MacRury et al 1990, compared controls (no known diabetes) 
to individuals with known diabetes. Some with diabetes had known neuropathy 
diagnosed in a ‘normal’ clinical fashion plus ‘fancy’ electromyography studies. The 
individuals with known diabetes were a mixture of type 1 and type 2, some of the 
type 2 individuals having Insulin therapy. It was found all people with diabetes had a 
higher, statistically different (p< 0.001) Plasma Viscosity. Interestingly those with 
diabetes and a diagnosis of neuropathy did not have a greater mean Plasma Viscosity 
compared to those with diabetes and no neuropathy. The number of participants with 
diabetes was small (n=39) and matching occurred within the diabetes known group 
for type of diabetes, age and gender. Other known causes of neuropathy were 
excluded and the controls were ‘free from pain or paraesthetic symptoms in their 
legs with a normal fasting blood glucose’. The planning shows some well considered 
thoughts. Trauma in patients with neuropathy is the major cause of diabetic foot 
ulceration that leads to osteomyelitis and as such considering the presence of nerve 
damage is prudent. 
 
The second study, Coppola et al 1997, was also based on small numbers (n=15 
healthy individuals i.e. not having a diagnosis of type 2 diabetes, and n= 15 of each 
diabetes and free from cardiovascular complications and with both clinical, and 
measured, evidence of coronary or peripheral vascular disease and n = 15 with 
diabetes and cardiovascular complications) and of a cross sectional design. The study 
was well designed in the fact that the individuals in the study were matched for age 
and Body Mass Index. The majority of patients that attend the Diabetes Foot Clinic 
have type 2 diabetes and a majority will have be peripheral vascular disease as part 
of their diabetic foot complications.  
 
The Coppola et al (1997) study used extensive methods to determine the presence of 
cardiovascular disease including history, clinical examination, Electrocardiogram, 
exercise stress testing and döppler ultrasonography. The study presented in this 
thesis used only patient history and medication (using drug records) as an 
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assumptive method of the presence or absence of cardiovascular disease. The 
Coppola et al (1997) study acknowledges the limitations of the study being cross 
sectional and having only a small number of participants. It is also recognised that 
the small numbers mean that any cause and effect relationship between type 2 
diabetes and alterations within the blood profile cannot be identified in diabetes 
related vascular disease. 
 
The study by Coppola et al (1997) investigating the effect of Insulin appears to be 
adding Insulin to blood samples and not considering Insulin as a medication. How 
applicable this is to the use of Insulin as a drug to control diabetes is unclear. The 
conclusion of the study was that ‘the beneficial effects of Insulin on blood viscosity 
are not evident in type 2 diabetic patients, especially those with vascular 
complications’. 
 
Recognition of the potential confounding factors suggested in these two papers was 
provided for in the data collection sheet. 
 
2.7.6 Procalcitonin 
 
Procalcitonin (PCT) is a 116 amino acid propeptide of calcitonin synthesized in the 
parafollicular C cells of the thyroid that has only recently been used as a potential 
marker for bacterial infection and associated sepsis. Procalcitonin levels had been 
noted to rise only during severe infections with systemic manifestations to over 
100ng/ml (Reinhart, Karzai and Meisner 2000).  
 
Procalcitonin is under normal metabolic conditions produced and secreted by the C 
cells of the thyroid. In severe bacterial infections and sepsis the origin is 
extrathyroidal. In marked inflammatory conditions the principal source is 
‘nonneuroendocrine parenchymal cells e.g. lung, liver, kidney, fat, muscle and 
stomach’ (Müller et al 2008). The normal level is very low (< 0.5 ng/ml). In 
microbial infections the amount of Procalcitonin can be seen to increase ‘up to a 
hundred times’ (Hladik et al 2005). A meta analysis comparing C Reactive Protein 
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and Procalcitonin has shown Procalcitonin to be superior in the diagnosis of bacterial 
as opposed to viral or non bacterial infection (Simon et al 2004). This meta analysis 
was of work performed on studies looking for bacterial infections in hospitalized 
patients. It was well conducted with specific inclusion and exclusion criteria with 
clear admissions of the limitations. Despite it being based around in patients some of 
the information it gives may be of use in comparison to this current study.  Other 
factors known to raise Procalcitonin levels which may also cause other markers to 
rise include neuro endocrine tumours, non infectious inflammation, general sepsis 
and trauma. (There is no elevation of the levels of the mature calcitonin in 
inflammatory induction.)  
 
Sitter et al (2002) have shown Procalcitonin not to be effected by renal disease when 
comparing results for the determination of bacterial infection or auto immune 
disease. The individuals in this study were classified according to their stage of renal 
disease and also taken into consideration was any immuno suppressive medication 
taken and auto immune disease. This study showed a lack of effect of renal disease 
on Procalcitonin echoes the work of Eberhard et al (1997) who looked at the use of 
Procalcitonin in the comparison of active auto immune disease and invasive bacterial 
infection. As renal impairment is a complication of diabetes that is often seen at the 
same stage of the disease as diabetic foot syndrome this is potentially very useful. 
Procalcitonin as a marker is not affected by immunosuppression or neutropenia.  
 
Stucker et al (2007) when examining the utility of Procalcitonin as a predictor of 
infection in elderly hospitalized patients (their definition of elderly being over 
seventy five the study mean ± standard deviation being 85.4 ± 6.7 years) included 
19% having had a prior diagnosis of diabetes and the nearest infective process to 
osteomyelitis was cellulitis in 6%. Procalcitonin was found to be associated with 
infection at a level of 0.5ng/ml by Stucker et al (2007) but not independently of other 
variables including other markers used in this thesis research. Delévaux et al (2003) 
had previously expressed this figure as the level at which bacterial infection could be 
differentiated from other inflammatory processes. Again this was for hospitalized 
patients. Delévaux et al (2003) admit this work was for those with systemic bacterial 
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infections and suggest that the level of Procalcitonin may not rise in localized 
bacterial infections but no definition of ‘localized’ is given so it is not clear where 
osteomyelitis fits within this grouping. This appears to reinforce the findings of 
Reinhart, Karzai and Meisner (2000) suggesting only ‘severe’ infections cause 
Procalcitonin to rise. 
 
An assessment of the clinical utility and limitations of Procalcitonin by Becker, 
Snider and Nylen (2008) has shown the degree of rise in levels that may be expected 
by a bacterial infection being the induction agent. The localised nature of 
osteomyelitis means that the results of this study were not of any use for comparison 
purposes. 
 
Procalcitonin levels prior to the work of Uzun et al (2007) and Jeandrot et al (2008) 
had been noted to rise only during severe infections with systemic manifestations. It 
should be noted that it has not been considered a useful marker, when used alone, of 
infection as such as the large rise does not occur in local infections. However the 
work of Uzun et al (ibid) and Jeandrot et al (ibid) has shown some potential use in 
the recognition of infection in diabetic foot ulcers when used with other markers. 
Both of these studies were however undertaken on patients that had been admitted to 
hospital as a direct consequence of the infected foot ulcer. Diabetes related foot 
infections do not always present with the expected systemic signs (Caragee et al 
1997 and Lewis et al 1998, Jeffcoate and Game 2006) presenting questions as to its 
usefulness alone.  
 
The meta analysis by Simon et al (2004) of both Procalcitonin and C Reactive 
Protein as markers in sepsis in hospitalized patients has shown Procalcitonin to be 
superior to C Reactive Protein in the recognition of bacterial infection as opposed to 
viral infection. This agrees with the work using C Reactive Protein in paediatric 
cases by Gendrel et al (1999). The application of this work by Gendrel et al (ibid) to 
this study is not clear as it is not in paediatric patients and bone infection is generally 
bacterial in origin.   
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Uzun et al (2007) examined the utility of Procalcitonin in patients with clinically 
diagnostic signs of infection, including presence of pus, plus two of redness, warmth, 
swelling and pain. As discussed in the background these symptoms can be absent in 
diabetes making the diagnosis more complicated. The Uzun (ibid) study population 
was small, 27 with a diagnosed diabetic foot infection and 22 with a non infected 
diabetic foot lesion (by their diagnostic criteria mentioned above). As seen in other 
papers again the individuals had been admitted to hospital as a result of their foot 
problem. The results suggest Procalcitonin of all the markers had the highest area 
under the curve and greatest statistical significance for association with infection. 
Seven of the twenty seven with a recognized foot infection were diagnosed as having 
osteomyelitis (by the probe to bone test) but these were not analysed separately.  
 
The recent pilot study by Jeandrot et al (2008) has suggested that Procalcitonin 
together with C Reactive Protein may be useful in the recognition of infection in 
diabetes foot ulcers. The aim of this Jeandrot et al (ibid) pilot study was to assess the 
diagnostic accuracy of inflammatory blood markers as an aid to making a distinction 
between non - infected ulcers (or those colonized with normal flora) and ulcers 
infected with virulent bacteria to determine the need for antibiotic therapy. It was a 
well conducted prospective study with reasonable numbers at the beginning (120 
patients with diabetes but no foot ulcer and 153 with a diabetes related foot ulcer) 
however after the exclusion of individuals who had antibiotics within the previous 
six months this only left 45 individuals. It would be unusual in clinical practice to 
have an individual antibiotic free for this period of time within the natural history of 
a foot ulcer infection.  
 
Jeandrot et al (2008) suggests a combination of C Reactive Protein and Procalcitonin 
derives, from a logistic regression with other markers, an Area Under the Curve 
result of 0.947. This was in comparison with other Receiver Operating Characteristic 
curves (the other markers included orosomcoid, haptoglobin, white cell count and 
Neutrophil Count, the first two not being readily available from most hospital 
laboratories). This study was performed in order to determine if early infection could 
be differentiated from bacterial colonisation. As many of the other previous studies 
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with inflammatory blood markers this was performed on hospitalized patients. 
However its suggested use in combination with C Reactive Protein led to its 
inclusion in this study.  
In the assay method used in this research it is stated that Haemoglobin (up to 500mg 
/ dl), Albumin (up to 1g / dl) and Triglyceride (up to 1g/ dl) have no ‘interference’. 
Other ‘interfering substances’ that may require consideration that it is not known 
whether they were present in the sample individuals include Furosemide (a loop 
diuretic drug) at levels of 2mg/dl and several antibiotics that it was unlikely the 
individuals were taking including Imipenen (at 1.18mg/ml), Vancomycin (at 
3.5mg/ml) and Cefotaxime (at 90mg/dl). 
Combining Procalcitonin, white blood cell count and C Reactive Protein has been 
shown to be beneficial particularly to diagnose infection Bell et al (2003), Castelli et 
al (2004), Thayyil et al (2005) and Kofoed et al (2007).  All these four studies show 
levels of all three markers to be raised in bacterial infections as opposed to other 
infections or non infectious causes of inflammation. However none of these papers 
are directly applicable to the individuals in this study. The papers with the exception 
of that by Thayyil et al (ibid) are studies of adults in Intensive Care settings. That of 
Thayyil et al (ibid) being based upon paediatric patients with no obvious focus of 
infection. 
The non specific markers of inflammation which may have some use appeared to be 
multiple. As non specific markers of inflammation i.e. not able to distinguish 
inflammation from infection the use of multiple markers seemed prudent.  
 
2.8 Proposed studies using inflammatory blood markers 
 
The final choice of markers was determined having examined the literature for those 
that had shown some possible use before; the use of inflammatory blood markers in 
an out patient setting is novel as is the proposed series of markers. Using a 
combination of short term markers (less than 24 hours), e.g. C Reactive Protein, and 
long term, e.g. Plasma Viscosity, allows a full coverage of the disease process. The 
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confusion over the affects of markers would suggest the need for the use of multiple 
markers and is confirmed by Sattar (2006a). The reasoning behind this is again the 
ineffective immunological response to pathogens.  Eneroth, Larsson and Apelqvist 
(1999) developed levels of Haemoglobin, Erythrocyte Sedimentation Rate, C 
Reactive Protein and White Blood Cell count that they considered typical of 
osteomyelitis only, deep soft tissue infection only and combined infection that 
maybe useful as a control to measure this research against.  
 
As non specific markers of inflammation a determination of a baseline level to 
recognise infection was found to be lacking in previous research. 
 
The difficulty with previous studies not defining the confounders e.g. cardiovascular 
disease and neuropathy has meant that there is a difficulty in being able to compare 
this work to previous work. The use definitions used of cardiovascular and 
neuropathy here are at the beginning of this thesis.  
 
The studies in this thesis were conducted in an attempt to find alternative methods of 
diagnosing osteomyelitis. The enquiry using inflammatory blood markers was 
conducted as the only work that could be found prior to this study was based upon 
patients that were so acutely unwell that they were in – patients within the hospital 
setting. It was hoped that a level of a single marker, or a group of markers would be 
found that would be suggestive enough to make osteomyelitis very probable. 
 
The final choice of markers was Neutrophil count, Haemoglobin, C Reactive Protein, 
Plasma Viscosity and Procalcitonin. 
  
Individuals were assessed as having a clean ulcer – no sign of infection as 
determined by clinical signs and symptoms despite the acknowledged problems that 
this has in individuals with diabetes, a cutaneous infection by a similar diagnostic 
strategy, suspected osteomyelitis determined by depth of wound and /or probing 
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bone and confirmed osteomyelitis by a probe to bone test being positive, plain X ray 
indicating bone destruction, MRI, SPECT/CT or bone biopsy.  
 
2.9 Proposed studies using SPECT/CT 
 
 
The investigation using the alternative scanning technique of SPECT/CT was carried 
out in an attempt to determine if this form of imaging is of comparative use to MRI. 
Some individuals are unable to undergo the MRI procedure and an alternative that 
gives as much detailed information would be very welcome. To determine 
comparability of the imaging techniques subjects in this part of the study had both 
forms of imaging with blind reading of the results by the relevant specialist 
radiologist. 
 
2.10 The study and wound classification 
 
 
The study also needed to attempt to recognise the ulcer from a classification view 
point to see if there was any link between results and ulcer classification that was 
quickly and simply available in a clinical setting. 
2.10.1 Ulcer classification systems 
 
In an attempt to correlate the stage of ulceration with the blood results two foot ulcer 
classification systems were adopted. Classifications enable selection of populations 
of similar lesions for prospective research (Macfarlane and Jeffcoate (1999). This 
means it is necessary to give precise descriptions, including the presence or absence 
of infection and vascular compromise (Lavery, Armstrong and Harkless 1996). Good 
classifications encourage clarity of thought and promote better understanding of 
disease processes, which in turn lead to better management (Jeffcoate, Macfarlane 
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and Fletcher 1993). They also should be simple enough to be remembered, and yet 
precise enough to be useful (ibid). The one system used was that known by the 
abbreviations of its components the S(AD) SAD was used.  This system grades the 
ulcer according to the variables of size – in both area and depth, the presence of 
sepsis, degree of arteriopathy (circulatory disease), and degree of denervation (nerve 
damage). These are the elements that contribute to that nature of the lesion. Each of 
the five categories is ranked on a four-point scale (0, 1, 2, 3). It is the only such 
classification with a process of validation against a wide variety of end-points to 
ensure its reliability is this S(AD) SAD system (Treece et al 2004). The clinical 
measurement methods of assessing ischaemia and neuropathy are recognised by the 
original authors as being imprecise but recognise typical clinical practice as opposed 
to research and are acknowledged as a possible downfall in this classification. The 
result is an arrangement simple enough to be universally understood and applied to a 
large number of lesions in routine practice, and yet, is precise enough to be 
meaningful (Jeffcoate and Game 2006). Macfarlane and Jeffcoate described the 
original classification in 1999. This system has distinct advantages over the other 
most frequently used classification, the Wagner Grading System. Wagner was meant 
to classify lesions and not infections (Eneroth, Larson and Apelqvist 1999). As a 
result it fails to address the localization of infection, the systemic manifestations, the 
vascular status and host factors in diabetic foot lesions (LeFrock and Joseph 1995); 
this is also true of the University of Texas San Antonio Diabetic Wound 
Classification System (Lavery, Armstrong and Harkless 1996).  As a successful 
classification it needs to be, and indeed is, based on all the key elements that 
contribute to the nature of the lesion (Macfarlane and Jeffcoate 1999).  
 
The key elements of the classification need to be subdivided according to the extent 
to which they contribute to the status of the lesion.  It is accepted that this will to 
some extent be empirical as the sub divisions maybe based on either quantitative or 
qualitative measures. Each of the components is explained with its levels of 
assessment. The categories do not follow a logical progression or even increasing 
severity but they are mutually exclusive and, individually, they are applicable to the 
vast majority of lesions seen in clinical practice. 
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In the S(AD) SAD classification of the severity of ischaemia is used when the 
ischaemia is not critical. As for infection the order of increasing score in the 
assessment tool is consistent with increasingly reduced likelihood of healing.  
 
Also included in the S(AD) SAD assessment tool are wound surface area and sepsis.  
Area is recognised by Macfarlane and Jeffcoate (1999) as being an important factor. 
They also advocate that in prospective research the measurement should be accurate 
and promote the use of sterile transparent sheets marked with a grid. In the S(AD) 
SAD classification system the gradation is skin intact, area < 1 cm2, 1-3 cm2, > 3 
cm2. Depth has been acknowledged as a risk factor for amputation (Armstrong, 
Lavery and Harkless 1998) and as such is as essential requirement in a classification 
system.  Following the work of Lavery, Armstrong and Harkless (1996), validated 
by Armstrong, Lavery and Harkless (1998), the ranking system is skin intact, either 
non-ulcerated or healed, superficial, involving skin and subcutaneous tissue but not 
tendon, periosteum, or joint capsule, penetrating to tendon, periosteum, or joint 
capsule, involving bone or joint spaces. 
 
Inefficient Neutrophil bacteriocidal mechanisms have been recognised for a long 
time as partially responsible for the increased susceptibility of patients with diabetes 
to infection (Tan et al 1975). Sepsis can be difficult to both diagnose and categorize. 
Macfarlane and Jeffcoate (1999) suggest that the diagnosis is primarily clinical but 
recognise the confounding of the problem by other diabetes complications, notably 
ischaemia and denervation. The sub division of sepsis is problematic as the 
categories are discontinuous and reflect qualitatively different types of infection. The 
division used in the S(AD) SAD system does have some conformity of increasingly 
poor prognosis. It is recognised that the cumulative effect of features such as depth 
and infection contribute to the increased likelihood of amputation (Armstrong, 
Lavery and Harkless 1998). 
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The Internal Working Group on the Diabetic Foot had developed the other 
classification system referred to as the PEDIS system (Apelqvist et al 1999). This is 
an abbreviation of the five categories assessed in the system – namely Perfusion, 
Extent/size, Depth/tissue loss, Infection and Sensation. These categories are, 
similarly to the SAD S(AD) system, clinically assessed with grading within 
perfusion, depth, infection and sensation. It is recognised that this system has yet to 
be validated formally. The categories and grades were defined on the basis of their 
relevance for research by internationally recognised experts (Schaper 2004) where 
this it is argued provides face validity. It is worth repeating the reproducibility in 
terms of intra – and inter – observer variability has yet to be evaluated (ibid). 
 
What is known to contribute to this syndrome of ‘the diabetic foot’ but is not included 
in either assessment tool, or many of the others available, are issues such as 
uncontrolled hyperglycaemia, limited joint mobility and structural foot deformities. 
 
No assessment tool has yet been developed and validated that includes all the 
variables that can add to this syndrome complicated further by the fact many of the 
factors can not be quantified. 
 
The use of  ulcer classification systems such as the S(AD) SAD and PEDIS as 
described however allowed recognition of the prime cause of the ulceration which 
was useful in the results section where the determination of the effect of neuropathy 
could be considered (see Chapter 5). 
 
The burden of diabetic foot disease is set to increase in the future since by the 
reckoning of Boulton et al (2005) as the contributory factors to foot disease, such as 
peripheral neuropathy and vascular disease are present in more than 10% of people 
diagnosed with type 2 diabetes (UKPDS 33) and it has been recognised by New et al 
(1998) the first year after diagnosis is a ‘period of danger for foot ulcers and 
amputations’.  
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The complex nature of the disease process including the diagnosis and provision of 
appropriate treatment can be seen to be challenging. 
 
This chapter has attempted to show the context in which this research was considered 
to be worthwhile showing what has been found to date and the gaps in the knowledge 
we currently have about diabetic foot infections. 
 
The following chapters will consider the research that was undertaken by describing 
the methodology, results and discussing the results. The discussion to previous work 
is limited by the lack of comparable work. 
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Chapter 3 Methodology The use of inflammatory blood 
markers in the diagnosis of osteomyelitis 
 
This chapter will outline the approach used in the research study that examined the 
potential use of inflammatory blood markers in the diagnosis of osteomyelitis. The 
need for these tests to have sufficiently high specificity and sensitivity in the 
diagnosis is not discussed at this point in time but in Chapter 5.  
  
3.1 Research question 
 
Do inflammatory blood markers have a role to play in the early diagnosis of bone 
infection in people with diabetes associated foot ulcers in an out patient setting? 
 
3.2 Aim 
 
To ascertain if a level of the chosen inflammatory blood marker(s) is useful for the 
early diagnosis of osteomyelitis in the diabetic foot.  
 
3.3 Research objectives 
 
To establish the ‘normal’ range of each marker in the diabetes population with 
 
1. A clean, non-infected, foot ulcer 
2. A skin infection associated with a foot ulcer 
3. An infected foot ulcer and suspected osteomyelitis  
4. An infected foot ulcer and proven osteomyelitis and 
5. To compare the range of  values of each marker in each sub group, and with 
the accepted ‘normal’ range. 
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Individuals were placed within these groups by clinical signs and symptoms plus, 
where appropriate, diagnostic imaging. 
 
A clean, non-infected, foot ulcer was diagnosed by the absence of any of the 
following: pus, heat, swelling, pain and obvious inflammation (Lipsky et al 2004). 
The wound was shallow with healthy granulation tissue evident. 
 
Infection was diagnosed clinically by the presence of purulent secretions or at least 
two of the cardinal manifestations of inflammation as described above i.e. redness, 
warmth, swelling or induration, and pain or tenderness (ibid). Differentiation 
between skin, cutaneous, infection, and osteomyelitis was made on the clinical 
grounds of a ‘positive probe to bone test’ that led to further imaging for confirmation 
(or to be able to discount) osteomyelitis. The simplest form of imaging being a plain 
X ray. If this was clearly diagnostic of osteomyelitis no further imaging examination 
was considered. If the X ray was inconclusive an MRI was ordered and if the patient 
was willing to undergo the imaging part of the research, a SPECT/CT was also 
booked. A non-healing ulcer at 4-6 weeks with suitable debridement and off loading 
without any other obvious cause was also suspected to have osteomyelitis and was 
investigated as described above in terms of imaging.  
 
Confirmed osteomyelitis was considered when a plain X ray was unmistakably 
showing bone destruction, or when either MRI or SPECT/CT was used and was 
diagnostic.   
 
The groups were not mutually exclusive in that an individual with a cutaneous 
infection may also have had osteomyelitis.  
 
3.4 Protocol 
 
The following conditions have been defined at the beginning of this document and 
this is how they are referred to within this work; 
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� Anaemia; 
� Cardiovascular disease; 
� estimated Glomerular Filtration Rate  (eGFR) 
� Neuropathy 
� Neutrophil 
� Peripheral Vascular Disease;  
� Reduced renal function. 
3.5 Summary 
 
This study investigates the use of inflammatory blood markers in making a diagnosis 
of osteomyelitis in foot ulcers associated with diabetes. 
 
3.6 Keywords 
 
Inflammatory blood marker Neutrophil  Procalcitonin  Haemoglobin  Plasma 
Viscosity   C Reactive Protein   Diagnosis  Osteomyelitis 
 
3.7 Confounding factors 
 
The use of antibiotics, either oral or intravenous, is not discussed in any previous 
papers as a potential source of reduction in the inflammatory response. In this piece 
of research their use was noted but not the duration of use and/or if the infection was 
acute or ongoing being contained by the use of the anti-microbial agent. Nor was the 
causative micro organism typed as it has been suggested that some may be more 
virulent than others and as such cause a response of different magnitude (Armstrong 
et al 1996b). In retrospect these may have had an impact worthy of consideration and 
should have had data collected about them. The taking of superficial wound swabs is 
not part of the usual practice in Bath due to this type of swab often giving little 
useful information. Very few individuals would have had a deep wound swab taken. 
The degree of inflammatory change may be related to the degree of inflammation 
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related to the acute or chronic nature of the wound and the virulence of any causative 
infecting organism.  
 
Cardiovascular disease was defined in this study, in the absence of any guidelines as 
to what other studies have used, by the use of medications associated with 
cardiovascular disease. These included statins, fibrates, anti-hypertensives (very 
broadly as such including thiazides and calcium channel blockers amongst others), 
anti - platelet drugs and anti-coagulants. 
 
3.7.1 Recognition of confounding factors 
 
The assessment and data gathering tool was designed to collect information about the 
potential confounding issues present at time of consent as recognised from the 
previous papers on the subject. This included renal function measurements, the use 
of different medications used to treat diabetes including Insulin and Metformin, 
history of both cardio- and peripheral vascular disease and both type and duration of 
diabetes as a disease, and the presence of neuropathy. 
 
3.7.2 Managing confounding factors 
 
The database set up to collate the data included information on the potential 
confounding factors. This allowed for the analysis to potentially consider the effects 
that each may have on the results. The problems of non specific use of terminology 
have been discussed before and the problem it presents in comparing research. 
 
The use of multiple markers reduced the potential for an error due to confounding if 
only one marker had been used. The different processes by which the markers are 
‘activated’ by the inflammatory process and with different potential confounding 
factors affecting different markers it was felt the result would be more robust. The 
markers used were C Reactive Protein, Haemoglobin, Neutrophil Count, Plasma 
Viscosity and Procalcitonin. Procalcitonin was added part way through the study 
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after the publication of a paper that had suggested its potential usefulness (Jeandrot 
et al 2008) in combination with C Reactive Protein in the recognition of infection in 
diabetic foot ulcers. (An amendment to the protocol was sent to the ethics 
committees involved and approval given before it was included.) 
 
3.8 Multiple versus single markers 
 
This confusion over the effect of disease on markers would suggest the need for the 
use of multiple markers and is confirmed by Sattar (2006). The reasoning behind this 
is, again, the time differential in producing markers, the effect of diabetes as a 
disease process and possibly an ineffective immunological response to pathogens.  
Eneroth, Larsson and Apelqvist (1999) developed levels of Haemoglobin, 
Erythrocyte Sedimentation Rate, C Reactive Protein and White Blood Cell count that 
they considered typical of osteomyelitis only, deep soft tissue infection only, and 
combined infection. This was considered potentially useful as a control to measure 
this research against for Haemoglobin and C Reactive Protein. 
 
No work appears to have looked at the utility of inflammatory blood markers in the 
out - patients setting exclusively. 
 
3.9 Setting of research studies 
 
The setting of the research was a multidisciplinary Diabetes Foot Clinic held in an 
English District General Hospital where the reseacher was the lead podiatrist. As 
such the setting was an out patient setting where individuals had been referred for 
help from the specialist team with ‘difficult’ or ‘non responding to treatment’ ulcers. 
The hospital has 687 beds and covers a population of some 550000 from  mixed 
urban and rural communities. It is suported by community hospitals with Minor 
Injury Units.  Referrals to the clinic came from community podiatrists, practice and 
district nurses and General Practitioners. Many of the individuals had marked co-
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morbities including a history of severe foot problems. Severe in this instance 
meaning a previous need for intra venous antibiotics and / or surgical debridment. 
 
3.10 Sample 
 
Individuals were approached that attended the multiprofessional Diabetes Foot 
Clinic in an acute district general hospital. The individuals had been referred for 
specialist care advice and treatment of their foot ulcer to the diabetes team by 
community podiatrists, practice and district nurses and General Practitioners. The 
Diabetes Foot Clinic team consist of a consultant diabetologist with a special interest 
in feet, a consultant vascular surgeon with a special interest in diabetes and feet, two 
experienced podiatrists, an orthotist all with rapid access to a consultant 
microbiologist with a special interest in infectious diseases, consultant 
dermatologists, consultants in orthopaedics, vascular technicians and plaster 
technicians. 
 
The use of broad non specific criteria for the recruitment process was an attempt to 
recruit as many individuals as possible without affecting clinical care. These may be 
the individuals who could be seen to be requiring immediate emergency care for the 
presenting problem. It was ensured it could be seen there was no coercion into 
partaking. Those with a disease different to diabetes that was likely to affect the 
inflammatory markers were not approached nor those who had the potential to be 
harmed by the process e.g. the exposure to an unborn child of the radiation in the 
Single Photon Computed Tomography / Computed Tomography part of the study. 
 
3.11 Method; Ethical statement 
 
Approval from the relevant NHS trusts and from both the University of Bath and 
COREC ethics system was sought and followed. This ensured that ‘good clinical 
practice’ was maintained throughout, and either taking part or refusal did not 
compromise clinical care for that individual or any others. Research governance 
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procedures including securing Research and Development (R&D) approval was also 
performed. The storage of patient sensitive information was also on a NHS computer 
that was sign – on and password protected with additional passwords to access any 
research material.  
 
3.12 Method; Ethical considerations 
 
The additional treatment over and above standard care received in the clinic involved 
the individual undertaking venepuncture where this was not routine practice. It is 
estimated this added approximately five minutes to the clinic attendance time with 
the potential to cause minor inconvenience and minor discomfort with the chance of 
a needlestick injury being rare.   
 
The confidentiality required in obtaining the participants personal information from 
the diabetes data base and laboratory system were covered in the course of normal 
clinical practice by the Caldicott Guardian and Data Protection principals. This 
means only the data that was required for the study was accessed and stored in a 
manner to keep it safe. 
 
Any unexpectedly abnormal blood results were referred to either the patient’s 
General Practitioner or a hospital specialist as agreed in the written consent.  
 
Patients attending for a plain X ray were sent to the main X ray department where a 
‘sit and wait’ system applies for individuals undergoing examination. No preferential 
treatment was given to speed up the process. 
 
All information was stored on a NHS computer user name and password protected. 
The results of the blood analysis and imaging techniques were accessed via 
electronic systems further user name and password protected. 
 
The data was anonymised within the results database. 
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3.13 Inclusion / exclusion criteria 
 
INCLUSION  
� to have  a diabetes related foot ulcer 
� to be able to give informed consent 
 
EXCLUSION 
� to have overwhelming sepsis requiring immediate medical and/or surgical 
treatment 
� to be unable to give informed consent 
� to have an estimated Glomerular Filtration Rate of less than 60ml/hour 
� to have a concurrent disease likely to affect inflammatory markers e.g. 
rheumatoid arthritis 
� to be pregnant 
� to be breast feeding. 
 
3.14 Consent 
 
Individuals were given the patient information sheet as they reported to reception in 
the Diabetes and Endocrinology centre to allow for some time to read the 
information prior to being approached to take part in the research. The patient 
information leaflet had been accepted by the ethics committee as having the wording 
of a certain size and font to assist legibility and also in language suitable for lay 
individuals.  
 
The care that the individual was booked into the clinic to receive was provided prior 
to any discussion about the research.  
 
The patient information sheet asked individuals to consider giving their consent for 
the researcher for both the research, i.e. venepuncture immediately and referral for 
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imaging where deemed appropriate, and, also in addition to use the diabetes database 
to determine basic demographic details and some baseline medical details stored 
about them. The diabetes database is ‘sign on’ and password protected. The details 
noted were age, gender, duration of diabetes, type of diabetes.  The laboratory results 
system that was used to gain access to information such as renal function is also 
‘sign on’ and password protected. (This was also the system for the return of the 
results of the venepuncture for the markers in the research.) Such co-morbid factors 
that required consideration included renal function and history of ischaemic heart 
disease.  
 
After the provision of clinical care the individual was approached by the researcher 
to ask if they had had the opportunity to consider the information provided. Two 
individuals admitted to not being able to read sufficiently well to comprehend the 
sheet. A brief summary was provided by the researcher with the offer of an 
independent individual (the clinic nurse) reading the sheet to them to allow an 
informed choice as to taking part. Both agreed to this and subsequently consented.  
 
Routine care was continued to be provided for all patients – those who choose to 
participate and those who did not. This included the use of antibiotic therapy and 
MRI scans where appropriate.  
 
Any questions that were asked were answered by the researcher. Consent was thus 
informed.  Written consent was obtained from all patients willing to participate. It 
was also made clear at this point that the individual may be asked to participate again 
should there be a significant change in the presentation of their ulcer. 
 
3.15 Method; Wound assessment 
 
To ensure comparisons of similar ulcers occurred they were classified using the two 
ulcer classification systems; the S(AD) SAD and PEDIS ulcer assessment systems.  
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The application of the tool was followed as described in the original paper 
(Macfarlane and Jeffcoate 1999) with the exception of assessment of neuropathy and 
this is detailed within the definitions section of this thesis and below. 
 
The measurements of; S size was measured using a sterile plastic film with a grid 
that can be placed against the wound to determine area (A), observation of depth 
used observation of tissue seen together with a sterile wound measuring probe (D), 
observation of tissue damage for (s)epsis was determined by the presence or absence 
of inflammation and the presence of exudate S, palpation of, or use of a hand held 
Döppler to evaluate pedal pulses (posterior tibial and dorsalis pedis) was performed 
by an experienced clinician to determine (a)rterial disease A, and the assessment of 
(n)erve damage (denervation) by the presence/reduction/ absence of pin prick 
sensation on the dorsum of the affected foot using a monofilament D. This it is 
acknowledged is different from the original research on this tool. The original used a 
Neurotip™, a disposable sharp plastic instrument for testing for the lack of 
sensation, which is now considered to be better tested using the monofilament as 
harm is less likely. 
 
The clinical measurement methods of assessing ischaemia and neuropathy are 
imprecise but recognise typical clinical practice as opposed to a research model and 
are acknowledged as a possible weakness in this classification.  
 
Each of the components of the wound is graded from 0 to 3. The resulting score is 
simple enough to be applied to a large number of lesions in routine practice, and yet, 
is precise enough to be meaningful (Jeffcoate and Game 2006).  
 
The PEDIS approach uses clinical assessments of the individual components and this 
was followed as in the original work described by Apelqvist et al (1999).  
 
A comparison of the two systems chosen was made to determine if either is useful 
either alone or in combination with the blood tests to establish a diagnosis of 
osteomyelitis. 
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The ulcer classifications were performed on a data gathering pro-forma that was kept 
securely with a copy of the patients consent in a locked filing cabinet. The original 
consent was filed in their medical notes and a third copy given to them to keep. 
 
3.16 Method; venepuncture 
 
The standard technique for taking venous blood using a tourniquet on the upper arm 
to distend the brachial and cephalic veins was used. The method used was the 
Vacutainer® manufactured by Becton Dickinson pre-analytical diagnostics. A total 
of two samples were taken; one for the full blood count (including Haemoglobin 
level and Neutrophil Count) and C Reactive Protein level and one for Procalcitonin 
and the Plasma Viscosity. This last sample was required to be both taken and used 
immediately for the Plasma Viscosity and then spun and stored separately in a 
freezer. This was because the samples for Procalcitonin analysis were sent away for 
analysis as a batch. This meant a total of 9 mls of venous blood in two samples was 
taken at or near as possible to the date of consent. 
 
The Becton Dickinson blood collection system is a closed evacuated system, which 
consists of a double-ended needle with safety valve, Becton Dickinson Vacutainer® 
holder and sterile Becton Dickinson Vacutainer® tubes with pre-measured vacuum. 
The collection tubes are made from medical grade Polyethylene Terepthalate which 
is clear, shatter resistant and safer clinical alternative to glass. Blood is collected by 
screwing the sleeve-covered end of the needle into the holder, then puncturing the 
patients’ vein with the other end. After performing venepuncture the tube is then 
pushed down into the holder, and the pre-measured vacuum of the tube allows the 
volume of blood to be drawn. The tubes are colour coded according to the 
appropriate additive and international standards (ISO 6710).  
 
The advantages to this system include; 
    Blood being drawn directly into the tube limits user exposure and 
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    The method of blood collection is standardized including the amount of blood 
mixing it with a consistent quality and quantity of additive.  
 
The tubes used were SST (the gold top) which contains a polymer gel and clot 
activator that accelerate the clotting process and EDTA (the lavender top). The 
additives are specific to the tests required. They were required to be drawn in that 
order i.e. coagulation followed by other additives. The SST tube upon centrifuging 
allows movement of the gel to the upper part of the tube forming a barrier between 
the top layer of serum and bottom layer of cells and fibrin. The gel allows easy 
separation of the two parts. The EDTA tube inhibits coagulation by eliminating the 
calcium in the blood reducing the platelet activation when the blood comes into 
contact with the inner surface of the tube. 
 
The C Reactive Protein, Haemoglobin level, Neutrophil Count and Plasma Viscosity 
were measured immediately within the Royal United Hospital, Bath pathology 
laboratory. As the Procalcitonin could not be processed on site after the Plasma 
Viscosity measurement the storage of the remainder of the SST tube was within the 
hospital laboratory freezer at -20°C. This storage was with access being limited to 
the researcher and one of the consultant clinical biochemists. The Instruction Manual 
from BRAHMS indicates that samples may be frozen and thawed three times 
(BRAHMS PCT LIA version 05us). 
 
For those individuals without clinical suspicion of osteomyelitis (or those in whom 
osteomyelitis was confirmed by plain X ray) this was all the blood taken for this 
episode.  
 
Should any of the ulcers have changed during the study period whilst the individual 
was under follow up they were asked to consider consenting to the entire process 
again.  
 
The venepuncture of the group undergoing imaging studies was at the consent and 
clinical suspicion phase and repeated at a time as close as possible to the 
 82 
confirmation/exclusion of bone infection by the MRI scanning procedure and if 
necessary and consented to SPECT/CT. To ensure this correlation between disease 
process and blood markers venepuncture was undertaken within a week of the MRI 
and SPECT/CT scans.  
3.17 Data collection tool 
 
The data collection tool was developed to allow all the information for each 
participant to be on one piece of paper and as such included date of consent, date of 
venepuncture, results of venepuncture, referral (or not) to imaging with second 
venepuncture results, S(AD) SAD ulcer score, age, gender, type of diabetes (1 or 2) , 
duration of disease, use of potential confounding medication to blood results – i.e. 
Insulin, Metformin hydrochloride, and history of renal impairment, cardiovascular 
and peripheral vascular disease. The completed forms were stored in a locked filing 
cabinet. The tool was amended as the protocol changed to include Procalcitonin.  
3.18 Method; Imaging studies 
 
Any wound with suspicion of osteomyelitis was sent for plain X ray as a baseline. 
Any individual with continued suspicion despite the result (made by the radiology 
team reading the film not just the clinicians in the Diabetic Foot Clinic looking at the 
film on the computer immediately after imaging) was referred for Magnetic 
Resonance Imaging (where appropriate both clinically and individually) and Single 
Photon Computed Tomography / Computed Tomography. If confirmed, the method 
used was noted in the results database. 
 
For more detail about the scanning methodology see chapter 6. 
3.19 Analysis; of the blood markers 
 
Data was returned from the pathology laboratory via an electronic system. This 
required the clinician collecting the data to have a ‘sign on’ name and password. An 
audit trail is produced whenever an individual 'logs on' and as such it can be ensured 
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that only relevant information is retrieved. Each individual will be identified by their 
unique hospital number to access the results. Access to the hospital appointment 
system to look up personal information from the number is also ‘sign on’ and 
password protected. Data was stored on a non networked PC with password access 
to open and also to change the document in terms of adding more results.  
 
3.20 Measurement of the specific inflammatory blood markers 
 
3.20.1 Haemoglobin and Neutrophil Count 
 
The measurement of Haemoglobin levels to determine the presence or absence of 
anaemia was performed on a Beckman Coulter LH750 automated analyser. This was 
also used for the determination of the Neutrophil Count. The quality control within 
the laboratory meant any grossly abnormal reading was checked ‘manually’ using a 
blood film and microscopy.  
 
3.20.2 Plasma Viscosity 
 
The measurement of Plasma Viscosity was performed on an automated Benson 
Viscometer with an in built quality control solution to ensure accuracy. 
 
3.20.3 C Reactive Protein 
 
The measurement of C Reactive Protein was analyzed on a Roche analyzer based 
upon a particle-enhanced immunturbidimetric assay – the immunological test 
principle. This involves the use of a buffer to produce an anti - C Reactive Protein 
antibody which is then coupled with latex microparticles. The level of the 
antibody/antigen complex can be determined turbidimetrically after agglutination 
and this is what gives the measurement.  
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3.20.4 Procalcitonin 
 
The measurement of Procalcitonin was using the B.R.A.H.M.S. 
Immunoluminometric assay. This method detects Procalcitonin at a very low level 
and is useful in the detection of bacterial infections. The method involves 
Procalcitonin acting as an antigen binding with two antigen-specific antibodies (two 
different sites exist). One of the complexes formed (the antibody acting as a tracer) is 
luminescence labelled and the other is fixed to the inner walls of the tubes. During 
the incubation of the sample both antigen-antibody complexes combine within the 
sample to form ‘sandwich complexes’. This allows the total amount of Procalcitonin 
is measured by an estimation of the luminescence. 
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Chapter 4 Results The use of inflammatory blood markers 
in the diagnosis of osteomyelitis 
 
4.1 Statistical analysis of results of blood samples 
 
The data was collated into a database specifically designed for the study and coded 
to allow for easy analysis of each of the markers and each of the groups of infection. 
The computer software package of the Statistical Package for Social Scientists 
(SPSS) version 14 was used. 
 
The following chapter provides the results of the analysis of the blood samples. The 
analysis includes a calculation of mean (and / or median) value of each marker 
overall and in each of the groups; clean, cutaneous infection, suspected osteomyelitis 
and conformed osteomyelitis. NB these groups are not mutually exclusive in that an 
individual may have a cutaneous infection in addition to a confirmed osteomyelitis. 
A Receiver Operator Characteristic curve was produced for each group and a 
regression analysis for each group.  The potential confounders were also considered 
within regression analysis.  Correlation between the inflammatory markers was 
explored to determine if there was any relationship between the different markers 
being used.  
 
A total of three individuals agreed and signed the consent but did not agree to have 
venepuncture whilst in clinic and did not go on to have blood taken. One asked at a 
latter date for the blood results to be withdrawn from the study and this wish was 
fulfilled. 
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4.2 Sample characteristics - age 
 
Descriptive statistics; age, minimum 35 years, maximum 93 years, mean 66 years 
(standard deviation  ± 14 years).  
 
Table 4.1 sample characteristics - gender 
 
Gender Frequency n (%) 
Male 70 (78%) 
Female 20 (22%) 
 
Table 4.2 sample characteristics - type of diabetes 
 
type of diabetes Frequency N (%) 
type 1 17 (19%) 
type 2 73 (81%) 
 
Table 4.3 sample characteristics – diabetes treatment  
 
Treatment  type 1 (n=17) (%) type 2 (n=73) (%) 
Insulin 17 (100%) 38 (52%) 
Metformin 2 (12%) 41 (56%) 
 
4.3 HbA1c levels 
 
(n=79) Mean 8.0% minimum 5.2% maximum 14.9% 
 
Table 4.4 sample characteristics – duration since diagnosis  
 
Duration  Years  
Minimum, maximum  1.00, 55.00 
Median years, interquartile range 13.50, 5.00 – 20.25 
 
Numbers with clean wounds / with cutaneous infection / with suspected 
osteomyelitis and with confirmed osteomyelitis (NB groups are not mutually 
exclusive i.e. an individual may have a cutaneous infection and also have confirmed 
osteomyelitis). 
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The use of the ulcer classification systems did not add to the diagnostic prediction of 
wound types either alone or in combination with the blood results but did allow for 
comparison of similar wounds to occur within the analysis. 
 
 
 
Table 4.5 numbers of wound types  
 
Wound type yes (%) no (%) 
Clean 33 (37) 57 (63) 
Cutaneous infection 61 (68) 29 (32) 
Suspected osteomyelitis  32 (36) 58 (64) 
Confirmed osteomyelitis   33 (37) 57 (63) 
 
Table 4.6 descriptive statistics in all wound types for each inflammatory 
marker  
 
Marker Accepted 
normal 
range 
Number Minimum Maximum Mean 
(±Std 
dev) 
Median 
(IQR)  
Neutrophil 
count  
x 109 / l 
2 – 7.5 90 1.9 16.0 6.07 
(±2.67) 
5.60 
(4.08 -
7.40) 
Haemoglobin  
g /dl 
>11 90 8.4 15.50 12.30 
(±1.61) 
12.40 
(11.18 – 
13.40) 
Haemoglobin  
g /dl 
excluding 
potential 
renal anaemia 
>11 83 8.6 15.10 12.38 
(±1.48) 
12.40 
(11.40 – 
13.40) 
C Reactive 
Protein g / l 
<5 90 4.99 215.00 22.95 
(±33.37) 
10.00 
(4.99 – 
27.00) 
Plasma 
Viscosity 
mpas 
1.50 – 
1.72 
89 1.50 2.72 1.83 
(±0.21) 
1.77 
(1.77 – 
1.91) 
Procalcitonin 
ng / ml 
<0.3 49 0.01 0.93 0.06 
(±0.14) 
0.03 
(0.02 – 
0.04) 
 
4.3 Summary statistics for each marker in each state separately  
 
The figures in Appendix 9 are descriptive for each marker and each wound condition 
with a summary table overleaf. Summary descriptive statistics are corrected to two 
decimal places except for Procalcitonin where the low figure has meant three 
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decimal places are used. (The individuals with a result ≥ 0.6 ng/ml have been 
removed see page 103). 
 
Those individuals with a reduced renal function, such that anaemia maybe a 
consequence have been removed from all statistics where Haemoglobin is considered 
from here on. 
 
Table 4.7 summary statistics of each inflammatory marker in each wound condition  
n = number SD = standard deviation IQR = interquartile range  
Marker  Accepted 
Normal 
range 
Clean 
wounds 
Cutaneous 
infection 
Suspected 
osteomyelitis 
Confirmed 
osteomyelitis 
Neutrophil 
count x109 / l 
(mean)  
2 – 7.5 5.57 6.43 6.34 6.40 
Haemoglobin 
g / dl (mean)  
>11 n = 28 
12.64 
SD ±1.54 
n = 57 
12.29 
SD ±1.50 
n = 30 
12.26 
SD ±1.57 
n = 29 
12.24 
SD ±1.64 
Haemoglobin 
g / dl 
(median)  
>11 n = 28 
12.60 
IQR 
11.95,13.75 
n = 57 
12.30 
IQR 
11.3,13.2  
n = 30 
12.30 
IQR 
10.98,13.87 
n = 29 
12.40 
IQR 
10.90,13.80 
C reactive 
protein 
(mean) mg / l  
>5 n = 30 
11.03 
SD ±15.89 
n = 61 
28.16 
SD ±38.51 
n = 32 
24.53 
SD ±40.65 
n = 33 
29.33 
SD ±42.58 
C reactive 
protein 
(median)  
mg / l 
>5 n = 30 
6.00 
IQR 
4.99,10.5 
n = 61 
13.00 
IQR 
5.49,32.00 
n = 32 
10.50 
IQR 4.99,24.25 
n = 33 
13.00 
IQR 4.99,31.50 
Plasma 
viscosity 
(mean) mpas  
1.5 – 1.72 n = 30 
1.76 
SD ±0.13 
n = 60 
1.87 
SD ±0.22 
n = 31 
1.83 
SD ±0.18 
n = 32 
1.86 
SD ±0.22 
Plasma 
viscosity 
(median) 
mpas  
1.5 – 1.72 n = 30 
1.75 
IQR 
1.66,1.86 
n = 60 
1.79 
IQR  
1.70, 1.98 
n = 31 
1.81 
IQR 1.70,1.93 
n = 32 
1.82 
IQR 1.71,1.95 
Procalcitonin 
(mean)  
ng / ml  
<0.3 n = 17 
0.027 
SD ±0.008 
n = 34  
0.101 
SD ±0.225 
n = 22 
0.035 
SD ±0.025 
n = 21 
0.100 
SD ±0.210 
Procalcitonin 
(median)  
ng / ml  
<0.3 n = 17 
0.030 
IQR 0.209, 
0.300 
n = 34 
0.030 
IQR 
0.020,0.020 
n = 22 
0.030 
IQR 
0.020,0.040 
n = 21 
0.030 
IQR 
0.020,0.050 
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4.4 Box plots of each marker in each wound state together 
 
Haemoglobin for those with the potential for renal anaemia removed. Accepted 
normal ranges for Neutrophil Count, Haemoglobin, C Reactive Protein and Plasma 
Viscosity are for the Royal United Hospital, Bath, United Kingdom and for 
Procalcitonin for Queens University, Belfast, United Kingdom. 
 
The term selected is used when a result has been selected as belonging to that state 
(that is either clean, with cutaneous infection, suspected or proven osteomyelitis). 
The extreme cases that do not fit within the range of the group are indicated by the 
circles. It can be seen some extreme cases appear over several markers but it is not 
consistently the same individual in all. 
 
 
 
 
Figure 4.4.1 Comparison of Neutrophil Count in all wound conditions  
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Figure 4.4.2 Comparison of Haemoglobin level in all wound conditions (excludes 
renal impairment)   
Accepted normal ♂ 13.5 – 15.5 g/ dl ♀ 11.5 – 15.5 g /dl 
  
 
 
 
Figure 4.4.3 Comparison of CRP level in all wound condition 
Accepted normal < 5 mg / l 
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Figure 4.4.4 Comparison of Plasma Viscosity level in all wound conditions  
Accepted normal 1.5 – 1.72 mpas 
  
 
Figure 4.4.5 Comparison of Procalcitonin level in all wound conditions  
Accepted normal in ‘healthy’ individuals <0.3ng/ml 
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4.5 Receiver Operator Characteristic Curves 
 
Receiver operator characteristic curves are a plot of the sensitivity (detection rate) 
versus false positive rate (100 - specificity %) for selected cut off points. An ideal 
situation gives a result with the graph having a line up the y axis to near the top left 
corner and across parallel to the x axis – high detection rate with a low false positive 
rate. An ideal test would be both specific and sensitive. 
confirmed osteomyelitis suspected ostemyelitis cutaneous  infection clean 
type of infection 
2.80 
2.60 
2.40 
2.20 
2.00 
1.80 
1.60 
le
v
e
l o
f P
la
sm
a
 
Vi
sc
o
si
ty
 
m
pa
s
 
 
 92 
 
Figure 4. 5.1 Receiver Operator Characteristic Curve – clean wounds 
This is for each inflammatory blood marker in clean wounds 
(With Haemoglobin excluding potential renal anaemia) 
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Area Under the Curve 
Test Result Variable(s) Area 
Neutrophil Count 
.383 
Haemoglobin 
.610 
C Reactive Protein 
.319 
Plasma Viscosity 
.334 
Procalcitonin 
.393 
 
 
 
 
 
 93 
 
Figure 4.5.2 Receiver Operator Characteristic Curve – cutaneous infection in wounds 
This is for each inflammatory blood marker in cutaneously infected wounds 
(With Haemoglobin excluding potential renal anaemia) 
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Figure 4.5.3 Receiver Operator Characteristic Curve – suspected osteomyelitis 
infected wounds 
This is for each inflammatory blood marker in suspected osteomyelitis infected 
wounds (With Haemoglobin excluding potential renal anaemia) 
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.480 
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Figure 4.5.4 Receiver Operator Characteristic Curve – confirmed osteomyelitis 
infected wounds 
This is for each inflammatory blood marker in proven osteomyelitis infected wounds 
(With Haemoglobin excluding potential renal anaemia) 
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Area Under the Curve 
Test Result Variable(s) Area 
Neutrophil Count 
.526 
Haemoglobin 
.472 
C Reactive Protein 
.498 
Plasma Viscosity 
.537 
Procalcitonin 
.590 
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4.6 Logistic Regression analysis without recognising confounders 
 
Regression is a method whereby a statistical method is used to predict an outcome 
variable (in this study the outcome variable is the wound being clean, having a 
cutaneous infection, having suspected or proven osteomyelitis) by the use of  
predictor variables (the inflammatory blood marker level). The level of significance 
used was p ≤ 0.5. The full results of the regression analysis can be found in 
Appendix 11. 
 
Table 4.8 Logistic Regression analysis without recognising potential confounders 
predicting all wound types  
 
Wound type Marker that is 
significant  
level of 
significance p = 
Exp(B) 95% 
Confidence 
intervals 
Clean Plasma 
Viscosity 
0.05 77.02 0.95, 
6245.65 
Cutaneous 
infection 
Neutrophil 
Count 
0.05 0.70 0.49, 0.99 
Suspected 
osteomyelitis  
None N/A   
Confirmed 
osteomyelitis   
None N/A   
 
4.7 Logistic Regression analysis with recognised potential confounders 
 
The same regression technique was used and the confounders of antibiotic use, 
Insulin use, Metformin use and the wound being predominantly neuropathic in origin 
are now presented. The patients attending the Diabetes Foot Clinic may not have 
been prescribed antibiotics by the primary care team that had referred them so the 
apparent anomaly of not using antibiotics in infections is thus explained. The level of 
significance of less than 0.05 was requested in the determination of the results and as 
such some levels are greater than the accepted norm of p < 0.05. The level is of 
sufficient for the inflammatory marker to be included in an equation to predict a 
wound condition. 
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Table 4.9 Potential confounders in regression analysis predicting clean wounds 
 
 
Confounder marker that is 
significant  
level of 
significance p = 
Exp(B) 95% 
Confidence 
intervals 
no antibiotics C Reactive 
Protein 
0.07 1.16 0.99, 1.36 
Insulin treatment None N/A   
Metformin 
treatment 
None N/A   
Etiology 
predominantly 
neuropathic 
None N/A   
 
 
 
 
 
 
 
Table 4.10 Potential confounders in regression analysis predicting wounds with 
cutaneous infection 
 
confounder marker that is 
significant  
level of 
significance p =  
Exp(B) 95% 
Confidence 
intervals 
no antibiotics Neutrophil 
Count 
0.09 0.54 0.27, 1.11 
Insulin treatment Neutrophil 
Count 
0.05 0.56 0.33, 0.96 
Metformin 
treatment 
None N/A   
Etiology 
predominantly 
neuropathic 
Neutrophil 
Count 
0.05 0.65 0.42, 0.99 
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Table 4.11 Potential confounders in regression analysis predicting wounds with 
suspected osteomyelitis 
 
confounder marker that is 
significant  
level of 
significance p =  
Exp(B) 95% 
Confidence 
intervals 
no antibiotics Plasma 
Viscosity 
0.06 < 0.01 0.00, 1.70 
Insulin treatment None  N/A   
Metformin 
treatment 
None  N/A   
Etiology 
predominantly 
neuropathic 
None  N/A   
 
 
 
 
 
 
Table 4.12 Potential confounders in regression analysis predicting wounds with 
confirmed osteomyelitis 
 
confounder marker that is 
significant  
level of 
significance p =   
Exp(B) 95% 
Confidence 
intervals 
no antibiotics Plasma 
Viscosity 
0.09 < 0.01 0.00, 4.10 
Insulin treatment None  N/A   
Metformin 
treatment 
None  N/A   
Etiology 
predominantly 
neuropathic 
None N/A   
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Table 4.13 Comparison of C Reactive Protein in all individuals with type 
2 diabetes to those with type 2 diabetes AND on Metformin and BMI 
>25 kg / m2 for all wound types 
 
 Type 2 diabetes Type 2 diabetes AND 
on Metformin 
AND BMI ≥ 
25 kg / m2 
Mean 
(±Standard 
deviation) 
23.76 (±35.82) 31.85 (±57.28) 
Median 
(Interquartile 
range) 
10.00(4.99, 
26.00) 
10.00 (4.99, 
26.50) 
 
 
 
The high probability of the level of each of the inflammatory markers being strongly 
correlated to at least one other marker is shown in the tables below. 
 
 
Table 4.14 Correlations between inflammatory markers in clean wounds   
  
 Neutrophil 
Count 
Haemoglobin C 
Reactive 
Protein 
Plasma 
Viscosity 
Procalcitonin 
Neutrophil 
Count 
1 - 0.048 0.666** 0.423* 0.546* 
Haemoglobin - 0.048 1 0.139 - 0.166 0.242 
C Reactive 
Protein 
0.666** 0.139 1 0.520** 0.228 
Plasma 
Viscosity 
0.423* - 0.166 0.520** 1 - 0.217 
Procalcitonin 0.546* 0.242 0.228 - 0.217 1 
 
Correlation is Pearson correlation 
** Correlation is significant at p ≤ 0.01 level (2 tailed) 
* Correlation is significant at p ≤ 0.05 level (2 tailed) 
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Table 4.15 Correlations between inflammatory markers in wounds with 
cutaneous infection  
 
 Neutrophil 
Count 
Haemoglobin C 
Reactive 
Protein 
Plasma 
Viscosity 
Procalcitonin 
Neutrophil 
Count 
1 - 0.042 0.513 0.426** 0.044 
Haemoglobin - 0.042 1 - 0.187 - 0.225 - 0.060 
C Reactive 
Protein 
0.513 -0.187 1 0.470** 0.204 
Plasma 
Viscosity 
0.426** - 0.225 0.470** 1 0.141 
Procalcitonin 0.044 - 0.060 0.204 0.141 1 
 
Correlation is Pearson correlation 
** Correlation is significant at p ≤ 0.01 level (2 tailed) 
* Correlation is significant at p ≤ 0.05 level (2 tailed) 
 
 
 
 
Table 4.16 Correlations between inflammatory markers in suspected 
osteomyelitis  
 
 Neutrophil 
Count 
Haemoglobin C 
Reactive 
Protein 
Plasma 
Viscosity 
Procalcitonin 
Neutrophil 
Count 
1 - 0.343 0.582** 0.177 - 0.201 
Haemoglobin - 0.343 1 - 0.211 - 0.458* - 0.245 
C Reactive 
Protein 
0.582** - 0.211 1 0.432* 0.165 
Plasma 
Viscosity 
0.177 - 0.458* 0.432* 1 - 0.051 
Procalcitonin - 0.201 - 0.245 0.165 -0.051 1 
 
Correlation is Pearson correlation 
** Correlation is significant at p ≤ 0.01 level (2 tailed) 
* Correlation is significant at p ≤ 0.05 level (2 tailed) 
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Table 4.17 Correlations between inflammatory markers in confirmed 
osteomyelitis  
 
 Neutrophil 
Count 
Haemoglobin C 
Reactive 
Protein 
Plasma 
Viscosity 
Procalcitonin 
Neutrophil 
Count 
1 - 0.193 0.629** 0.341 0.081 
Haemoglobin - 0.193 1 - 0.102 - 0.124 - 0.064 
C Reactive 
Protein 
0.629** - 0.102 1 0.510** 0.355 
Plasma 
Viscosity 
0.341 - 0.124 0.510** 1 0.225 
Procalcitonin 0.081 - 0.064 0.355 0.225 1 
 
Correlation is Pearson correlation 
* Correlation is significant at p ≤ 0.01 level (2 tailed) 
** Correlation is significant at p ≤ 0.05 level (2 tailed) 
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Chapter 5 Discussion The use of inflammatory blood 
markers in the diagnosis of osteomyelitis 
 
This chapter will discuss the results found and consider them in relation to the 
previous studies that have been identified. However it is worth restating the fact that 
none of the papers found to date about the use of inflammatory markers have 
considered using them in an out - patient setting. 
 
5.1 Sample characteristics 
 
The sample in this research shows characteristics broadly similar to that of Eneroth , 
Larson and Apelqvist (1999) in terms of mean age, this study 66 years compared to 
70 years, being older than that of Armstrong et al (1996b) – 58.7 - 62.3 years (3 
centres) and Leichter et al (1988) – 53.5 years. These other papers are describing 
patients who had been admitted as a consequence of their foot lesion.  
 
In terms of duration of diabetes Armstrong et al (1996b) shows his three centres to 
have a mean range of duration from 14.7 years to 15.8 years, in this study the mean 
was 14.9 years, similar and that of Lavery et al (2006) at 13.9 years. 
 
The ‘excess’ male patients is a well recognized occurrence in diabetic foot disease 
being noted by amongst others Reiber (1996), El-Shazley et al (1998), Wikblad, 
Wibell and Montin (1990) and Benotame et al (2000). 
 
Leichter et al (1988) describe a proportion of some 70% having type 2 diabetes as 
opposed to 80% in this study. The increase in patients with diabetes has seen the 
largest increase in type 2 diabetes in latter years and this maybe shown in part by the 
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larger numbers here presented. 
 
The use of Insulin in treatment in this study – 61% is not comparable to that of 
Eneroth et al  (1999) reporting 70% in infections that were either deep soft tissue or 
a combination it did not include the clean wounds of this study but more like that of 
Leichter et al (1988) reporting 63.6%. 
 
The results may have been affected by the nature of the presenting problem in a 
number of individuals making them atypical out patients. Although seen in an out – 
patient setting there was a total of two who were being treated with home intra – 
venous antibiotics and this historically has been an in – patient procedure, one had an 
infection that the team would to have preferred to have treated as an in – patient but 
he refused admission and an additional two were admitted not from clinic but within 
a couple of days for surgical debridement and further investigations as to determine 
if the infection was local and contained within the skin or had progressed to bone 
infection. This was most noticeable in the results for Procalcitonin where the mean 
(with standard deviation) and median for cutaneous infection including these to not 
including them was 0.05 ng / ml (± 0.08 ng /ml), median, 0.03 ng /ml (accepted 
normal 0.03 ng /ml), in suspected osteomyelitis 0.04 ng /ml (±0.03 ng /ml), median 
0.03 ng / ml and in proven osteomyelitis 0.06 ng /ml (±0.10 ng /ml) median 0.03 ng 
/ml. The data presented has still included them in most results presented however it 
could be argued they should be excluded as they are in Table 4.7 on page 86. 
  
5.2 Descriptive statistics of Inflammatory blood markers 
 
The following is a discussion about the results of the study overall and not for each 
of the wound types that follows after. Table 4.7 on page 85 summarizes the range of 
the inflammatory blood markers results within this study with an accepted normal 
for comparison.  
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5.2.1 Neutrophil Count 
The range and mean of the Neutrophil Count appears to be in line with the accepted 
normal of the pathology laboratory. This is with a group of individuals where 
infection is suspected in 63% so the level may have been expected to be high. The 
mean is seen to be towards the ‘high end of normal’. 
 
5.2.2 Haemoglobin 
The Haemoglobin levels show the range to be generally at the ‘lower end of normal’ 
even when the potential for renal anaemia is excluded. The effect of chronic disease 
causing anaemia has been discussed previously. Chronic infection can add to this too 
and there was no effort made within this study to determine how long the wounds 
had been present. The level is approaching that considered to be indicative of 
anaemia of 11g /dl by the World Health Organization. 
 
5.2.3 C Reactive Protein 
This study was limited by the pathology laboratory not being able to analyze C 
Reactive Protein below 5 mg / l for the biggest part of this study. This has limited the 
results in that many were reported as < 5 mg / l and considered to be ‘normal’ and 
the results are difficult to interpret from this. It also is a marker that, as can be seen, 
has a very large range. The mean is above the considered normal and this would be 
expected in wounds of any description.  
 
5.2.4 Plasma Viscosity 
The range of readings shows the mean to be just above that to be considered normal. 
This is discussed in more detail in the section about confounders in regression as it is 
recognized that the haematological determinants of blood flow resistance do have 
some association with endocrine and vascular disorders (MacRury et al 1990 and 
Coppola et al 1997), namely neuropathy and Insulin in type 2 diabetes. 
 105 
5.2.5 Procalcitonin 
To date little is known about the effect of diabetic foot ulceration on levels of 
Procalcitonin as it has been used more commonly in Systemic Inflammatory 
Response Syndrome. There were five individuals in this study that although they 
were being treated in an out patients setting in – patient care may have been more 
usual and this may have had a profound effect on the results. Removing these 
individuals the remainders appear to be contrary to the work reported by both Uzun 
et al (2007) and Jeandrot et al (2008). The median (used as the central point as in the 
two studies mentioned above) does not appear to rise in the series presented here 
from clean wounds to those with proven osteomyelitis. (The atypical use of an out-
patients setting is discussed in more detail in the section about sample 
characteristics.) 
   
5.3 Inflammatory blood markers in clean wounds 
 
The mean Neutrophil Count is within the ‘normal’ range expected when no infection 
is present. The Haemoglobin is within the ‘normal’ range. C Reactive Protein shows 
some rise compared to ‘normal’ and this maybe due to the disease process of 
diabetes being an inflammatory process which is discussed later. Plasma Viscosity is 
close to ‘normal’ when looking at the mean, Coppola et al (1997) has shown this 
high end of ‘normal’ to be present in type 2 diabetes and with Insulin use. MacRury 
et al (1990) had shown the rise of Plasma Viscosity to be associated with neuropathy 
in diabetes. Individuals with foot wounds associated with diabetes would be 
expected to show some degree of neuropathy. The mean Procalcitonin level is as 
would be expected low.  
 
5.4 Inflammatory blood markers in cutaneous infection  
 
The expected pattern when infection occurs would be for Haemoglobin to reduce and 
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all other markers to rise.  
 
The Neutrophil Count is seen to have risen compared to clean wounds but is still 
within the ‘normal’ range. Most diabetic foot ulcers, when showing signs of 
infection, are infected by bacteria. As neutrophils are the cell responsible for 
bacterial killing it would be expected that a rise above ‘normal’ would occur. This 
maybe from the recognized defects in leucocyte chemotactic factors that have been 
observed when a poor inflammatory response occurs (Bagdale, Root and Bulger 
1974, Tan et al 1975 and Molenaar et al 1976). The poor inflammatory response is a 
complication associated with chronic hyperglycaemia and includes the prime 
problems of diabetic foot disease, namely neuropathy and ischaemia. 
 
C Reactive Protein shows a rise that is consistent with infection causing an acute 
phase reaction to occur when comparing both mean and median to ‘normal’, normal 
<5 mg/l, mean 28.16 mg /l, median 13.00 mg /l.  
 
Plasma Viscosity rises a little more than in clean wounds, the change is small. 
 
Procalcitonin rises but is still at a level that is considered to be ‘normal’. 
  
As has been discussed in the introduction questions have been raised about the 
response of people with diabetes to develop these markers (Armstrong et al 1996 and 
Leichter et al 1998, Oncul et al 2006). It has been recognized that the cardinal signs 
of infection can be both mimicked and obscured by the diabetes associated 
complications of ischaemia or neuropathy (Cavanagh et al 2005).  The changes in 
the microvessels affect both delivery of the cells required and the inflammatory 
response (Sannomyia, Pereira and Garcia-Leme 1990).  
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5.5 Inflammatory blood markers in suspected osteomyelitis 
 
None of the markers show any significant change between cutaneous infection and 
suspected osteomyelitis. From this study it is unclear if the use of antibiotic therapy 
has reduced the inflammatory response and as such the markers do not show any 
change. 
 
5.6 Inflammatory blood markers in proven osteomyelitis  
 
Again none of the markers show any significant change between cutaneous infection 
and suspected osteomyelitis. From this study it is unclear if the use of antibiotic 
therapy has reduced the inflammatory response and as such the markers do not show 
any change. 
 
The lack of change in levels of the markers maybe affected by the disease process of 
diabetes as discussed above and in the introduction or due to the use antibiotics 
 
5.7 Receiver Operator Characteristic curve in clean wounds 
 
None of the inflammatory markers show any sign of being of potential use with 
clean wounds. The lack of both sensitivity and specificity is seen by the lines being 
close to the reference line. Haemoglobin shows a low sensitivity at the ‘highest’ 
point of about 40% with a specificity of 80%. The other markers are both less 
sensitive and specific. 
5.8 Receiver Operator Characteristic curve in cutaneous infection 
 
The influence of infection on Haemoglobin appears to be evident in this Receiver 
Operator Characteristic (ROC) curve in this in comparison to that for clean wounds 
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in that the Haemoglobin in that it is becoming less sensitive. The other markers are 
nearer the area of the curve where a useful marker would be – the top right being 
both sensitive and specific. The Area Under the Curve statistic is better when the 
value is nearer 1. Plasma Viscosity shows the greatest Area Under the Curve at 
0.654. 
 
Neutrophil Count, C Reactive Protein and Plasma Viscosity all show a sensitivity of 
approximately 60% with a specificity of 30% at best. These may be useful when 
combined with clinical findings. 
 
5.9 Receiver Operator Characteristic curve in suspected osteomyelitis 
 
As in the clean wounds no marker shows any sign of being of potential benefit with 
Plasma Viscosity showing the best result at 55% sensitivity and 30% specificity or 
60% sensitive and 90% specific. This may be useful when combined with clinical 
suspicion. However the Neutrophil Count provides a greater Area Under the Curve 
of 0.505 with the sensitivity of 85% and specificity of 70%. 
 
5.10 Receiver Operator Characteristic curve in proven osteomyelitis 
 
The markers seem to show an equal non specific and non sensitivity to confirmed 
osteomyelitis. 
 
None of the ROC curves show any outstanding benefit of using a marker in the 
diagnosis of a cutaneous or bone infection in this series. 
5.11 Regression models with no confounders in clean wounds 
 
The regression model shows Plasma Viscosity to be predictive of the condition 
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unlike the Receiver Operator Characteristic curve. Plasma Viscosity in this model 
has a statistical significance of p = 0.053. 
  
5.12 Regression models with no confounders in cutaneous infection 
 
Neutrophil Count has a statistical significance of p = 0.08 and is predictive of the 
condition. 
 
5.13 Regression models with no confounders in suspected osteomyelitis 
 
No marker is of clear use with levels of significance far above the accepted p < 0.05. 
 
5.14 Regression models with no confounders in proven osteomyelitis 
 
No marker is of clear use with levels of significance far above the accepted p < 0.05. 
 
 
5.15 Regression models with confounders in clean wounds 
 
5.15.1 No antibiotic use 
 
C Reactive Protein is marginally statistically significant, (p = 0.07) and is recognized 
as being of sufficient value to add to any equation to determine a clean wound. This 
would follow the argument of Upchurch et al 1997) that diabetes and (my emphasis) 
having a foot wound raises the C Reactive Protein level. 
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5.15.2 Use of Insulin 
 
Neutrophil Count is significant and recognized as being of sufficient value to add to 
any equation to determine a clean wound (p = 0.05). 
 
Plasma Viscosity is no longer significant (p = 0.29 Insulin use vs. p = 0.05 no 
confounders)  and is not recognized as being of sufficient value to add to any 
equation to determine a clean wound as suggested by Coppola et al (1997). 
 
5.15.3 Use of Metformin 
 
No marker is significant. 
 
5.15.4 Predominantly neuropathic wounds 
 
No marker is significant Plasma Viscosity is less significant (p = 0.07 neuropathic 
vs. p=0.05 no confounder) in agreement with the suggestion by MacRury et al 
(1990). 
 
C Reactive Protein is still no longer significant (p = 0.05 neuropathic vs. p = 0.13 no 
confounder). This would follow the argument of Upchurch et al 1997) that diabetes 
and (my emphasis) having a foot wound raises the C Reactive Protein level. If it can 
be argued that ischaemia means C Reactive Protein rises then a predominantly 
neuropathic wound with a lesser influence by ischaemia then C Reactive Protein 
should reduce this result is counter to the argument of Yu et al (2004). 
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5.16 Regression models with confounders in cutaneous infection 
 
5.16.1 No antibiotic use 
 
Neutrophil Count remains significant, within the equation but not statistically, (p = 
0.09 no antibiotic use vs.  p = 0.05 no confounder) and is predictive. Pittet et al 
(1999) suggested Neutrophil Count was not able to predict outcome of foot lesions. 
 
C Reactive Protein remains non significant (p=0.24 no antibiotic vs.  p = 0.19 no 
confounder). 
 
Plasma Viscosity remains non significant (p = 0.19 no antibiotic vs.  p = 0.20 no 
confounder). 
 
5.16.2 Use of Insulin 
 
Neutrophil Count remains significant (p = 0.04 Insulin use vs.  p = 0.05 no 
confounder) and is still considered to be in an equation to determine cutaneous 
infection. Again this is counter to the work of Pittet et al (1999) suggesting 
Neutrophil Count was not able to predict outcome of foot lesions. 
 
C Reactive Protein is not of a level to be significant in the equation (p = 0.04 Insulin 
use vs.  p = 0.19 no confounder). 
 
Plasma Viscosity is not of a level to be significant (p = 0.09 Insulin use vs.  p = 0.20 
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no confounder) but has become of marginal significance as suggested by Coppola et 
al (1997). 
 
5.16.3 Use of Metformin 
 
No marker is predictive of the condition. 
 
Neutrophil Count is no longer significant (p = 0.42 Metformin use vs.  p = 0.05 no 
confounder). This follows the work of Pittet et al (1999) suggesting Neutrophil 
Count was not able to predict outcome of foot lesions. 
 
C Reactive Protein is not significant (p = 0.20 Metformin use vs. p = 0.19 no 
confounder). It is known that 24 individuals in this study were ‘overweight’ and had 
‘type 2 diabetes’ together, this follows the suggestion by Carter et al (2005) that 
Metformin reduces C Reactive Protein. The Carter et al (ibid) study was however on 
individuals with type 2 and ‘overweight’ and on Metformin, in this study of 
osteomyelitis only 14 individuals had all three characteristics making any inference 
lacking in power. 
 
Plasma Viscosity is not significant (p = 0.32 Metformin use vs. p = 0.20 no 
confounder). 
 
5.16.4 Predominantly neuropathic wounds 
 
Neutrophil Count keeps the same significance (p = 0.05 neuropathic vs. p = 0.05 no 
confounder) and remains in the equation to predict cutaneous infection. Again this is 
counter to the work of Pittet et al (1999) suggesting Neutrophil Count was not able 
to predict outcome of foot lesions. 
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C Reactive Protein remains of non significance (p = 0.12 no confounder vs. p = 0.16 
neuropathic). It is known a total of 24 individuals in this study were ‘overweight’ 
and had ‘type 2 diabetes’ together, and 14 were all three of type 2, ‘overweight’ and 
took Metformin, this follows the suggestion by Carter et al (2005) that Metformin 
reduces C Reactive Protein. As in clean wounds if it can be argued that ischaemia 
means C Reactive Protein rises then a predominantly neuropathic wound with a 
lesser influence by ischaemia then C Reactive Protein should reduce this result is 
again counter to the argument of Yu et al (2004). 
 
Plasma Viscosity is not significant (p = 0.02 vs. p = 0.14) as suggested by MacRury 
et al (1990). 
5.17 Regression models with confounders in suspected osteomyelitis 
 
5.17.1 No antibiotic use 
 
Neutrophil Count is not significant (p = 0.65 no antibiotic vs. p = 0.76 no 
confounder). Again this follows the work of Pittet et al (1999) suggesting Neutrophil 
Count was not able to predict outcome of foot lesions. 
 
Plasma Viscosity is significant with being considered to be in an equation to 
determine suspected osteomyelitis (p = 0.06 no antibiotic vs. p = 0.63 no 
confounder). 
  
5.17.2 Use of Insulin 
 
Plasma Viscosity is not significant with not being considered to be in an equation to 
determine suspected osteomyelitis (p = 0.83 Insulin use vs. p = 0.63 no confounder), 
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as suggested by Coppola et al (1990).  
 
5.17.3 Use of Metformin 
 
Plasma Viscosity is not significant with no longer being considered to be in an 
equation to determine suspected osteomyelitis (p = 0.71 Metformin use vs. p = 0.63 
no confounder). 
 
5.17.4 Predominantly neuropathic wounds 
 
Plasma Viscosity is not significant with no longer being considered to be in an 
equation to determine suspected osteomyelitis (p = 0.94 neuropathic vs. p = 0.63 no 
confounder), counter to the suggestion by MacRury et al (1997). 
 
5.18 Regression models with confounders in proven osteomyelitis 
 
5.18.1 No antibiotic use 
 
Neutrophil Count is not significant (p = 0.81 no antibiotic vs. p = 0.72 no 
confounder). Again this follows the work of Pittet et al (1999) suggesting Neutrophil 
Count was not able to predict outcome of foot lesions. 
 
Plasma Viscosity becomes significant and can predict the condition (p = 0.09 no 
antibiotic vs. p =  0.65 no confounder). 
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5.18.2 Use of Insulin 
 
All markers remain not significant.  
 
5.18.3 Use of Metformin 
 
All markers remain not significant. It is not known only 14 in this study were 
‘overweight’, had ‘type 2 diabetes’ and took Metformin this may follow the 
suggestion by Carter et al (2005) that Metformin reduces C Reactive Protein, p = 
0.77 no confounder vs. p =  0.61 Metformin use. 
 
5.18.4 Predominantly neuropathic wounds 
 
All markers remain not significant.  
 
This is against the work of Katsaros et al (2008), Jeandrot et al (2008) and Fleischer 
et al (2009) who all claim an increase in markers particularly C Reactive Protein in 
osteomyelitis (p = 0.89 neuropathic vs. p =  0.77 no confounders). 
 
5.19 Comparative results to other studies for Neutrophil Count 
 
Neutrophil Count is not commonly used in previous studies. The study by Al-Gwaiz 
and Babay (2007) was looking at patients with a positive blood culture for bacterial 
infection as and such is not directly comparable to this study. The work they 
produced suggests that a ‘severe’ infection, with no definition, can be recognised by 
an absolute Neutrophil Count to be >8.0 x 109 / l, this was not achieved in comparing 
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the mean values in any of the groups in this research. The maximum in both the 
suspected and proven osteomyelitis group did however reach this level.  
 
Tan et al (1975) suggested the inefficient neutrophil capacity in diabetes maybe 
associated with the increased susceptibility to infection. This paper was however 
considering the impairment of intracellular killing by phagocytosis and did not 
examine if this was related to low neutrophil numbers as well as poor activity. 
 
The work by Pittet et al (1999) was in diabetic foot infections and on patients that 
had been admitted as a consequence of their foot problem so is not directly 
comparable to this work. Pittet et al (1999) found a Neutrophil Count failed to 
predict the outcome in 105 patients including 55% with suspected deep tissue and 
osteomyelitis combined. In this thesis Neutrophil Count was the most useful marker 
in prediction of cutaneous infection across all confounding groups (and no 
confounders) with the exception of Metformin use. 
 
The apparent lack of change in the mean and standard deviation of the four groups 
within this research may agree with the work by Armstrong et al (1996b) studying 
338 consecutive admissions for a primary diagnosis of infected foot ulceration 
associated with diabetes showed 56% to have a total white cell count within their 
‘normal’ limit.  
  
The work of Uzun et al (2007) shows a total white blood cell count was found to be 
higher comparing the mean count in a control group to those with an infection but 
not comparing a non infected diabetic foot wound to an infected one.  This latter 
paper suggests that a rise in level does occur in infections.  
 
5.20 Comparative results to other studies for Haemoglobin 
 
The recognised potential effect of renal disease on the capacity to produce 
erythropoietin (Thomas and Rampersad 2004) has meant that for the results this has 
 117 
been removed and the discussion is related to the remaining 83 individuals in this 
research.  
 
The effect of diabetes alone without compromised renal function anaemia seems to 
give a conflicting prevalence of anaemia from 10%; Stevens et al (2003), 23%; 
Thomas et al (2003) to 50% by Bosman et al (2001).  
 
A foot infection in diabetes reduces Haemoglobin statistically compared to patients 
with diabetes and no foot ulcer and patients (as they were hospitalized but unclear 
why)  without diabetes in a study by Upchurch et al (1997), again this is a study 
performed on patients admitted to hospital as a result of their foot problem.  
  
This study reported here about inflammatory markers shows a gradual decline in 
mean Haemoglobin from clean wounds through the spectrum to confirmed 
osteomyelitis. It is not possible to tell if this is the anaemia of chronic disease with 
no data collected to compare with an analysis of the duration of disease specifically 
with the different wound conditions.  
 
5.21 Comparative results to other studies for C Reactive Protein 
 
C Reactive Protein is commonly used in studies and as a result this section will be 
discussing other studies found to offer additional materials to this report are given in 
date order.  
 
Upchurch et al (1997) showed the rise of C Reactive Protein associated with both 
having diabetes and having a foot ulcer associated with diabetes. The assay method 
was not comparable to that used in this study with reports of diabetes and infected 
foot ulcer of a level of 5.6 mg /ml, diabetes alone 0.78 mg /ml, no diabetes            
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0.71 mg /ml. This appears to be the start of considering the acute phase reaction as 
being a quantifiable entity that may assist in recognition of the severity of foot 
disease.  
Yu et al (2004) used C Reactive Protein as a predictor of peripheral vascular disease 
in diabetes. The study was cross sectional and concluded that a higher C Reactive 
Protein level (one at 0.282 mg / dl) was indicative of peripheral vascular disease in 
type 2 diabetes. Peripheral vascular disease is large component of diabetic foot 
disease and it is not clear how these relate to each other. This study about 
inflammatory markers does show a rise in level of C Reactive Protein (both mean an 
median) in clean wounds compared to ‘normal’ (<5g /l) mean 6mg/ l, median 11 mg 
/ l and across the range from clean to confirmed osteomyelitis mean 13g / l, median 
29.33g/ l but has no comparable work for ‘normal’ level in diabetes without active 
foot disease. Nesto (2004) suggests that the rise in C Reactive Protein in diabetes is a 
result of the disease having chronic sub clinical inflammation as a major component. 
Atherosclerosis also placed within this group of diseases. 
 
Katsaros et al (2008) using MRI as the gold standard diagnostic test for 
osteomyelitis in a study of 64 patients found C Reactive Protein to be significantly 
raised in osteomyelitis. The pre test probability in this study is not discussed as in 
many of the other studies it is based on patients admitted to hospital as a direct 
consequence of the foot infection.  
 
Jeandrot et al (2008) with the antibiotic naive patients with foot ulcers in comparison 
to ulcer free patients found C Reactive Protein to be of use in distinguishing infected 
from non-infected ulcers. (The study claims to have matched ulcer patients to 
controls in terms of peripheral and / or cardiovascular disease and neuropathy 
however there is no definition of both peripheral or cardiovascular disease and 
neuropathy.) The rise found in the Jeandrot et al (ibid) study level was continuous 
from ulcer free to severe, limb threatening, infection (grade 4 of the Infectious 
Diseases Society of America guidelines) but only significantly between cutaneous 
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infection and control and cutaneous infection and clean. This inflammatory blood 
marker study presented is difficult to compare to that of Jeandrot et al (ibid) as the 
use of antibiotics was not easily separated but has been discussed in the regression 
section with confounders. 
 
The rise in C Reactive Protein in osteomyelitis is also noted by Fleischer et al 
(2009), again in hospitalized patients. Fleischer et al (ibid) advocate that a                
C Reactive Protein, in conjunction with assessment of ulcer depth, is a sensitive 
strategy for determining early osteomyelitis. The nature of the study was to detect 
early disease as determined and confirmed by histological examination of bone 
samples. This again is a difference that some of the patients in this thesis report may 
have had chronic osteomyelitis by the histological definition used by Fleischer et al 
(ibid). 
 
5.22 Comparative results to other studies for Plasma Viscosity 
 
MacRury et al (1990) performed a study to examine the role of blood viscosity in 
peripheral neuropathy associated with diabetes. Diabetes had a statistically 
significant effect raising the mean level of Plasma Viscosity compared to controls. 
The rise was for all people with diabetes, the rise associated with diabetes and 
neuropathy as a separate entity was not statistically significant. In this study reported 
in this thesis over the entire group the mean was above the ‘normal’ limit and above 
‘normal’ in all wound conditions i.e. clean, cutaneous infection, suspected and 
confirmed osteomyelitis. There was however little rise between the different 
infective states. Neuropathy was defined in a clinically meaningful way that meant it 
was applicable to the definition of neuropathy used here. 
 
The significance reported in the regression studies for Plasma Viscosity is seen to 
reduce when the infection changes in the series presented in this work from clean to 
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cutaneous infection to suspected osteomyelitis to confirmed osteomyelitis. It is not 
clear what link there is between neuropathy and ‘severity’ of infection. 
 
Coppola et al (1997) showed abnormalities in blood viscosity in type 2 diabetes and 
the use of Insulin but it is unclear as to cause and effect. The effect was significant in 
those patients with diabetes and evidence of vascular disease as opposed to ‘healthy’ 
i.e. non diabetic subjects. In this thesis the majority of individuals had evidence of 
vascular disease and it was significant in the majority of the foot ulcers few were 
predominantly neuropathic in origin. The definition of cardiovascular disease was far 
more complex in the Coppola study but did include history which although not 
defined may include the use of medication as used in the definitions in this thesis. 
 
The significance of Insulin as a confounder on the marker of Plasma Viscosity is not 
clear from the regression studies, it is certainly not linear. 
 
Plasma Viscosity in this reported thesis was predictive in the equation to suggest 
both suspected and confirmed osteomyelitis and showed the greatest Area Under the 
Curve in the ROC curve for suspected osteomyelitis and was the second highest 
Area Under the Curve in the ROC curve for confirmed osteomyelitis. 
 
5.23 Comparative results to other studies for Procalcitonin  
 
The two studies to date examining the use of Procalcitonin in diabetic foot ulceration 
have been in patients admitted to hospital. That by Uzun et al (2007) used a 
prospective method whereby the patients were determined to have, or not have, an 
infection or not using the criteria suggested by Lipsky et al (2004) for the Infectious 
Diseases Society of America guidelines (validated by Lavery et al 2007) similar 
numbers were noted to be taking antibiotics on admission when the blood samples 
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were taken. The group with an infected ulcer had a Procalcitonin mean level of 
0.18ng / ml higher than that suggested by this study. The assay however does not 
appear to be as sensitive as that used here as the lower detection limit was 0.06 ng 
/ml as opposed to 0.01ng / ml. The patients in this study were all hospitalized – a 
difference to this here reported study where the majority were out patients and would 
have been treated that way, five it could be argued were atypical out patients (see 
section 5.1).  
 
The paper by Jeandrot et al (2008) also used the Infectious Diseases Society of 
America guidelines as a defining infection protocol and again a different assay where 
the functional sensitivity was reported as 0.04 mg /ml however they report levels 
from 0.0 to 0.84 ng / ml. The 0.0 ng / ml is in a control group. A statistically 
significant rise is noted in the control and grade 1 ulcers and between grade 1 and 
grade 2. Grade 1 is no infection; grade 2 is skin and sub cutaneous tissue similar to 
the cutaneous infection group in this research. The patients were different from this 
research in that they were antibiotic naive for 6 months prior to the research and also 
in the fact they were admitted to hospital for the foot lesion. The difference between 
the clean and cutaneous infection groups in this research compared to the Jeandrot et 
al work maybe the unknown and quantifiable nature of antibiotic use (see later).  
 
5.24 Comparative results for other confounders 
 
5.24.1 Metformin use  
 
Chu et al (2002) have shown in a study about cardiovascular risk factors that a 
statistically significant reduction in C Reactive Protein can occur after taking 
Metformin for a period as short as 4 months. The number of individuals taking 
Metformin in this study about osteomyelitis and inflammatory blood markers did 
note the taking of the drug but not the duration of treatment. The reduction in C 
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Reactive Protein was the only affect of Metformin produced that is of relevance to 
this osteomyelitis study and regrettably the data that would be required to determine 
if the individuals taking the drug have a lower level compared to those not taking it 
are not available. The Chu et al (ibid) study also used Metformin to achieve an 
agreed fasting blood glucose level that again was not noted within this study on 
osteomyelitis.  
Carter et al (2005) suggested that Metformin dampened down chronic inflammation 
and as such C Reactive Protein synthesis or secretion without effect on glycaemic 
control in ‘overweight’ patients. This was not seen in this research on osteomyelitis 
comparing the C Reactive Protein levels as measured by mean (and standard 
deviation) and median (and interquartile range) of the two groups. 
 
The nature of foot disease and chronic nature suggests that these studies may show 
some confounding of the results but in an unquantifiable way due to the unknown 
nature of Metformin use. 
   
5.24.2 Antibiotic use 
 
The use of antibiotics to treat any infections would be expected to alter the 
inflammatory reaction. The use of antibiotics in all other papers has not been 
described adequately for the analysis of my results to be divided into groups for 
comparison with no antibiotic therapy, oral antibiotics and intra – venous antibiotics. 
The change of practice whereby we are now able to send patients home with intra - 
venous antibiotics may make the out patient setting described here more like the in - 
patient setting of the other papers.    
 
When antibiotics were not being prescribed in cutaneous infection C Reactive 
Protein was the most significant inflammatory marker with p = 0.074, this had the 
effect of changing the significance by minus 0.005 when removed from the equation 
but did not affect the overall result to make any other marker of more benefit. 
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Neutrophil Count was the most significant in suspected osteomyelitis when 
antibiotics were not prescribed (p = 0.042) followed by Plasma Viscosity (p = 0.60). 
Neutrophil Count remained the most significant in proven osteomyelitis (p=0.095) 
with a change when removed of (p = 0.030).  
 
No one single, or indeed any combination of, markers has shown to be of benefit in 
the detection of osteomyelitis associated with foot ulcers in diabetes. The multiple 
confounding factors do not help. 
 
 
5.25 Correlation effect of inflammatory markers with no confounders  
 
5.25.1 Clean wounds 
 
There is a highly significant statistical correlation in two areas; between Neutrophil 
Count and C Reactive Protein (p ≤ 0.001) and between Plasma Viscosity and C 
Reactive Protein (p ≤ 0.001). By examining the correlation coefficient it can be seen 
that the most relevant clinically is the relationship between and Neutrophil Count 
and C Reactive Protein with 44% of each being due to the relationship, Plasma 
Viscosity and C Reactive Protein still has a noticeable inter relationship with an r2 
value of 27%. 
 
Neutrophil Count is also statistically significant relationship with both Plasma 
Viscosity and Procalcitonin (both ≤ 0.005). Clinically (by the r2) relationship this is 
only evident in the Plasma Viscosity correlation.  
 
All correlations in this wound type were positive – as one marker increased so did 
the other. 
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This interrelationship of the markers is seen by the clustering appearance of these 
within the Receiver Operator Curve. No variable was considered in regression. 
 
5.25.2 Cutaneous infection  
 
Neutrophil Count was found, again, to be statistically significantly correlated with C 
Reactive Protein and Plasma Viscosity. The clinical association remained at the same 
level (18%) between Neutrophil Count and Plasma Viscosity as in clean wounds. 
The clinical relationship with C Reactive Protein was higher at r2 = 26%. 
 
C Reactive Protein and Plasma Viscosity continue to have a statistically significant 
interrelationship (p ≤ 0.01) with a clinical significance of 22%. 
 
All statistically significant correlations in this wound type were positive – as one 
marker increased so did the other. There is a negative correlation between Neutrophil 
Count, C Reactive Protein, Plasma Viscosity, Procalcitonin and Haemoglobin levels. 
 
This interrelationship of the markers is seen by the clustering appearance of these 
within the Receiver Operator Curve and separation of the Haemoglobin graph. No 
variable was considered in regression. 
 
5.25.3 Suspected osteomyelitis 
 
Neutrophil Count and C Reactive Protein remain highly statistically significantly 
correlated (p ≤ 0.001) and clinically too with a clinical significance of 34%. 
 
The significant statistical correlation continues to exist between Plasma Viscosity 
and C Reactive Protein (p ≤ 0.005) which is clinically positive – an r2 value of 26% 
and between Haemoglobin and Plasma Viscosity (p ≤ 0.005) but clinically this is 
seen to be a negative correlation (92%). Plasma Viscosity was the variable to be 
significant in the regression model. 
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The other markers (Neutrophil Count, C Reactive Protein and Procalcitonin) also 
show this negative correlation but not to a statistically significant level. The 
divergence of Haemoglobin is seen in the Receiver Operator Curve.  
 
5.25.4 Confirmed osteomyelitis  
 
Neutrophil Count and C Reactive Protein remain highly statistically significantly 
correlated (p≤ 0.001) and clinically too with a higher clinical significance of 39%. 
 
C Reactive Protein and Plasma Viscosity continue to have a statistically significant 
interrelationship (p≤ 0.01) with a clinical significance of 26%. 
 
The other markers (Neutrophil Count, C Reactive Protein and Procalcitonin) also 
show this negative correlation but not to a statistically significant level. The 
divergence of Haemoglobin is seen in the Receiver Operator Curve. No variable was 
considered in regression. 
 
5.26 Correlation effect of inflammatory markers with confounders 
 
5.26.1 Clean wounds 
 
No marker was evident as being of greater significance within clean wounds and this 
maybe due to the noted statistically significant correlations between all the markers, 
except Haemoglobin, as noted in the regression model. 
 
5.26.2 Cutaneous infection  
 
C Reactive Protein was the variable in the regression that was considered to be most 
likely to in the model when antibiotics were not used, it can be seen to be highly 
statistically and clinically correlated with both the Neutrophil Count and Plasma 
Viscosity in the correlation table. 
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The use of Insulin is important in the regression model for clean wounds and is seen 
as above to be clinically associated with C Reactive Protein and Plasma Viscosity.  
 
5.26.3 Suspected osteomyelitis 
 
No marker was evident as being of greater significance within suspected 
osteomyelitis; C Reactive Protein and Neutrophil Count are highly significantly and 
clinically correlated.  
 
5.26.4 Confirmed osteomyelitis  
 
Neutrophil Count was the variable in the regression that was considered to be most 
likely to in the model when antibiotics were not used, it can be seen to be highly 
statistically and clinically correlated with C Reactive Protein.  
 
5.27 Correlation and relationship to other studies about inflammatory 
markers 
 
This section will attempt to show any relationship between previous studies about 
inflammatory markers in diabetic foot disease and the correlation seen here. 
 
5.27.1 Correlation and the marker of Neutrophil Count 
 
The inability of Neutrophil Count to predict diabetes associated foot infections as 
suggested by Pittet et al (2008) although based on in – patients maybe in part 
explained by the statistical and clinical correlation with C Reactive Protein and to a 
lesser statistical and clinical degree (but still significant) Plasma Viscosity in 
cutaneous infection and C Reactive Protein in both suspected and confirmed 
osteomyelitis in this study.  
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5.27.2 Correlation and the marker of Haemoglobin 
 
The study on in – patients by Upchurch et al (1997) suggested diabetes and foot 
infection was likely to reduce Haemoglobin. The negative correlations seen here 
with all wounds with infection may support this. 
 
5.27.3 Correlation and the marker of C Reactive Protein 
 
C Reactive Protein is consistently and statistically significantly (p ≤ 0.001) 
correlated with Neutrophil Count across this study. In clean wounds the Pearson 
correlation coefficient is 0.666, in cutaneous infection 0.513, in suspected 
osteomyelitis 0.582, and in confirmed osteomyelitis 0.629. The effect of diabetes as 
a disease on C Reactive Protein is not fully explained in relation to foot disease by 
Nesto (2004). The suggested rise caused by diabetes alone may in part explain the 
association with Neutrophil Count which from the healing process of a wound would 
be expected to be raised.  
 
5.27.4 Correlation and the marker of Plasma Viscosity 
 
Plasma Viscosity, if associated with neuropathy as put forward by Mac Rury et al 
(1990), may be expected to be more strongly correlated with the other markers and 
this is not seen. 
  
5.27.5 Correlation and the marker of Procalcitonin 
 
Procalcitonin shows only one correlation and that is with Neutrophil Count in clean                                
wounds. In this situation the expected level of Procalcitonin would be very low as 
would the level of Neutrophils as they prime function of this cell group is bacterial 
ingestion – not necessary in a clean wound.           
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Chapter 6 Methodology The use of SPECT/CT in the 
diagnosis of osteomyelitis 
 
This chapter will provide an outline of the method of the second part of the study in 
which the use of Single Photon Emission Computed Tomography / Computed 
Tomography (SPECT/CT) scans were compared to a reference test of Magnetic 
Resonace Imaging (MRI). 
 
6.1 Research question 
 
Is SPECT/CT a useful diagnostic tool for recognising osteomyelitis in patients with 
diabetic foot ulcers? 
 
6.2 Research aim 
 
To determine the sensitivity and specificity of SPECT/CT in the diagnosis of 
osteomyelitis in diabetic foot ulcers compared to MRI as the gold standard. 
 
6.3 Research objective 
 
To compare the diagnostic accuracy of SPECT/CT in recognising osteomyelitis in 
diabetic foot ulcers against MRI. 
 
6.4 Protocol 
 
The use of an alternative scanning technique for the diagnosis of osteomyelitis 
associated with diabetic foot ulcers would be very useful and this research was 
conducted to determine if the new technique of SPECT/CT is comparable in the 
results it produces to MRI. 
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6.5 Summary 
 
This study investigates the potential use of the imaging technique of Single Photon 
Computed Tomography / Computed Tomography in making a diagnosis of 
osteomyelitis in foot ulcers associated with diabetes. 
 
6.6 Keywords 
 
Imaging  Diagnosis Osteomyelitis 
 
6.7 Rationale of method 
 
MRI is the most commonly used method to diagnose osteomyelitis within the usual 
practice of the diabetic foot team in the Royal United Hospital, Bath. Experienced 
musculoskeletal radiologists read the scans ensuring that continuity and as such inter 
and intra rater reliability is maintained. The use of MRI to confirm suspect 
osteomyelitis continues to be the confirmatory diagnostic tool. However not all 
individuals are able to undergo the MRI procedure for a number of reasons including 
claustrophobia and metal implants. The use of another form of three dimensional 
imaging that can determine the extent of infection would be most useful. The 
additional anatomic data provided by the Computed Tomography element of the 
SPECT/CT may suggest an improvement in the diagnostic sensitivity of the usual 
nuclear medicine bone scan. The advancement is made by the combination of the 
standard technique of nuclear imaging with computed tomography to provide this 
option. This use in diabetic foot infection detection is a new development for this 
technique. The experienced consultant radiologist involved in the nuclear medicine 
department was used as the constant reader of the scans (as for the MRI s being read 
by the same individual) to ensure a consistent inter and intra rater reliability was 
maintained. 
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6.7.1 Imaging techniques used 
 
The many different imaging techniques available are discussed in more depth in the 
introduction. The rationale for the choice of the reference test is also discussed.   
 
MRI was chosen as the reference test in this study to assess the clinical utility of 
SPECT/CT against. Each of the techniques used in this reported study will be 
discussed in greater depth. 
 
6.7.1.1 Magnetic Resonance Imaging 
 
MRI reveals active medullary osteomyelitis as an area of abnormal marrow with 
altered signal. It is this that is looked for when the scan is read with the possibility of 
intraosseous collections. The nature of the scan producing slices of image allows 
localisation of any defect. 
 
6.7.1.2 Single Photon Emission Computed Tomography /Computed Tomography 
 
The changes that occur in this scan that indicate a pathological process are uptake of 
the tracer within the bones that is a result of the increased blood flow to the diseased 
areas. The computed tomography element allows localization of the diseased area by 
the acquisition of a three dimensional image of the foot by producing slices of the 
image in body planes.  
 
6.8 Imaging and the disease of diabetes 
 
Diabetes can cause problems with the imaging. This is from the fact that concurrent 
renal disease can reduce the capacity for an individual to clear any contrast medium 
that is used to enhance the images produced. This is particularly true for the 
Gadoteric acid as used in MRI. The obesity of some patients with in particular type 2 
diabetes, makes them unsuitable for the MRI scanner in Bath as it is enclosed. On 
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occasion there has been the capacity to perform the scan by the patient being 
‘reversed’ and only the lower limb entering the data acquisition area.  
 
6.9 Confounding factors 
 
The presence of Charcot neuroarthropathy (another complication associated with 
diabetic foot disease) can cause diagnostic difficulties when looking for a diagnosis 
of infection (Tan and Teh 2007). This is the case for all imaging techniques. 
 
6.9.1 Recognition and Managing of confounding factors 
 
In an attempt to limit the uncertainty caused when Charcot is present no patients with 
active Charcot joints (recognized clinically by abnormal skin temperatures taken 
using an infra-red thermometer and deformity of the foot) were enrolled into the 
study.  
 
Individuals that had both scans were booked for the imaging as close together as 
practical to avoid changes in the disease process and avoid the second scan which 
ever that was being influenced by the results of the first being known.  
 
The analysis of image results is by its very nature a subjective analytical technique 
using human beings to read results from what their experience tells them they are 
seeing within the scan. In an attempt to reduce the variability of this the Consultant 
Radiologist with a specific interest in Musculoskeletal imaging for the Magnetic 
Resonance Imaging and likewise for Nuclear Medicine imaging for the Single 
Photon Computed Tomography / Computed Tomography imaging agreed to report 
the results. This was to make certain that the more experienced clinicians were 
looking at the scans and as reading a scan has some level of subjectivity this was 
reduced. 
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6.10 Sample 
 
Individuals were approached that attended the multiprofessional Diabetes Foot 
Clinic in an acute district general hospital. The hospital is a 687 bed hospital 
covering geographical area that is a mixture of rural and urban with some towns and 
villages, having a population of some 550000. Within the catchment area there are 
community hospitals and Minor Injury Units. The individuals had been referred for 
specialist care advice and treatment of their foot ulcer to the diabetes team by 
community podiatrists, practice and district nurses and General Practitioners. The 
Diabetes Foot Clinic team consist of a consultant diabetologist with a special interest 
in feet, a consultant vascular surgeon with a special interest in diabetes and feet, two 
experienced podiatrists, an orthotist all with rapid access to a consultant 
microbiologist with a special interest in infectious diseases, consultant 
dermatologists, consultants in orthopaedics, vascular technicians and plaster 
technicians. 
 
They agreed with formal written consent to take part. The individuals were those in 
whom the usual clinical care in Bath would be to have a referral for an MRI scan due 
to unsure diagnosis.  
 
The use of broad non specific criteria for the recruitment process was an attempt to 
recruit as many individuals as possible without including individuals who  
� could be seen to be requiring immediate emergency care for the 
presenting problem,  
� to be seen to potentially been coerced into partaking,  
� to have a disease different to diabetes that was likely to affect the 
inflammatory markers and that had the potential to be harmed by the 
process e.g. the exposure to an unborn child of the radiation in the 
Single Photon Computed Tomography /  Computed Tomography part 
of the study. 
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6.11 Method; Ethical statement 
 
Approval from the relevant NHS trusts and from both the University of Bath and 
COREC ethics system was sought and followed. This ensured that ‘good clinical 
practice’ was maintained throughout, and either taking part or refusal did not 
compromise clinical care for that individual or any others. Research governance 
procedures including securing Research and Development (R&D) approval was also 
performed. The storage of patient sensitive information was also on a NHS computer 
that was sign – on and password protected with additional passwords to access any 
research material.  
 
6.12 Method; Ethical considerations 
 
Exposure to radiation through the process of the SPECT/CT scan was explained in 
the verbal explanation of the research and was included on the patient information 
sheet. This was described in a manner that made the degree of exposure 
understandable – likening it to living in the county of Cornwall for 33 days.  
Additional information about both scans was provided by the relevant departments. 
The additional time taken for the scan was explained and so was the need to return to 
the department several times for scans at different stages over the course of several 
hours but the ability to ‘come and go’ as they wished between scans. 
 
Discussions between the researcher and radiology and nuclear medicine departments 
took place to ensure that the research patients did not compromise the waiting of 
‘ordinary’ patients for the scans. 
 
Parking permits were only available to those individuals who were asked to 
undertake the additional scanning technique as this involved an additional attendance 
above normal clinical expectations. 
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The confidentiality required in obtaining the participants personal information from 
the diabetes data base was covered in the course of normal clinical practice by the 
Caldicott Guardian and Data Protection principals. 
 
All information was stored on a NHS computer user name and password protected. 
The results of the imaging techniques were further user name and password 
protected on a web based image capture system. 
 
The data was anonymised within the results database. 
 
6.13 Inclusion  / exclusion criteria 
 
INCLUSION  
� to have  a diabetes related foot ulcer 
� to be able to give informed consent 
� to be able to have both MRI and SPECT/CT scans 
 
EXCLUSION 
� to have overwhelming sepsis requiring immediate medical and/or surgical 
treatment 
� to be unable to give informed consent 
� to be unable to have MRI scan  for example having a  metal implant or due to 
claustrophobia (or MRI restriction by patient size) 
� to have a reduced renal function that prevents the use of contrast medium in 
the imaging processes 
� to have a concurrent disease likely to affect inflammatory markers e.g. 
rheumatoid arthritis 
� to be pregnant 
� to be breast feeding. 
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6.14 Consent 
 
Individuals were given the patient information sheet as they reported to reception in 
the Diabetes and Endocrinology centre for the Diabetes foot Clinic to allow for some 
time to read the information prior to being approached taking part in the research. 
The patient information leaflet had been accepted by the ethics committee as having 
the wording of a certain size and font to assist legibility and also in a language 
suitable for lay individuals.  
 
The patient information sheet asked individuals to consider giving their consent for 
the researcher for both the research, i.e. venepuncture immediately and referral for 
imaging where deemed appropriate. Not all individuals partook in both parts of the 
study.  
 
The care the individual was booked into the clinic to receive was provided prior to 
any discussion about the research. 
 
Information about the method of using the different scanning techniques was 
provided in clinic to anybody consenting to the use of the two different techniques. 
Examples of this are the length of time the appointment was likely to last and the 
degree to which they would be exposed to radiation as the term nuclear medicine 
(the department where the Single Photon Computed Tomography / Computed 
Tomography scan takes place) was alarming to some. Both the radiology and nuclear 
medicine departments sent out further information about the scans with the 
appointment bookings. 
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6.15 Method of study 
 
16.15.1 Using MRI as the reference test 
 
Magnetic Resonance Imaging (MRI) is used commonly as the gold standard imaging 
technique in the United Kingdom to recognise infection is because it presents both a 
detailed accurate image including areas of soft tissue oedema and bone abscesses 
(Mader, Cripps and Calhoun 1999). Sartoris (1994) has performed a meta analysis 
on ten previous studies to assist recognition of abnormal soft tissue signals with 
MRI. It is also more sensitive and precedes these changes than plain film or simple 
Computerised Tomography (Crim and Seeger 1994). MRI can be used to give good 
structural visualization and spatial resolution (Paluska 2004), superior contrast 
resolution and a multiplanar examination (Flemming, Murphey and McCarthy 2005). 
Reported sensitivities are high ranging from 88%-100% with a specificity of 53%- 
94% (ibid). It is recognised that specialist technical and interpretive skills are 
required to achieve these levels (Berendt and Lipsky 2004). This puts forward the 
suggestion of another test, for example the three dimensional scanning technique 
Single Photon Computed Tomography / Computed Tomography, being used in 
addition.   
 
Another meta-analysis of MRI studies has shown that the procedure performs well in 
the diagnosis of osteomyelitis of the foot and ankle in adults (Kapoor et al 2007). 
This study is good in that it acknowledges the problems associated with the 
combination of the studies. These include using English language only articles with 
few studies following the assessment of individuals with scan results read blind to 
other diagnostic techniques or with biopsy as a confirmatory tool. The presence or 
absence of Charcot foot was not typically documented and it is recognised that this is 
one of the potential differential diagnoses particularly in the diabetic population. The 
advancements made in the MRI technique are also acknowledged as possible ways 
of diagnosis being made with greater certainty in the more recent studies, for 
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example the use of Gadolinium as a tracer and the use of secondary diagnostic signs 
such as cortical breaks.  
 
 
6.16 Methodology  
 
The usual practices of referral for MRI was used when clinical suspicion of deep 
infection was present without any positive suggestion of either abscess or bone 
infection. This was then also performed using the SPECT/CT scan. 
 
SPECT/CT is a new method of combining nuclear medicine techniques of bone 
scanning with computerised tomography to localise any bony abnormality found. To 
recognise if SPECT/CT will be of benefit in diagnosis of osteomyelitis especially in 
these patients, each patient will also have both a MRI and a SPECT/CT scan. The 
SPECT/CT results will be compared to those of the MRI. The additional amount of 
radiation exposure in delivering the CT element of the scan is less than 0.1 mSv. In 
lay terms this is the equivalent of living in Cornwall for five days. The amount of 
radiation to which an individual was exposed during such a scan was controlled by 
the Medical physics department. The administration of the radioisotope was using 
Diphosphonate labelled to 99mTechnetium, equivalent to 600 Milli Bequels. The 
trade name for this being HMDP®. The clinical effectiveness will be measured by 
comparing diagnostic rates of MRI to SPECT/CT.  
 
Written additional information about both forms of scans was provided and sent by 
the relevant departments when booking the patient’s appointment.  
 
The request sent to the departments informed them that the patient had diabetes and a 
foot ulcer, with the anatomic site named, with a query about the presence of deep 
infection such as abscess or osteomyelitis.  
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6.16.1 Magnetic Resonance Image acquisition protocol  
 
Due to the nature of the MRI scanning procedure patients were required to remove 
any metal containing clothing and if necessary to wear a hospital gown.  
 
The standard protocol for imaging suspected osteomyelitis in the foot was 
performed. This involves the following sequence of image attainment; 
 T1 axial 
 Stir axial 
 Proton density fat saturated axial 
 STIR coronal. (STIR being the acronym for short-tau inversion-recovery 
sequences when water is ‘bright’ on the images the inverse of the usual fat 
‘brightness’). 
Followed by the administration of contrast medium and sequence; 
 T1 axial 
 T1 coronal. 
These are through the axial and coronal body planes. The effect is to produce ‘sliced’ 
images across the width of the foot (axial) and along the length of the foot (coronal) 
allowing accurate localization of any abnormality. The slice width being of the order 
of 3-4 mm. 
 
The contrast medium used was Dotarem® made by Guerbet. This has Gadoteric acid 
as its active ingredient formed in situ from DOTA and gadolinium oxide at an 
equivalent level of 0.5mmol/ml. The dose of drug given being calculated by body 
mass at 0.2ml per kilogram mass. Administration is by the use of calibrated pre-
filled syringes into a vein. It is the gadolinium oxide that is the magnetic agent and 
enhances the images produced.  
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6.16.2 Single Photon Computed Tomography / Computed Tomography Image 
acquisition protocol 
 
The SPECT/CT scanning procedure allows an individual to remain fully clothed 
providing access to a vein is possible for injection of the tracer material.  
 
A standard 3 phase bone scan was performed followed by SPECT/CT images of the 
feet. The standard scan involves the patient being injected intravenously with 
Diphosphonate labelled with 99mTechnetium to a level of 600Milli Bequels. This is 
a standard dose that is only altered very occasionally dependant on body mass. For 
all images patient lies supine on scanning table. All images are obtained using a 
double head Infinia gamma camera with Low Energy High Resolution collimators.  
 
The bone scan involves; 
� 1st phase  –with immediate images obtained of the feet (16 frames at 3 
second intervals) 
� 2nd phase – 2 minutes post injection - static blood image of feet obtained (the 
images are taken to a total of 200000 radioactive ‘counts’ to provide a 
‘good’ image) 
� 3rd phase – anterior & posterior whole body scan performed 3 hours post 
injection. Scanning from head to toes. 
 
 Exposure time per image – 240secs with a speed of travel of scanner 
10cm/minute. The result of this is a whole body scan takes approximately 30 
minutes with an additional 20 minutes imaging of the feet.   
                  
The SPECT/CT images of feet are then obtained using the following protocol;  
� Matrix size 128x128, which is the size of image used and is a 
compromise between image clarity and ‘noise’ (unwanted 
image detail). 
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� Slice step 5-10mm, which is images are taken at 5 – 10 mm 
intervals throughout the image acquisition. The movement of 
the cameras is through 60 degrees each 30 seconds within a 
total angular range of 360 degrees.   
            
6.17 Diagnosing Osteomyelitis in a MRI scan 
 
As described by the diagnostic papers by Yuh et al (1989), Weinstein et al (1993) 
and Ertugrul et al (2006) the diagnostic method for identifying osteomyelitis 
associated with a diabetic foot ulcer the criteria used for positivity were ‘decreased 
or low signal intensity on T1 weighted images in areas of bone marrow with focal 
enhancement after the administration of contrast medium and increased signal 
intensity on STIR and T2 weighted images’. These were also recognised by Dinh, 
Abad and Safdar in 2008. Rozzanigo et al (2008) describe this as a primary sign of 
evidence. In addition the presence of a ‘cortical breach or intraosseous abscess may 
also indicate osteomyelitis’ (Morrison et al 1995). Secondary signs are described by 
Rozzanigo et al (2008) as being ‘identified close to the altered bone marrow signal 
and include oedema caused by septic inflammation (cellulitis or phlegmon), soft 
tissue abscess, skin ulcer and fistula, with possible interruption of the cortical bone’. 
Yuh et al (1989) recognize the clarity offered in the T1 weighted images. The use of 
contrast media such as gadolinium has been suggested, using the analysis of case 
studies, by Morrison et al (1998) and Tan and Teh (2007) to offer no increase in 
accuracy of diagnosis of osteomyelitis but to improve the diagnosis of soft tissue 
pathology.  
 
6.18 Diagnosing Osteomyelitis in a SPECT/CT scan 
 
As described by the diagnostic paper by Yuh et al (1989) the diagnostic method for 
identifying osteomyelitis associated with a diabetic foot ulcer the criteria used for 
positivity were ‘increased blood flow and blood-pool activity and abnormally 
increased intensity localized to the bone’. The presence and evaluation of cortical 
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erosions, focal areas of lucency and sequestra has also been noted by Teh, Berendt 
and Lipsky (2010). 
 
This method of confirmation was originally described for a 3-phase bone scan but is 
equally applicable to a SPECT/CT scan. 
 
6.19 Analysis of imaging results 
 
The analysis of the written reports was performed by comparison of the wording 
describing three areas of the two scan reports for each individual. These areas were 
the anatomical site of concern; with appropriate detail, the detail in which the 
surrounding tissues were described, and the overall conclusion.  
 
Each of the reports was provided by the relevant medical consultant within their 
specialty, i.e. musculoskeletal Magnetic Resonance Imaging or musculoskeletal 
Nuclear Medicine. The reports were made ‘blind’ to the other scan results. 
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Chapter 7 Results The use of SPECT/CT in the diagnosis of 
osteomyelitis 
 
This chapter will provide information gained form the reports of the two scanning 
techniques that were compared in this research along with the clinical diagnosis or 
suspicion for each patient. Two patients consented to having both forms of scans but 
withdrew consent after the MRI had been performed before the SPECT/CT was 
performed.  
  
7.1 Sample characteristics  
 
The individuals who underwent scans all had a clinical suspicion of osteomyelitis. 
There were 3 females and 7 males with an age range of 39 - 80 years, mean 61 years. 
The range and mean duration of diabetes was 1 - 30 years, mean 15 years.  
 
None reported any adverse complication or event of having either scan.  
 
The scans were compared by searching the written reports for commonality in the 
three areas of site of problem the detail provided and overall conclusion. 
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7.2 Scan results  
Table 7.2.1 Patient 1  
clinical presentation/ suspicion - Deep or bone infection and / or new Charcot 
process on top of old in right mid foot 
                                          
MRI         SPECT/CT 
Site;  Mid foot, tarsal 
bones, calcaneum –
posterior subtalar 
joint 
Calcaneo talar and talo navicular 
joints 
Detail  Oedema, cyst formation, 7mm 
diameter abscess 
Very aggressive destruction of 
joints 
Conclusion  Suspicious for intraosseous 
abscess in calcaneum  
Suspicious for osteomyelitis 
Agreement 
with 
clinical 
presentation  
Yes  Yes  
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Table 7.2.2.Patient 2  
clinical presentation / suspicion – abscess an / or osteomyelitis right 2nd metatarsal 
head 
       
                        MRI                                              SPECT/CT 
Site;  2nd metatarsal 
phalangeal joint 
Mid right fore foot,  
Detail  Proximal phalanx of 2nd toe, 
discontinuity of FDL tendon 
Distal ½ 2nd metatarsal 
Conclusion  Highly convincing for 
Osteomyelitis  
Osteomyelitis of distal right 2nd 
metatarsal  
Agreement 
with 
clinical 
presentation 
Yes  Yes  
 
Table 7.2.3 Patient 3  
clinical presentation / suspicion – right heel infection probably cutaneous only 
         
                        MRI                                             SPECT/CT 
Site;  Calcaneum Calcaneum and cuboid, 
navicular and base of 4 &5 
metatarsal  
Detail  Tiny fluid collection Suggestive of infection 
Conclusion  In keeping with cellulitis, 
possibly an area of 
osteomyelitis  
Osteomyelitis of Calcaneum and 
cuboid with probable 
involvement of the navicular and 
base of 4 &5 metatarsal 
Agreement 
with 
clinical 
presentation 
Yes  Yes 
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Table 7.2.4 Patient 4  
clinical presentation / suspicion – osteomyelitis of right heel 
           
  MRI                                               SPECT/CT 
Site;  Right heel Right hind foot, right calcaneum 
Detail  Subcutaneous collection 
2.2cm diameter, horizontal 
cleavage of the os calcis with 
elevation of the upper half 
Medial anterior aspect of 
calcaneum 
Conclusion  Not possible to tell if infective 
or not 
Acute infection and/or healing 
trauma 
Agreement 
with 
clinical 
presentation 
No  Yes  
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Table 7.2.5 Patient 5  
clinical presentation / suspicion – osteomyelitis of left hallux 
        
                         MRI                                             SPECT/CT 
Site;  Terminal phalanx 
big toe 
Left great toe metarsophalangeal 
joint 
Detail  1st metatarsal head, 1st MTPJ 
and proximal phalanx of the 
big toe, area of non 
enhancement in 1st proximal 
phalanx measuring 
1.4x0.5x0.5 cm consistent 
with a focus of osteomyelitis / 
osseous abscess, thickening of 
flexor hallucis tendon  
Head of the left great toe 
metatarsal extending into the left 
great toe 
Conclusion  Deep ulceration below the 1st 
MT and MTPJ with 
underlying osteomyelitis  
Osteomyelitis  
Agreement 
with 
clinical 
presentation 
Yes Yes  
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Table 7.2.6 Patient 6  
clinical presentation / suspicion – osteomyelitis of left first metatarsal head 
           
             MRI                                              SPECT/CT 
Site;  1st MTP Right great toe metatarsal head 
Detail  Sinus track running from soft 
tissue towards the joint, 
several small pockets of fluid/ 
abscesses  
Extends from the head of the 
metatarsal into the proximal 
phalanx of the right great toe, 
superior and inferior aspects 
Conclusion  Consistent with Osteomyelitis 
of 1st metatarsal and proximal 
phalanx 
Osteomyelitis or septic arthritis 
although this is not entirely 
specific 
Agreement 
with 
clinical 
presentation 
Yes  Yes  
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Table 7.2.7 Patient 7  
clinical presentation / suspicion – Deep infection likely osteomyelitis with severe 
cutaneous infection of right fifth toe 
         
                        MRI                                              SPECT/CT 
Site;  4th and 5th metatarsal 
heads 
Head of right 5th metatarsal and 
proximal phalanx of 5th toe 
Detail  Abscess between the 4th and 
5th metatarsal heads extending 
to the level of the middle or 
distal phalanx of the little toe 
3cmx1cm, proximal phalanx 
enhances suggesting infection 
right 5th metatarsal head and 
proximal phalanx, not extending 
significantly up the shaft of the 
metatarsal  
Conclusion  The major abnormality is in 
the soft tissue but it is likely 
the little toe proximal phalanx 
is involved by osteomyelitis 
with septic arthritis 
Bone scanning alone would 
suggest infection however the 
differential includes an intense 
inflammatory arthropathy 
Agreement 
with 
clinical 
presentation 
Yes  Yes 
 
Table 7.2.8 Patient 8  
clinical presentation / suspicion – left deep heel infection, osteomyelitis  
           
    
                        MRI                                              SPECT/CT 
Site;  Os calcis  Left heel 
 
Detail  Concave defect 2 x 1.8 x 1 cm 
and oedema extending into the 
body of the calcaneum 
Postero lateral aspect of the left 
calcaneum 
Conclusion  Osteomyelitis  Osteomyelitis  
Agreement 
with 
clinical 
presentation 
Yes  Yes 
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Table 7.2.9 Patient 9  
clinical presentation / suspicion – osteomyelitis of right distal hallux 
 
                                MRI                                             SPECT/CT 
Site;  Right hallux Right big toe 
Detail  There is soft tissue swelling 
and oedema, especially of the 
hallux. No soft tissue 
collections, There is some 
marrow oedema in the 
phalanges of the hallux but no 
suggestion of intra osseous 
collection. The marrow 
oedema could be reactive and 
thee is no evidence of 
complications of 
osteomyelitis.  
Markedly increased tracer flow 
within the right foot …………. 
Within the right big toe on the 
blood pool and delayed images 
Conclusion  Extensive inflammatory 
change but no MRI evidence 
of osteomyelitis. 
Right big toe bone infection  
Agreement 
with 
clinical 
presentation 
No  Yes  
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Table 7.2.10 Patient 10  
clinical presentation / suspicion – cellulitis to mid foot with apical ulcer 2nd toe 
complicated by ?osteomyelitis? 
   
                       MRI                                              SPECT/CT 
Site;  Terminal phalanx 
second toe 
Tip of left second toe 
Detail  The terminal phalanx of the 
second toe has low signal in its 
marrow and this does not 
enhance suggesting bone 
necrosis. The oedema of the 
proximal and middle 
phalanges does enhance, 
showing perfusion. No soft 
tissue fluid collection is seen. 
There is marked increased blood 
flow and mild increased uptake 
in the tip of the left second toe. 
Conclusion  Bone necrosis with infection. The findings in the left second 
toe could represent osteomyelitis 
although are not entirely 
specific. 
Agreement 
with 
clinical 
presentation 
Yes.  Yes. 
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Chapter 8 Discussion The use of SPECT/CT in the 
diagnosis of osteomyelitis 
 
This chapter will provide a discussion about the two forms of imaging used in this 
study and the clinical utility of both. There was however insufficient numbers of 
scans performed to make any meaningful measure of specificity and sensitivity.   
 
Both tests in this series were influenced by the predictive value in that it was 
influenced by the underlying prevalence of disease. Review bias was eliminated as 
far as was practical and using the same expert practitioners to read the scans 
reducing the subjective element of reading a scan.  
 
From a medical view it is necessary to be able to evaluate the extent of both soft 
tissue and bone involvement (Berendt et al 2008). This determines the need for 
antibiotic therapy and all the decisions that encompasses and the need for referral to 
surgery. 
 
From a surgical view again it is necessary to be able to evaluate the extent of both 
soft tissue and bone involvement to assist in surgical planning (Berendt et al 2008).  
 
Only one paper has been found discussing the use of computed tomography and not 
specifically SPECT/CT in the diagnosis of foot infection for comparison with the 
results of this research. In most the use of bone scans is discussed but not with the 
additional Computerised Tomography element. MRI is well documented as a 
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diagnostic tool in examining the foot in diabetes for determination of the presence 
and / or absence of bone infection. 
 
Prior to the introduction of SPECT/CT CT was limited by the small surface area 
involved in foot infections and lack of multi planar activity (Weinstein et al 1993). 
The images that can now be produced allow viewing in all body planes and as such 
allow a greater amount of detail for precise positioning of pathological disease to be 
recognised. This was previously only seen within the images of MRI.  
 
The criteria used for a positive diagnosis of osteomyelitis within this study were the 
same as those proposed by Yuh et al (1989), Weinstein et al (1993), Ertugrul et al 
(2006) and Dinh, Abad and Sadfar (2008). Namely when using MRI ‘a decreased 
signal intensity on T1 images with focal enhancement after contrast and increased 
signal intensity on T2 weighted images’. When using bone scintography a positive 
result for the diagnosis of osteomyelitis was used when ‘an increased blood flow and 
blood-pool activity and abnormality increased intensity localised to the bone’ (Yuh 
et al 1998) was present.   
 
The diagnostic signs of osteomyelitis with MRI require some experience to 
recognise them and to interpret the results and help in the difficult differential 
diagnosis of infection and Charcot neuroarthropathy. A consideration that may be 
used as a sign diagnostic of osteomyelitis by Tan and Teh (2007) in MRI imaging is 
the visualization of abnormal signal and enhancement extending from the skin to a 
bone in question. Other features of images suggested by Ahmadi et al (2006) that 
may assist in the differential diagnosis on MR that may become more evident with 
greater use of SPECT/CT are sinus tracts, replacement of the soft tissue fat, fluid 
collections and extensive marrow abnormalities. These changes are clearly not as 
easy to consider in the images produced by SPECT/CT imaging although it may 
become so with more experience of reading the scans. Teh, Berendt and Lipsky 
(2010) suggest the soft tissue contrast in computed tomography is poor compared to 
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Magnetic Resonance Imaging but offer no more clarity as to why or how it may be 
improved. 
 
SPECT/CT has three advantages; in that as the scanning method is the patient is not 
required to be enclosed by the data acquisition head (it moves around the patient) 
there is less concern for the morbidly obese patient as many patients with diabetes 
are and as such unable to fit within the MRI scanner, there is no impact should there 
be metal within the patient e.g. a foreign body within the eye or a joint prosthesis, 
and no contrast that is likely to effect renal function is required to enhance the 
images; important in many patients with diabetes and established renal disease. If an 
increased determination of sinus tracks and or soft tissue abscesses contrast can be 
administered but is generally not required for the recognition of bone disease. The 
need to administer a small amount of radioactive material to the individual patient 
maybe seen as a disadvantage to some. The problem that may cause SPECT/CT to 
be less sensitive is the diabetes complication of ischaemia reducing the peripheral 
uptake of the radioactive marker; the diphosphonate distributes in an amount 
proportional to blood flow. However as the result is a comparison of 1) both limbs as 
opposed to an absolute and 2) the relative uptake within the affected limb it may be 
this is not clinically important. 
 
Both imaging modalities appear to give the information required to determine the 
presence or absence of bone disease and the extent to which this affects the foot as a 
whole system. So in conclusion SPECT/CT seems a reasonable alternative to MRI 
where this is either not available or not suitable. 
 
A general discussion of the diagnosis of osteomyelitis follows in the next chapter. 
This includes mention of the problems that need addressing in any future study.  
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Chapter 9 General Discussion, Recommendations and 
Conclusions  
 
Osteomyelitis remains a challenge to diagnose or exclude as the many tests available 
provide ambiguous results (Lipsky et al 2004). It has been suggested that 
unexplained inflammatory markers should arouse suspicion of bone infection 
(Kaleta, Fleischli and Reilly 2001) with no clear guidance as to what a raised level is 
for most of the markers commonly used. It is given the strength of evidence as B –
moderate evidence to support and the standard of evidence as ІІ – evidence from ≥1 
well designed clinical trail without randomisation; from cohort or case controlled 
analytic studies (preferably from >1 centre). Of the markers I have measured and 
reported here it can be seen Neutrophil Count is at the high end of the accepted 
normal range, C Reactive Protein is raised above the accepted normal range, Plasma 
Visosity is raised above the accepted normal range and Procalcitonin is raised above 
the normal level in osteomyelitis but with no clear pattern in any marker, or group of 
markers, that could be used as a diagnostic test.  
 
The many confounding factors within wound care make any study difficult to 
intrepret and provides limited broad applicability. It was hoped that a combination of 
blood tests for inflammatory markers may have shown some positive indication of 
osteomyelitis. This has not proved possible; in this study the participants were 
neither new presentations and as such having the potential to be antibiotic naïve or 
were ill enough to require admission to hospital. Many of the previous studies have 
been used on in - patients and some have been able to enrol antibiotic naïve 
individuals, this has limited the comparability to other work.  
 
The results presented illustrate a lack of clarity when using inflammatory blood 
markers to assist in the diagnosis of any infection in diabetic foot ulcers. Major 
pathogens have been shown to adhere to bone by expressing adhesion factors for 
components of bone matrix (Hartmann-Heurtier and Senneville 2008) and this may 
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be a partial explanation for some of the unexpected results. The infective bacteria in 
this scenario being ‘hidden’ from the immune response may reduce the degree of 
inflammation produced. The inflammation is the start of the defence system against 
infection. The inability to see a clear pattern within the blood markers to recognise 
either cutaneous infection or osteomyelitis was disappointing.  Any future study that 
uses inflammatory blood markers needs to consider the data gathering in an attempt 
to recognise and allow for confounding factors. The confounders not considered in 
this research include making any attempt to both define and stratify into groups 
(using cluster sampling and analysis), the chronicity of the wound and, where 
appropriate, the same for osteomyelitis. The virulence of the causative micro 
organism in infection may also be of interest.  The nature of the disease process of 
diabetes alone confounding the results makes it complex without the addition of 
potential confounding from diabetes associated complications and the medications 
associated with treatment. Any future study may do well to consider these points. 
Unfortunately these and other confounding factors that could have the potential to 
affect the results of the blood tests are the reality faced in the out patient diabetic foot 
clinic.  
 
Currently there is insufficient evidence to consider any change in current practice. 
The use of the inflammatory markers alone for diagnostic purposes has not been seen 
to be possible and as such they should continue to be used alongside clinical signs, 
symptoms and judgement to determine the extent of disease. 
 
Imaging studies continue to help diagnose or better define deep, soft tissue purulent 
collections and detecting pathological processes in bone (Lipsky et al 2004). 
SPECT/CT looks promising for those individual unable to have a MRI through 
reasons including obesity, renal impairment and metallic inplants. The diagnostic 
accuracy from the limited cases presented here appears promising. Greater 
experience in the reading of SPECT/CT scans in relation to the diagnosis of 
osteomyelitis will assist in the diagnostic features seen in this form of imaging.  
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In terms of the imaging study it would be beneficial to have a wider range of 
conditions examined and a greater number of individuals included. 
 
SPECT/CT relies on blood flow (and pooling) increasing to allow recognition of the 
area of pathological change. In this study the inflammation initiated by the infective 
process causes the increased blood surge. The additional CT element to previous 
nuclear medicine bone scanning techniques does not appear to have increased the 
specificity in localising the pathology to skin and or bone. However, nor has it 
provided the precise detail MRI can offer. This may improve with the development 
of the skills of the staff concerned in the recognition of normal and abnormal 
findings in the foot.  
 
The most appropriate method of diagnosing osteomyelitis with the most robust 
technique, in suitable individuals, would appear to be an image guided percutaneous 
bone biopsy through skin adjacent to the ulcer.  This reduces the risks of 
contamination from cutaneous and other superficial micro organisms and can allow 
the collection of the causative micro organisms in the bone. Clearly the problems of 
introducing a further wound are far from ideal in this population, and the risks and 
benefits of creating another wound must be considered carefully. 
 
As a second line of diagnosis it would appear practical to consider MRI when used 
with Gadoteric Acid to enhance the images. Using highly skilled staff in reading the 
scan is also essential. This is the ideal situation where the individual does not have 
renal impairment which many foot clinic patients do have; renal disease has the 
capacity to affect the ability to excrete the contrast drug. A non-enhanced MRI can 
also be beneficial when evaluated by a highly skilled radiologist.  
 
SPECT/CT continues to have initial problems with producing the precise definitions 
that MRI is capable of for soft tissue and the accurate sizes of bony defects. These 
may well reduce as the technique is used more and the clinicians involved learn more 
about the functionality it provides in diagnostic procedures in the lower limb and 
foot in particular. 
 157 
Until these problems are overcome osteomyelitis associated with diabetes will 
remain a condition which is difficult to recognise and in which treatment often fails, 
with the end result of an amputation to remove the infected tissues. 
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Chapter 10 Appendices 
 
10.1 Ethics approval 
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10.2 Ethics approval for amendment  
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10.3 Research and Development approval 
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10.4 Research and Development approval following ethics amendment  
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10.5 Patient Information Sheet 
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10.6 Consent form  
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10.7 Data collection tool 
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10.8 Proposed consensus criteria for diagnosing osteomyelitis in the 
diabetic foot 
 
From Berendt et al (2008) 
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10.9 Histograms and summary statistics of each inflammatory marker in 
each wound condition 
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Neutrophil Count in clean wounds 
Normal range is 2 – 7.5 x 109 / l 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Neutrophil Count 2.50 13.30 5.57 2.39 
 Haemoglobin in clean wounds (not including renal impairment) 
Normal range is ♀ 11.5 – 15.5 g /dl ♂ 13.5 – 15.5 g / dl anaemia is < 11g /dl 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Haemoglobin 8.60 14.80 12.64 1.54 
 
15.00 14.00 13.00 12.00 11.00 10.00 9.00 8.00 
Level of Haemoglobin g /dl 
8 
6 
4 
2 
0 
Frequency 
 
 
  
Histogram of Haemoglobin in clean wounds with normal curve 
12.50 10.00 7.50 5.00 2.50 
Level of neutrophil count x 109 / l 
8 
6 
4 
2 
0  
 
  
Histogram of Neutrophil Count in clean wounds with normal curve 
Frequency 
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CRP in clean wounds  
Normal is less than 5mg/l 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Median  
C Reactive Protein 4.99 89.00 11.03 15.89 11.08 
 
Plasma Viscosity in clean wounds 
Normal range is 1.5 – 1.72 mpas 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Plasma Viscosity 1.50 2.10 1.76 0.13 
 
100.00 80.00 60.00 40.00 20.00 0.00 
Level of C Reactive Protein mg / l 
25 
20 
15 
10 
5 
0 
 
 
 
 
Histogram of C Reactive Protein in clean wounds with normal curve 
Frequency 
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Histogram of Plasma Viscosity in clean wounds with normal curve  
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Procalcitonin in clean wounds 
Normal range in ‘healthy’ individuals <0.3ng/ml 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Median 
Procalctonin 0.01 0.04 0.03 0.00 0.3 
 
Neutrophil Count in cutaneous infection 
Normal range is 2 – 7.5 x 109 / l 
 Descriptive Statistics 
 
Minimum Maximum Mean Std. Deviation 
Neutrophil Count 2.80 16.10 6.43 2.81 
 
0.04 0.035 0.03 0.025 0.02 0.015 0.01 
Level of Procalcitonin ng / ml 
8 
6 
4 
2 
0 
Frequency 
    
Histogram of Procalcitonin in clean wounds with normal 
curve  
15.00 10.00 5.00 
Level of Neutrophil Count x 109 / l 
20 
15 
10 
5 
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Frequency 
    
Histogram of Neutrophil Count in cutaneous infection with normal curve 
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Haemoglobin in cutaneous infection (not including renal impairment) 
Normal range is ♀ 11.5 – 15.5 g /dl ♂ 13.5 – 15.5 g / dl anaemia is < 11g /dl 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Haemoglobin 8.60 15.10 12.29 1.50 
 
CRP in cutaneous infection 
Normal range is less than 5mg/l 
 Descriptive Statistics 
 
Minimum Maximum Mean Std. Deviation 
Median 
C Reactive Protein 4.99 215.00 28.16 38.51 13.00 
 
15.00 12.50 10.00 
Level of Haemoglobin g /dl 
10 
8 
6 
4 
2 
0 
Frequency 
    
Histogram of Haemoglobin in cutaneous infection with normal curve  
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Histogram of C Reactive Protein in cutaneous infection with normal curve   
Frequency 
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Plasma Viscosity in cutaneous infection 
Normal range is 1.5 – 1.72 mpas 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Plasma Viscosity 1.62 2.72 1.87 0.22 
Procalcitonin in cutaneous infection 
Normal range in ‘healthy’ individuals <0.3ng/ml 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Median 
Procalcitonin 0.01 0.93 0.10 0.22 0.03 
 
2.75 2.50 2.25 2.00 1.75 
Level of Plasma Viscosity mpas 
20 
15 
10 
5 
0 
Frequency 
   
Histogram of Plasma Viscosity in cutaneous infection with normal curve 
1.00 0.80 0.60 0.40 0.20 0.00 
Level of Procalcitonin ng /ml 
30 
25 
20 
15 
10 
5 
0 
Frequency 
    
Histogram of Procalcitonin in cutaneous infection with normal curve  
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Neutrophil Count in suspected osteomyelitis 
Normal range is 2 – 7.5 x 109 / l 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Neutrophil Count 2.80 16.10 6.34 2.94 
 
 
Haemoglobin in suspected osteomyelitis (not including renal impairment) 
Normal range is ♀ 11.5 – 15.5 g /dl ♂ 13.5 – 15.5 g / dl anaemia is < 11g /dl 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Haemoglobin 8.60 15.10 12.26 1.57 
 
15.00 10.00 5.00 
Level of Neutrophil Count x 109 / l 
20 
15 
10 
5 
0 
Frequency 
 
.   
Histogram of Neutrophil Count in suspected osteomyelitis with normal curve  
15.00 12.50 10.00 
Level of Haemoglobin g /dl 
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Frequency 
    
Histogram of Haemoglobin in suspected osteomyelitis with normal curve  
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CRP in suspected osteomyelitis  
Normal range is below 5mg/l 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Median 
C Reactive Protein 4.99 215.00 24.53 40.65 10.50 
Plasma Viscosity in suspected osteomyelitis  
Normal range is 1.5 – 1.72 mpas 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Plasma Viscosity 1.53 2.38 1.83 0.18 
2.25 2.00 1.75 1.50 
Level of Plasma Viscosity mpas 
10 
8 
6 
4 
2 
0 
Frequency 
  
 
Histogram of Plasma Viscosity in suspected osteomyelitis with normal curve  
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Histogram of C Reactive Protein in suspected osteomyelitis with normal curve  
 190 
Procalcitonin in suspected osteomyelitis 
Normal range in ‘healthy’ individuals <0.3ng/ml 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Median  
Procalcitonin 0.02 0.93 0.07 0.19 0.03 
 
Neutrophil Count in proven osteomyelitis 
Normal range is 2 – 7.5 x 109 / l 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Neutrophil Count 2.80 16.10 6.41 3.10 
 
 
15.00 10.00 5.00 
Level of Neutrophil Count x 109  / 
12 
10 
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Neutrophil Count in confirmed osteomyelitis with normal curve 
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Histogram of Procalcitonin in suspected osteomyelitis with normal curve  
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Haemoglobin in proven osteomyelitis (not including renal impairment 
Normal range is ♀ 11.5 – 15.5 g /dl ♂ 13.5 – 15.5 g / dl anaemia is < 11g /dl 
 Descriptive 
Statistics 
 
N 
Minimu
m 
Maximu
m Mean 
Std. 
Deviation 
Haemoglobin 29 8.60 14.70 12.24 1.64 
 CRP in proven osteomyelitis  
Normal range is less than 5mg/l 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
C Reactive Protein 4.99 215.00 29.33 42.58 
  
15.00 14.00 13.00 12.00 11.00 10.00 9.00 8.00 
Level of Haemoglobin g /dl 
8 
6 
4 
2 
0 
Frequency 
   
Histogram of Haemoglobin in confirmed osteomyelitis with normal curve 
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Histogram of C Reactive Protein in confirmed osteomyelitis with normal curve  
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Plasma Viscosity in proven osteomyelitis  
Normal range is 1.5 – 1.72 mpas 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Plasma Viscosity 1.53 2.59 1.86 0.22 
Procalcitonin in proven osteomyelitis 
Normal range in ‘healthy’ individuals <0.3ng/ml 
 Descriptive Statistics 
 Minimum Maximum Mean Std. Deviation 
Median  
Procalcitonin 0.02 0.93 0.10 0.21 0.30 
2.50 2.25 2.00 1.75 1.50 
Level of Plasma Viscosity mpas 
8 
6 
4 
2 
0 
Frequency 
    
Histogram of Plasma Viscosity in confirmed osteomyelitis with normal curve  
1.00 0.80 0.60 0.40 0.20 0.00 
Level of Procalcitonin ng / ml 
20 
15 
10 
5 
0     
Histogram of Procalcitonin in confirmed osteomyelitis with normal curve  
Frequency 
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10.10 Regression analysis results   
 
10.10.1 Regression models without confounders  
 
10.10.1.1 Regression models without confounders in clean wounds 
 
Variables in the Equation 
 
 
95.0% C.I.for EXP(B) 
  B S.E. Wald df Sig. Exp(B) Lower Upper 
PV 4.344 2.243 3.752 1 .053 77.018 .950 6245.649 Step 
1(a) Constant 
-7.396 4.058 3.322 1 .068 .001     
a  Variable(s) entered on step 1: PV. 
 
Model if Term Removed(a) 
 
Variable 
Model Log 
Likelihood 
Change in -
2 Log 
Likelihood df 
Sig. of the 
Change 
Step 1 PV 
-30.846 5.911 1 .015 
a  Based on conditional parameter estimates 
 
Variables not in the Equation 
 
  Score df Sig. 
Ncount 
.709 1 .400 
Hb 
.273 1 .601 
CRP 2.354 1 .125 
Variables 
PCN 1.122 1 .289 
Step 1 
Overall Statistics 3.809 4 .432 
 
10.10.1.2Regression models without confounders in cutaneous infected wounds 
 
Variables in the Equation 
 
95.0% C.I.for EXP(B) 
  B S.E. Wald df Sig. Exp(B) Lower Upper 
Ncount 
-.362 .181 4.003 1 .045 .696 .488 .993 Step 
1(a) Constant 1.185 1.014 1.364 1 .243 3.270     
a  Variable(s) entered on step 1: Ncount. 
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Model if Term Removed(a) 
 
Variable 
Model Log 
Likelihood 
Change in -
2 Log 
Likelihood df 
Sig. of the 
Change 
Step 1 Ncount 
-28.707 5.325 1 .021 
a  Based on conditional parameter estimates 
 
Variables not in the Equation 
 
  Score df Sig. 
Hb 
.515 1 .473 
CRP 1.684 1 .194 
PV 1.615 1 .204 
Variables 
PCN 
.853 1 .356 
Step 1 
Overall Statistics 2.779 4 .595 
 
10.10.1.3  Regression models without confounders in suspected osteomyelitis  
 
Variables not in the Equation 
 
  Score df Sig. 
Ncount 
.094 1 .759 
Hb 
.353 1 .552 
CRP 
.416 1 .519 
PV 
.228 1 .633 
Variables 
PCN 
.270 1 .604 
Step 0 
Overall Statistics 1.620 5 .899 
 
10.10.1.4  Regression models without confounders in confirmed osteomyelitis 
  
Variables not in the Equation 
 
  Score df Sig. 
Ncount 
.125 1 .724 
Hb 
.218 1 .641 
CRP 
.088 1 .766 
PV 
.203 1 .652 
Variables 
PCN 2.657 1 .103 
Step 0 
Overall Statistics 2.961 5 .706 
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10.10.2 Regression models with confounders 
 
10.10.2.1 Regression models with confounders in clean wounds 
 
confounder not on antibiotics 
 
Variables in the Equation 
 
95.0% C.I.for EXP(B) 
  B S.E. Wald df Sig. Exp(B) Lower Upper 
CRP 
.147 .082 3.193 1 .074 1.158 .986 1.361 Step 
1(a) Constant 
-2.106 1.098 3.680 1 .055 .122     
a  Variable(s) entered on step 1: CRP. 
 
Model if Term Removed(a) 
 
Variable 
Model Log 
Likelihood 
Change in -
2 Log 
Likelihood df 
Sig. of the 
Change 
Step 1 CRP 
-12.020 7.738 1 .005 
a  Based on conditional parameter estimates 
 
 Variables not in the Equation 
 
  Score df Sig. 
Ncount 1.543 1 .214 
Hb 
.104 1 .747 
PV 
.206 1 .650 
Variables 
PCN 
.558 1 .455 
Step 1 
Overall Statistics 1.933 4 .748 
 
confounder on Insulin 
 
Variables not in the Equation 
 
  Score df Sig. 
Ncount 3.749 1 .053 
Hb 
.171 1 .679 
CRP 2.489 1 .115 
PV 3.116 1 .078 
Variables 
PCN 1.113 1 .291 
Step 0 
Overall Statistics 4.599 5 .467 
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confounder on Metformin 
 
Variables not in the Equation 
 
  Score df Sig. 
Ncount 1.678 1 .195 
Hb 2.005 1 .157 
CRP 2.042 1 .153 
PV 2.026 1 .155 
Variables 
PCN 
.946 1 .331 
Step 0 
Overall Statistics 4.042 5 .543 
 
confounder predominant etiology neuropathy 
 
Variables not in the Equation 
 
  Score df Sig. 
Ncount 1.773 1 .183 
Hb 1.574 1 .210 
CRP 3.761 1 .052 
PV 3.265 1 .071 
Variables 
PCN 
.968 1 .325 
Step 0 
Overall Statistics 5.706 5 .336 
 
10.10.2.2 Regression models with confounders in cutaneous infected wounds 
 
confounder not on antibiotics 
 
Variables in the Equation 
 
95.0% C.I.for EXP(B) 
  B S.E. Wald df Sig. Exp(B) Lower Upper 
Ncount 
-.608 .364 2.789 1 .095 .544 .267 1.111 Step 
1(a) Constant 3.774 2.094 3.249 1 .071 43.554     
a  Variable(s) entered on step 1: Ncount. 
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Model if Term Removed(a) 
 
Variable 
Model Log 
Likelihood 
Change in -
2 Log 
Likelihood df 
Sig. of the 
Change 
Step 1 Ncount 
-11.523 4.700 1 .030 
a  Based on conditional parameter estimates 
 
Variables not in the Equation 
 
  Score df Sig. 
Hb 
.176 1 .675 
CRP 1.406 1 .236 
PV 1.687 1 .194 
Variables 
PCN 
.075 1 .784 
Step 1 
Overall Statistics 2.312 4 .679 
 
confounder on Insulin 
 
Variables in the Equation 
 
95.0% C.I.for EXP(B) 
  B S.E. Wald df Sig. Exp(B) Lower Upper 
Ncount 
-.582 .277 4.434 1 .035 .559 .325 .961 Step 
1(a) Constant 2.409 1.477 2.661 1 .103 11.126     
a  Variable(s) entered on step 1: Ncount. 
 
Model if Term Removed(a) 
 
Variable 
Model Log 
Likelihood 
Change in -
2 Log 
Likelihood df 
Sig. of the 
Change 
Step 1 Ncount 
-16.285 7.646 1 .006 
a  Based on conditional parameter estimates 
 
 Variables not in the Equation 
 
  Score df Sig. 
Hb 
.030 1 .862 
CRP 
.037 1 .848 
PV 
.087 1 .768 
Variables 
PCN 
.068 1 .794 
Step 1 
Overall Statistics 
.316 4 .989 
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confounder on Metformin 
 
Variables not in the Equation 
 
  Score df Sig. 
Ncount 
.643 1 .423 
Hb 2.436 1 .119 
CRP 1.627 1 .202 
PV 
.971 1 .324 
Variables 
PCN 
.777 1 .378 
Step 0 
Overall Statistics 3.073 5 .689 
 
confounder predominant etiology neuropathy 
 
Variables in the Equation 
 
95.0% C.I.for EXP(B) 
  B S.E. Wald df Sig. Exp(B) Lower Upper 
Ncount 
-.439 .222 3.907 1 .048 .645 .417 .996 Step 
1(a) Constant 1.615 1.194 1.831 1 .176 5.029     
a  Variable(s) entered on step 1: Ncount. 
 
Model if Term Removed(a) 
 
Variable 
Model Log 
Likelihood 
Change in -
2 Log 
Likelihood df 
Sig. of the 
Change 
Step 1 Ncount 
-23.362 4.852 1 .028 
a  Based on conditional parameter estimates 
 
Variables not in the Equation 
 
  Score df Sig. 
Hb 
.369 1 .543 
CRP 1.043 1 .307 
PV 
.377 1 .539 
Variables 
PCN 
.819 1 .366 
Step 1 
Overall Statistics 1.626 4 .804 
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10.10.2.3 Regression models with confounders in suspected osteomyelitis 
 
confounder not on antibiotics 
 
Variables in the Equation 
 
95.0% C.I.for EXP(B) 
  B S.E. Wald df Sig. Exp(B) Lower Upper 
PV 
-13.051 6.927 3.550 1 .060 .000 .000 1.691 Step 
1(a) Constant 25.071 12.835 3.816 1 .051 77329155073.191     
a  Variable(s) entered on step 1: PV. 
 
Model if Term Removed(a) 
 
Variable 
Model Log 
Likelihood 
Change in -
2 Log 
Likelihood df 
Sig. of the 
Change 
Step 1 PV 
-10.303 7.890 1 .005 
a  Based on conditional parameter estimates 
 
 Variables not in the Equation 
 
  Score df Sig. 
Ncount 
.206 1 .650 
Hb 
.209 1 .647 
CRP 
.208 1 .649 
Variables 
PCN 
.198 1 .656 
Step 1 
Overall Statistics 2.578 4 .631 
 
confounder on Insulin 
 
Variables not in the Equation 
 
  Score df Sig. 
Ncount 
.103 1 .748 
Hb 1.597 1 .206 
CRP 
.242 1 .623 
PV 
.047 1 .828 
Variables 
PCN 
.842 1 .359 
Step 0 
Overall Statistics 3.628 5 .604 
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confounder on Metformin 
 
Variables not in the Equation 
 
  Score df Sig. 
Ncount 
.176 1 .674 
Hb 
.019 1 .891 
CRP 
.165 1 .685 
PV 
.135 1 .713 
Variables 
PCN 1.259 1 .262 
Step 0 
Overall Statistics 1.627 5 .898 
 
confounder predominant etiology neuropathy 
 
Variables not in the Equation 
 
  Score df Sig. 
Ncount 
.814 1 .367 
Hb 
.222 1 .638 
CRP 
.165 1 .685 
PV 
.006 1 .938 
Variables 
PCN 
.896 1 .344 
Step 0 
Overall Statistics 3.279 5 .657 
 
10.10.2.4 Regression models with confounders in confirmed osteomyelitis 
 
confounder not on antibiotics 
 
Variables in the Equation 
 
95.0% C.I.for EXP(B) 
  B S.E. Wald df Sig. Exp(B) Lower Upper 
PV 
-7.482 4.537 2.719 1 .099 .001 .000 4.101 Step 
1(a) Constant 15.180 8.536 3.162 1 .075 3911964.001     
a  Variable(s) entered on step 1: PV. 
 
Model if Term Removed(a) 
 
Variable 
Model Log 
Likelihood 
Change in -
2 Log 
Likelihood df 
Sig. of the 
Change 
Step 1 PV 
-9.277 4.393 1 .036 
a  Based on conditional parameter estimates 
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Variables not in the Equation 
 
  Score df Sig. 
Ncount 
.053 1 .818 
Hb 
.202 1 .653 
CRP 
.150 1 .698 
Variables 
PCN 
.127 1 .722 
Step 1 
Overall Statistics 1.724 4 .786 
 
confounder on Insulin 
 
Variables not in the Equation 
 
  Score df Sig. 
Ncount 1.337 1 .248 
Hb 
.404 1 .525 
CRP 2.606 1 .106 
PV 
.620 1 .431 
Variables 
PCN 1.079 1 .299 
Step 0 
Overall Statistics 3.296 5 .654 
 
confounder on Metformin 
 
Variables not in the Equation 
 
  Score df Sig. 
Ncount 
.236 1 .627 
Hb 
.144 1 .704 
CRP 
.099 1 .753 
PV 
.264 1 .607 
Variables 
PCN 1.886 1 .170 
Step 0 
Overall Statistics 2.208 5 .820 
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confounder predominant etiology neuropathy 
 
 Variables not in the Equation 
 
  Score df Sig. 
Ncount 
.361 1 .548 
Hb 
.681 1 .409 
CRP 
.020 1 .887 
PV 
.001 1 .981 
Variables 
PCN 1.394 1 .238 
Step 0 
Overall Statistics 2.943 5 .709 
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